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ABSTRACT OF THE DISSERTATION
Post-Translational Regulation of FAS-Mediated PPARĮ Activation
by
Anne P L Jensen-Urstad
Doctor of Philosophy in Molecular Cell Biology
Washington University in St. Louis, 2013
Professor Clay F Semenkovich, Chairperson
The liver is a central organ to whole-body metabolism and mediates many of the
adaptive responses to changes in nutrient availability, such that the appropriate energy
sources are used and blood glucose levels maintained, whether directly after a meal or after a
twelve-hour fast. The adaptive responses to fasting in liver are largely mediated by the
nuclear receptor peroxisome proliferator-activated receptor Į, or PPARĮ.
PPARĮ can be activated by a de novo synthesized lipid ligand—16:0/18:1glycerophosphocholine (16:0/18:1-GPC)—the synthesis of which is dependent on fatty acid
synthase (FAS), but little is known about the regulation of this pathway. My thesis focused
on post-translational mechanisms controlling endogenous activation of PPARĮ in the liver
and used mouse liver and a hepatocyte cell line as model systems.
In addition to its role in PPARĮ activation during fasting, FAS helps store excess
calories as fat during feeding. We demonstrated that this paradoxical relationship involves the
differential regulation of FAS in at least two distinct subcellular pools: cytoplasmic and
membrane-associated FAS, the latter being attached to membranes by a strong peripheral
membrane association. To find candidate proteins mediating FAS membrane localization we
used a proteomics approach to identify compartment-specific FAS-associated proteins. We
identified three proteins—Septin-2, Septin-7, and 40S ribosomal protein S18—that in two
different liver model systems associate with FAS exclusively in the membrane fraction.
xi

Because the septins are involved in membrane structuring and scaffolding, these proteins may
be involved in FAS membrane localization.
The ratio of cytoplasmic to membrane FAS specific activity was increased with
fasting or in the absence of insulin, indicating higher cytoplasmic FAS activity under
conditions associated with PPARĮ activation. This effect was due to a nutrient-dependent and
compartment-selective covalent modification of FAS: cytoplasmic FAS was preferentially
phosphorylated during feeding or insulin treatment at Thr-1029 and Thr-1033, which flank a
dehydratase domain catalytic residue. Mutating these sites to alanines promoted PPARĮ
target gene expression. mTORC1, a mediator of the feeding/insulin signal to induce
lipogenesis, emerged as a mediator of FAS phosphorylation, inhibiting cytoplasmic FAS
activity and reducing PPARĮ target gene expression in a FAS-dependent manner.
Next, we investigated the role of ligand transport in FAS-mediated PPARĮ activation.
16:0/18:1-GPC is synthesized in the cytoplasm and it is not known how it reaches the nuclear
PPARĮ. We identified phosphatidylcholine transfer protein (PCTP) as a possible transport
protein for this ligand. PCTP knockdown in Hepa1-6 hepatocytes caused dramatic reductions
in expression of PPARĮ target genes, and PCTP co-immunoprecipitated with PPARĮ.
Immunofluorescent imaging showed that starvation of cells caused an accumulation of PCTP
in the nucleus, consistent with a shuttling function controlled by nutrition. Using mass
spectrometry, we demonstrated that PCTP binds 16:0/18:1-GPC. We further showed that the
binding of this ligand to PCTP is FAS-dependent: in mice with liver-specific knockout of
FAS, the amount of 16:0/18:1-GPC bound to PCTP in the nucleus was significantly reduced.
Together, these findings suggest that multiple modes of post-translational regulation
of FAS combined with regulation of lipid delivery by PCTP control fasting-induced PPARĮ
activation in liver.
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Chapter 1:
Introduction and Significance

1

Portions of this chapter are adapted from: Jensen-Urstad APL, Semenkovich CF. “Fatty acid
synthase and liver triglyceride metabolism: housekeeper or messenger?” Biochim Biophys
Acta 2012. 1821(5):747-53.
HEPATIC LIVER METABOLISM IN HEALTH AND DISEASE
The liver plays a central role in both glucose and lipid metabolism. Through a finely
tuned regulation of hepatic glycolysis, gluconeogenesis, glycogen synthesis and
glycogenolysis, the liver enables the control of blood glucose levels within certain narrow
physiological limits both in the fed and fasted state. This process becomes disturbed in type II
diabetes, in which dysregulation of hepatic glucose metabolism combined with reduced
glucose uptake by peripheral tissues lead to hyperglycemia. The liver is the hub for lipid and
lipoprotein production, secretion, uptake, and breakdown, as well as the primary regulator of
plasma cholesterol levels. In healthy individuals, the regulation of lipid metabolism and
glucose metabolism in the liver are tightly interlinked, allowing for appropriate substrate
utilization both after meals and during periods of fasting (reviewed in [1]). In diabetes, both
glucose and lipid metabolism become disturbed, as does this nutrient-responsive adaptation.

Hepatic lipid metabolism: lipoprotein synthesis, secretion, and uptake
Systemic transport of lipids is primarily carried out by lipoproteins, complexes of
lipid and protein (apolipoproteins) with a core of neutral lipids (triglycerides, diglycerides,
cholesterol esters) and a surface monolayer of amphipathic phospholipids and proteins that
promotes interaction of the lipoprotein with the aqueous environment of the blood. As the
liver is the key organ for synthesis, secretion, and uptake of lipoproteins, the basics of
lipoprotein metabolism will be reviewed below.
Lipoproteins are synthesized and secreted by the liver and, to a smaller extent, by the
small intestine. They transport lipid to peripheral tissues (primarily adipose tissue and
muscle) and return to the liver for uptake and breakdown or recycling. During their time in
2

the circulation, lipoproteins are modified by losing lipid to peripheral tissues; by lipid
exchange with other lipoproteins, remodeling their relative lipid compositions (such as
through the action of cholesterol ester transfer protein (CETP) that exchanges cholesterol
esters for triglycerides); and by loss or gain of apolipoproteins. Some lipoproteins are
involved in reverse lipid transport, i.e. the transport of lipids from peripheral tissues to the
liver (an important example being reverse cholesterol transport by HDL from macrophages to
the liver, from which the cholesterol is then excreted as bile).
Lipoproteins can be roughly divided into five classes: chylomicrons and their
remnants, very-low-density lipoproteins (VLDL), low-density lipoproteins (LDL),
intermediate-density lipoproteins (IDL), and high-density lipoprotein (HDL). Generally, the
density of a lipoprotein increases as the ratio of protein to lipid increases, hence VLDL is
lipid-rich and protein-poor while HDL is protein-rich and lipid-poor. These classes of lipids
differ in their lipid composition and their associated apolipoproteins. The apolipoproteins can
function as ligands for lipoprotein receptors stimulating their uptake (such as the LDLR
binding domain on apoB100) or as activators or inhibitors of various lipid metabolic enzymes.
Important apolipoproteins include apoB100, which is present in VLDL, IDL, and
LDL; apoB48 (a truncated version 48% the size of apoB100), which is present in
chylomicrons and chylomicron remnants; and apoA1, which is present in HDL. Most
apolipoproteins can be synthesized in the liver with the important exception of apoB48,
which in humans is only synthesized in the small intestine. ApoB48 lacks the LDL receptor
binding capacity and so has a different plasma clearance profile from apoB100. In mice,
apoB48-containing lipoproteins are synthesized in the liver as well, an important distinction
between mouse and human lipoprotein metabolism (along with the absence of CETP, in
mice; hamsters are actually more similar to humans in that they have CETP and cannot
synthesize hepatic apoB48, and are so sometimes used as an alternative rodent model for
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lipoprotein metabolism [2, 3]).
The liver synthesizes and secretes VLDL (which is hydrolyzed in the circulation to
IDL and then LDL) and a precursor form of HDL. VLDL is synthesized in the Golgi and ER
of hepatocytes through stepwise lipidation of an apolipoprotein. After entering the circulation,
lipoproteins deliver lipids to peripheral tissues by lipolysis and may be remodeled by the gain
or loss of apolipoproteins or by lipid exchange via CETP. Finally, LDL and IDL bind to
receptors on the surface of hepatocytes (primarily the LDL receptor (LDLR) and LDL-related
protein (LRP)). Largely due to the regulation of LDL uptake from circulation via LDLR, the
liver is the primary regulator of plasma cholesterol. The receptor-bound lipoproteins are
endocytosed into hepatocytes and their lipids are stored or re-packaged into VLDL for
secretion. HDL made by liver or intestine takes up cholesterol from peripheral tissues, may
be remodeled by lipid exchange by CETP, and is taken up by the liver in part by scavenger
receptor-BI (SR-BI), after which its cholesterol is converted to bile acids and excreted.
Chylomicrons are synthesized in the small intestine from dietary fat following a meal
and are transported to the vena cava, bypassing the liver to directly deliver lipids (primarily
triglycerides) to peripheral tissues. They eventually reach the liver in the form of chylomicron
remnants and the cholesterol and remaining triglycerides they carry are taken up by the liver
for storage or (re-)secretion.

Hepatic lipid metabolism: extra- and intrahepatic lipid sources
The liver takes up fat from circulation: free fatty acids (FFAs), dietary fats
(cholesterol and to a smaller degree triglycerides) from intestinally derived chylomicron
remnants, lipids from LDL and IDL, and lipids from HDL (primarily cholesterol). The FFAs
are mostly derived from adipose tissue lipolysis that, in a healthy insulin sensitive individual,
occurs mainly during fasting. Uptake of FFAs is not regulated, so FFA uptake by the liver is
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directly proportional to the FFA concentration in plasma, and should increase during fasting
in order to be used for fuel via fatty acid oxidation.
In addition to exogenous lipid uptake, lipids can be synthesized completely de novo in
the liver by fatty acid synthase (FAS). These lipids can be further incorporated into
phospholipids, diglycerides or triglycerides; however, in most cases FAS-derived lipids are a
quantitatively minor contributor to stored and secreted lipid, as will be reviewed in detail
below. De novo synthesis of cholesterol is more quantitatively important, and the bulk of
cholesterol synthesis takes place in the liver.
Lipids can be stored in the liver as intrahepatic lipid droplets and released as needed:
excessive lipid stored in this manner is referred to as fatty liver. Lipid droplets have a
structure resembling lipoproteins: they contain a core of neutral/esterified lipids (such as
triglycerides and cholesterol esters) surrounded by an amphipathic phospholipid monolayer
and various structural proteins (reviewed in [4] and [5]). A large proportion of the lipid
incorporated into VLDL for secretion seems to be derived from intrahepatic lipid droplets [68]. The mechanism by which lipids are transferred from lipid droplets to lipoproteins is
debated, with evidence both for a hydrolysis-reesterification cycle whereby droplet lipids are
hydrolyzed to FFAs that enter the ER and are re-esterified in the ER lumen prior to
incorporation into lipoproteins [7, 9], and for direct fusion of lipid droplets (presumably preexisting in the ER lumen) with pre-VLDL [10].

The fasting response
Under nutrient-replete conditions, the primary fuel of the liver is glucose rather than
fat. Dietary fat in the form of chylomicron remnants is taken up by the liver, but fatty acids
are not subjected to β-oxidation and instead are incorporated into triglycerides for storage in
lipid droplets or secretion in VLDL. De novo synthesis of fatty acids by FAS may make a
5

modest contribution to storing energy as fat when nutrients are present in excess.
“The fasting response” refers to the adaptive changes in metabolism that occur during
fasting or starvation in order to maintain blood glucose levels and provide alternative energy
in the form of ketones. During fasting, the primary fuel of the liver switches to fat. Plasma
insulin levels fall, relieving inhibition of lipases and stimulating lipolysis in peripheral tissues
(primarily adipose tissue). This increases the levels of plasma free fatty acids (FFAs), which
are taken up by the liver.
In the liver, fatty acids from peripheral tissues and from intrahepatic lipid droplets are
catabolized through ȕ-oxidation to form acetyl-CoA, which is either channeled into the TCA
cycle or used as substrate to produce ketones that provide energy to other tissues when
glucose is scarce. ȕ-oxidation also produces reducing equivalents in the form of FADH2 and
NADH. Energy in the form of ATP from the TCA cycle and electron transport chain (via
acetyl-CoA from ȕ-oxidation) and reducing equivalents directly derived from ȕ-oxidation are
used to fuel gluconeogenesis. The process of fatty acid catabolism and glucose anabolism
during fasting is thus interrelated through the dependency of gluconeogenesis on ȕ-oxidation
for energy.
An important protein for the fasting response in the liver is peroxisome proliferatoractivated receptor Į (PPARĮ), which promotes the transcription of genes necessary for the
fasting response (such as those encoding enzymes involved in ȕ-oxidation and ketogenesis).
PPARĮ will be discussed in more detail below.

Hepatic lipid metabolism in the metabolic syndrome and diabetes
The prevalence of type II diabetes is estimated to be 13% among adult Americans
[11] and 6% (6.4%) among adults worldwide [12]. The metabolic syndrome is estimated to
affect 24% of adult Americans [13] (criteria as defined by the National Cholesterol Education
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Program (NCEP)). Both diabetes and the metabolic syndrome are risk factors for
cardiovascular disease [14, 15], which is the leading cause of death worldwide [16]. Because
the liver is central to controlling systemic glucose and lipid metabolism, it is also central to
understanding the pathogenesis of diabetes and for designing treatments. Many of the most
important hyperlipidemia and diabetes drugs currently available, including metformin, statins,
and fibrates, have the liver as their site of action.
The diagnostic criteria for type II diabetes includes a fasting plasma glucose level
over 126 mg/dl or 7.0 mmol/l (according to WHO and ADA recommendations [17, 18]). The
hallmark of type II diabetes is insulin resistance, which refers to a state in which the tissues of
the body have a decreased sensitivity and responsiveness to insulin. Because of this decreased
responsiveness, higher levels of insulin must be produced by the pancreas in order to elicit
desired responses, which include stimulating peripheral tissues to take up glucose and
suppressing glucose synthesis by the liver. Type II diabetes refers to what happens when,
because of resistance to the actions of insulin, the insulin present is no longer enough to
maintain appropriate blood glucose levels, leading to hyperglycemia.
The metabolic syndrome refers to risk factors that together increase the risk of
diabetes and cardiovascular disease. The criteria for metabolic syndrome differ between
institutions (IDF, WHO, NCEP, and AHA), but all include some combination and definition
of central obesity, high plasma triglycerides, low HDL cholesterol, high blood pressure, and
high fasting blood glucose or insulin resistance. These risk factors are interrelated and tend to
cluster together.
In insulin resistance, insulin fails to suppress lipolysis in peripheral tissues even when
nutrients are abundant, resulting in high circulating levels of FFAs that are taken up by the
liver. Increased FFA uptake and perhaps increased de novo synthesis of fat in the liver
overwhelms the capacity for fatty acid oxidation, leading to fat accumulation and eventually
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the development of hepatosteatosis or fatty liver (non-alcoholic fatty liver disease, NAFLD).
Fatty liver has been estimated to affect a fifth to a third of adult Americans (21.4% in a
nationally representative cohort from 1988 to 1994 [19] and 31% in a cohort from Dallas
county from 2000 to 2002 [20]) and is associated with insulin resistance [21] and a high BMI
[20, 21]. NAFLD thus constitutes one of the major metabolic disorders along with diabetes
and heart disease accompanying the obesity epidemic.
Hepatosteatosis can progress to nonalcoholic steatohepatitis (NASH), which in
addition to fat accumulation is marked by inflammation, hepatocyte injury and/or fibrosis. A
significant proportion of patients with NASH develop cirrhosis (10-29% within 10 years
[22]), which in turn may progress into hepatocellular carcinoma, a type of cancer with very
poor prognosis: the 5-year survival rate is less than 10% [23].
Fatty liver can be diagnosed noninvasively (as was done in the studies estimating
NAFLD mentioned above, where ultrasound [19] and proton magnetic resonance
spectroscopy were used [20]). Diagnosing the presence of hepatic inflammation or fibrosis,
however, requires a liver biopsy. Therapeutic options for NAFLD are very limited; there is
currently no medical or surgical treatment for NAFLD approved by the FDA or the EMA.
Weight loss or treatment with the insulin-sensitizing thiazolidinedione drugs improve
steatosis and inflammation [24, 25]; the latter, however, cause significant weight gain. There
is thus a need for novel non-invasive diagnostic methods and for novel therapies for NAFLD
and NASH.
The strong association between insulin resistance and fatty liver has led to speculation
of a bidirectional cause-and-effect relationship between the two, in essence a vicious cycle
wherein the fatty liver caused by insulin resistance further exacerbates the insulin resistance.
However, there are many examples of mouse models that exhibit fatty liver but have normal
or improved insulin sensitivity [26, 27], and examples of genetic defects in humans that cause
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fatty liver but do not affect insulin sensitivity [26]. These data suggest that fatty liver does not
necessarily cause insulin resistance in itself [27].
In addition to fatty liver, changes in hepatic lipoprotein metabolism lead to the
dyslipidemia that accompanies the metabolic syndrome and insulin resistance, characterized
by the so-called lipid triad: high levels of plasma triglycerides, low levels of HDL cholesterol,
and the presence of small, dense LDL (sdLDL) (reviewed in [28]). Additionally, increased
postprandial triglyceride and apoB48 levels are a hallmark of diabetic dyslipidemia [29, 30]
and is in part due to increased intestinal chylomicron production [31, 32] and decreased
clearance of chylomicron remnants by the liver [32, 33]. These lipid abnormalities are
atherogenic and promote cardiovascular disease, the leading cause of death among diabetics
(52% of type II diabetics in a multinational study by the WHO) [34] and overall (30%
worldwide) [16].
The high level of plasma triglycerides is primarily due to an overproduction of
triglyceride-rich VLDL by the liver (reviewed in [35]). This, in turn, at least partially
originates in the increased amount of triglycerides stored in cytosolic lipid droplets resulting
from fatty liver: stored hepatic triglycerides are quantitatively important components of
VLDL [6, 7]. In obese patients, the degree of hepatic steatosis correlates positively with
VLDL secretion rates [36].
The decrease in HDL cholesterol (both in particle number as reflected by decreased
apoA1 levels and in cholesterol content of each particle) is due to increased catabolism of
apoA1 by the liver [37, 38] and increased activity of CETP in the plasma in transferring
triglycerides from triglyceride-rich lipoproteins such as VLDL to HDL in exchange for
cholesterol esters, resulting in a net depletion of HDL-associated cholesterol [39]. The
increase in CETP-mediated lipid exchange is, to some degree, stimulated by the high levels
of triglyceride-rich VLDL [40]. However, liver insulin receptor knockout (LIRKO) mice, a
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model for purely hepatic insulin resistance, do not have fatty liver or hypertriglyceridemia,
yet these mice have the low HDL cholesterol (and conversely, cholesterol-enriched VLDL)
characteristic of the metabolic syndrome [41]. The studies on LIRKO mice suggest that the
features of insulin resistance-associated dyslipidemia can be separated into those due to the
hepatic fat accumulation resulting from peripheral insulin resistance (increased plasma
triglycerides) and those due to central (hepatic) insulin resistance (decreased HDL
cholesterol).
The third component of the lipid triad, the presence of sdLDL, is less directly related
to intrahepatic lipid metabolism. CETP in the plasma promotes the transfer of triglycerides
from VLDL to LDL, and the resulting triglyceride-rich LDL is a preferred substrate for
hepatic lipase on the surface of the liver, which hydrolyses it into sdLDL.

PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR ǹ
The peroxisome proliferator-activated receptors (PPARs) consist of three known
nuclear receptors that have emerged as clinically significant targets for treatment of metabolic
syndrome. Each of the three family members, PPARĮ, PPARį, and PPARȖ, are key
metabolic regulators: PPARĮ controls fatty acid oxidation and is necessary for the adaptive
responses to fasting in the liver, PPARȖ is necessary for adipogenesis and promotes lipid
storage in adipose tissue, and PPARį is important for muscle and liver lipid metabolism.
Drugs that target PPARĮ and PPARȖ are currently on the market for treatment of
metabolic diseases: fibrate drugs target PPARĮ and are used to treat dyslipidemia (reviewed
in [42]) while thiazolidinediones target PPARȖ and are used to treat type II diabetes. Fibrates
are carboxylic acids that bind to PPARĮ, thereby functioning as agonistic ligands; fenofibrate
and gemfibrozil of this drug class are FDA-approved for treatment of hyperlipidemia.
PPARĮ activation by fibrates lowers plasma triglycerides and raises HDL cholesterol.
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The former is due to increased clearance of plasma triglycerides by the liver [43] and,
probably, to the decreased availability of fatty acids for triglyceride synthesis due to
increased ß-oxidation (in mouse [44] and rat [45] liver following fenofibrate treatment). The
increase in HDL cholesterol is dependent on increased production of the HDL
apolipoproteins apoAI and apoAII [46, 47].
While PPARȖ agonists have fallen out of favor due to side effects, PPARĮ and
PPARį agonists continue to be of therapeutic interest for treating the metabolic syndrome. At
the time of writing, a dual PPARĮ/PPARį agonist, GFT505, is in phase IIB clinical trials in
the US and several EU countries for treatment of non-alcoholic hepatosteatosis, and in
numerous pilot studies for treatment of dyslipidemia, obesity, and type II diabetes.

Function of PPARĮ in the fasting response
PPARĮ is expressed in several metabolically active tissues, including liver, muscle,
and heart. In the liver, PPARĮ is a key regulator of fatty acid metabolism and necessary for
fasting response: PPARĮ-null mice are deficient in both ketogenesis and gluconeogenesis and
are unable to adapt when challenged with fasting, developing hypoglycemia and
hypoketonemia [48]. PPARĮ promotes the cellular uptake and catabolism of fatty acids by
upregulating genes involved in fatty acid transport, peroxisomal and mitochondrial fatty acid
ȕ-oxidation, and ketogenesis, leading to an increased uptake and break-down of fatty acids to
generate ketones, reducing equivalents and ATP when PPARĮ is activated during fasting [48,
49].
Some important PPARĮ target genes/proteins in both mice and humans (reviewed in
[50]) that are involved in lipid metabolism include: ACO1 (encoded by Acox1), which
catalyzes the first step in peroxisomal ȕ-oxidation; carnitine palmitoyl transferase 1 and 2
(CPT1 and CPT2, encoded by Cpt1a and Cpt2, respectively), which mediate the transport of
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long-chain fatty acids across the mitochondrial membrane such that they can be oxidized;
FGF21 (encoded by Fgf21), a hormone important for ketogenesis; apoAI (encoded by Apoa1),
the key apolipoprotein in HDL; and ATP-binding cassette transporter 1 (ABCA1, encoded by
ABCA1), a cholesterol transporter.
PPARĮ is also crucial to fasting-induced gluconeogenesis. In the absence of PPARĮ,
mice become hypoglycemic within just hours of fasting onset (probably reflecting the
reduced liver glycogen in these mice, as glucose levels are primarily maintained by
glycogenolysis during the first hours of fasting), and the blood glucose continues to drop
steeply as fasting progresses, reaching a low of less than half of that of the wild type controls
after 24 hours of fasting (45 mg/dl vs. to 100 mg/dl) [48]. “Fasting” in this study and studies
on mice and humans cited below refers to complete withdrawal of food but ad lib access to
water. Fasting data are relative to ad lib feeding (mice) unless otherwise specified or the latest
meal (humans). “Fasting” will be used interchangeably with “starvation.”
The importance of PPARĮ for fasting-induced gluconeogenesis may largely be due to
the dependency of gluconeogenesis on fatty acid ȕ-oxidation for reducing equivalents in the
form of NADH. ȕ-oxidation is a quantitatively important source of NADH: in rat liver,
inhibition of ȕ-oxidation with bromooctanoate causes an over 60% reduction in NADH levels
[51]. The decreased hepatic glucose production in PPARĮ-null mice stems from a
dramatically decreased use of lactate as a substrate for gluconeogenesis, despite normal
lactate levels [52]. Gluconeogenesis from glycerol, on the other hand, is in fact increased 2.5fold in PPARĮ-null mice [52]. Conversion of one molecule of lactate to pyruvate to
eventually glyceraldehyde-3-phosphate (G3P) requires the use of two molecules of NADH
whereas conversion of glycerol to G3P requires none, explaining how this compensatory
increase in the glycerol-G3P arm of gluconeogenesis in PPARĮ-null mice is possible.
To some degree, PPARĮ also affects glucose metabolism via expression of
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gluconeogenic genes: the expression of pyruvate kinase is decreased 16-fold in fasted
PPARĮ-null mice [52]. However, the gene encoding phosphoenolpyruvate carboxykinase
(PEPCK), the rate-limiting enzyme in gluconeogenesis, is expressed normally in PPARĮ-null
mice [48, 52].

Hormonal and nutritional regulation of fasting and PPARĮ
PPARĮ is activated during periods of fasting or starvation. The main physiological
effects of PPARĮ activation are increased plasma ketone levels and maintenance of
euglycemia. Because regulation of glucose levels is complex, ketone levels are a better
surrogate for inferring PPARĮ activity and will be used as such below. Another surrogate is
protein or mRNA expression levels of classical PPARĮ target genes in the liver such as those
mentioned above. Expression levels of the mRNA for PPARĮ itself increases as well during
fasting, but follows the same time course as induction of other PPARĮ target genes [53],
suggesting a positive feedback loop. Ligand activation occurs much sooner and is the primary
method of regulation of PPARĮ.
Hepatic mRNA levels of the PPARĮ target genes ACO1 and CPT1 are unchanged at
4 hours of fasting and increased 2-fold and over 4-fold, respectively, after 8 hours of fasting
in mice [53]. Plasma levels of ȕ-hydroxybutyrate, a ketone body formed from fatty acid
oxidation/ketogenesis, start increasing after 12 hours of fasting in humans [54] and sometime
between 6 and 12 hours of fasting in mice (ȕ-hydroxybutyrate levels are unchanged at 6
hours of fasting [55] but 10-fold increased at 12 hours of fasting [56]), consistent with the
time needed for the mRNA to be translated into active proteins promoting ketogenesis. We
can conclude that in mice, PPARĮ is activated sometime within the first 8 hours of fasting,
and its physiological effects become evident within 12 hours of fasting.
The many changes in nutrient and hormone levels that accompany fasting make it

13

difficult to pinpoint which specific stimulus that causes this activation of PPARĮ. During
fasting, plasma insulin and leptin levels as well as plasma glucose progressively drop, while
the levels of plasma free fatty acids and glucagon rise. In mice, insulin levels are down 70%
by six hours of fasting [55]. In humans, insulin levels decrease at a steady rate immediately
from the onset of fasting, decreasing by 30% after 6 hours of fasting and 50% after 12 hours
of fasting [57]. Leptin levels decrease by 50% after 12 hours of fasting in humans [58]; in
mice, leptin levels are start decreasing after 4 hours of fasting and are down by 75% after 12
hours of fasting [59]. Plasma free fatty acids increase progressively from the onset of fasting,
mirroring the decrease in insulin levels, and have increased by 60-70% at 12 hours of fasting
in humans [57] and mice [60]. Glucagon levels are rapidly and dramatically regulated in mice,
being increased 5-fold by 6 hours of fasting [55], but much more slowly in humans, where
glucagon levels are unchanged after 6 hours of fasting and increased 25% by 12 hours of
fasting [57].
In addition, there is species-specific regulation of hormones by fasting. In humans,
growth hormone also starts rising after 12 hours of fasting and stimulates lipolysis [57]; in
mice, however, growth hormone secretion is actually suppressed by fasting and does not
affect lipolysis [59]. Levels of ghrelin, an appetite-stimulating hormone, increase two-fold by
12 hours of fasting in mice [59], but in humans, ghrelin levels actually decrease with fasting
(20% by 12 hours and 30% by 24 hours of fasting) [61]. Catecholamines (i.e. epinephrine and
norepinephrine) and cortisol levels rise and fall cyclically throughout prolonged fasting in
humans with a drop to below fed levels between 15 and 24 hours after fasting onset [57], and
are hence probably not involved in the adaptive responses to typical fasting periods.
Among these stimuli, plasma glucose, insulin, glucagon, leptin, and FFA levels are
the most likely candidates for physiological regulators of the fasting response via PPARĮ, as
they are regulated in the same direction in both mice and humans and because of the time
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course of their increase or decrease in plasma.
The role of plasma glucose is difficult to study as an independent variable, and little
information is available on the effects of glucose deprivation/overload on PPARĮ targets in
liver cell lines. In cultured primary hepatocytes, mRNA expression of Acox1, Cpt1, and Cpt2
were unchanged by incubation with 20 mM glucose for 5 hours compared to 6 ௗmM, but this
may have been too short of an incubation time to see gene expression effects [62].
In mice lacking the liver insulin receptor, plasma ketone levels and expression of the
PPARĮ target gene Cpt1 are twice as high as in wild type mice during ad lib feeding (during
fasting, plasma ketone levels are the same, Cpt1 expression ~75% higher than in controls)
[63], suggesting that hepatic insulin signaling is important for suppression of the fasting
response/PPARĮ activity during feeding.
Fasting induction of some, but not all, PPARĮ target genes is abolished in mice
lacking glucagon receptor, and treatment of hepatocytes with glucagon induces expression of
PPARĮ target genes and fatty acid oxidation, the latter demonstrated to be in a PPARĮdependent manner [64].
Mice lacking leptin (ob/ob) have increased expression of Cpt1 in the ad lib fed state
compared to wild type mice (information is lacking about its fasting induction, however),
[65], but interpretation with regards to any direct role of leptin in promoting the fasting
response is complicated by the obesity and insulin resistance of the ob/ob mice; insulin
resistance would blunt insulin suppression of the fasting response in the fed state, and the
mice have elevated circulating FFAs. Any role of FFAs in activating the fasting response is
difficult to study in vivo due to the lack of any single FFA receptor or transporter that can be
genetically modified, but in vitro, various long-chain fatty acids activate PPARĮ
(demonstrated using a PPRE-containing reporter gene); these experiments were among the
first studies on PPARĮ [66].
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In summary, the interrelationship between circulating nutrients and hormones makes
it difficult to study the effects of a single nutrient or hormone on PPARĮ. However, thanks to
studies on mice lacking liver insulin receptor and on mice lacking (whole-body) glucagon
receptor, we can conclude that hepatic insulin signaling is important for suppressing PPARĮ
activity during feeding, while glucagon signaling is important for induction of PPARĮ
activity during fasting.

Ligand activation of PPARĮ
PPARĮ is primarily ligand-activated. Ligand binding causes it to adopt an active
conformation and heterodimerize with the nuclear receptor retinoid X receptor-alpha (RXRĮ),
allowing the PPARĮ-RXRĮ complex to bind to peroxisome proliferator response elements
(PPREs) on target genes and activate gene transcription [67, 68].
While the fibrate drugs previously described are synthetic agonistic ligands for
PPARĮ, a physiological ligand for PPARĮ was only identified recently [69]: in mouse liver,
the phosphatidylcholine (PC) species 1-palmitoyl-2-oleoyl-sn-glycerol-3-phosphocholine
(16:0/18:1-GPC) acts as an endogenously synthesized PPARĮ ligand [69]. The interaction
between this particular ligand and PPARĮ requires the activity of fatty acid synthase (FAS;
described in more detail below) as well as choline-ethanolamine phosphotransferase-1
(CEPT1), the enzyme catalyzing the final step in PC synthesis [69, 70].
It is not known how the 16:0/18:1-GPC ligand reaches PPARĮ from CEPT1. CEPT1
is localized to the ER and nuclear membranes (the active site facing the cytoplasm) [71],
while PPARĮ is localized to the nucleus [72], precluding a direct interaction between CEPT1
and PPARĮ. Simple diffusion of the ligand is unlikely to be a physiologically relevant
mechanism of transport, as the cytoplasmic movement of amphipathic molecules such as PC
is extremely inefficient [73]. A more likely possibility is that the PC ligand is transported to
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PPARĮ in association with a soluble lipid-binding protein.

FATTY ACID SYNTHASE
Fatty acid synthase (FAS, encoded by Fasn) catalyzes the biosynthesis of saturated
fatty acids from simple precursors (de novo lipogenesis). The primary product of the FAS
reaction is palmitate (C16:0), but stearate (C18:0) and shorter fatty acids may also be
produced. FAS substrates are acetyl-CoA, malonyl-CoA, and NADPH. Acetyl-CoA functions
as a primer for the reaction, while NADPH provides reducing equivalents. The fatty acid is
elongated from the initial acetyl-CoA by repeated condensations with malonyl-CoA, which
donates two carbons in each cycle of condensation. Palmitate synthesis thus requires seven
cycles of malonyl-CoA addition to an acetyl-CoA primer to yield a saturated, 16-carbon fatty
acid.
The FAS protein exists as a homodimer of 273 kDa subunits. Each monomer contains
seven protein domains required for fatty acid synthesis: acyl carrier, acyl transferase, ȕketoacyl synthase, ȕ-ketoacyl reductase, ȕ-hydroxylacyl dehydratase, enoyl reductase, and
thioesterase (reviewed in [74-76]). However, FAS is only enzymatically active in the dimeric
form [77]. The monomers were initially thought to be oriented head-to-tail to form the dimer
[78, 79], but recent structural data demonstrate a head-to-head orientation of the monomers
that are intertwined at their middle to form an X-shape [80-83]. Mammalian FAS is a type I
FAS complex with the domains consolidated in a single peptide; prokaryotes and yeast have a
type II FAS with separate proteins catalyzing the individual reactions. Type II FAS
complexes capable of synthesizing short-chain (up to 14 carbons) fatty acids are also found in
mammalian mitochondria [84].
FAS is a soluble protein and thought to be localized in the cytoplasm, although the
specifics of its subcellular localization are largely unexplored. Its tissue distribution is broad
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with highest levels in the liver, adipose tissue, and lungs [85, 86]. Whole-body knockout of
FAS causes embryonic lethality in mice, suggesting that de novo lipogenesis is necessary
early during development [87]. A likely possibility is that FAS is required to provide lipids
for cell membranes of the growing embryo. Viable tissue-specific FAS knockout mice have
been generated, including a liver-specific knockout (discussed below).

Functions of hepatic FAS: Contribution to stored and secreted lipids
Hepatic FAS synthesizes lipids that are stored as lipid droplets or secreted in VLDL in
the fed state. In mice, the contribution of liver FAS to secreted VLDL is minor. Ob/ob mice
have 10-fold increased hepatic de novo lipogenesis compared to lean mice, but no significant
differences in serum triglycerides [88]. In mice with liver-specific knockout of FAS
(FASKOL mice), serum triglycerides are normal on a chow diet [69].
The contribution of de novo lipogenesis to secreted triglycerides has been studied in
humans in the setting of various diets. On diets low in fat and high in carbohydrate (10% of
calories as fat and 75% as carbohydrate), de novo lipogenesis makes a significant
contribution to circulating lipids as almost half of VLDL triglyceride is derived from de novo
lipogenesis under these conditions [89]. However, a typical Western diet is high in fat as well
as carbohydrates. In similar studies using diets higher in fat (30% fat and 55% carbohydrate
or 40% fat and 45% carbohydrate), the contribution of de novo lipogenesis to VLDL
triglycerides is undetectable or minor, at 0-10% [89, 90]. These diets are more representative
of the high fat, high carbohydrate content of a typical Western diet, indicating that under
common dietary conditions, de novo lipogenesis is not a significant contributor to VLDL
triglycerides. Substituting starch for sugar in a high-carbohydrate diet also decreases the
contribution of de novo lipogenesis to 0-1% or 5% [91, 92]. Obese individuals do not appear
to have increased FAS-derived VLDL triglycerides compared to lean individuals [90]. Under
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the high-fat, high-carbohydrate dietary conditions common in the Western world today,
hepatic FAS thus appears to be a minor contributor to VLDL triglycerides.
FAS may contribute to triglycerides stored in hepatic lipid droplets. In rats fed a chow
diet, 11 ± 1% of hepatic triglycerides are derived from de novo lipogenesis [93]. On a highfat diet, de novo lipogenesis is suppressed and only 1.0 ± 0.2% of hepatic triglycerides are
derived from FAS [93]. FASKOL mice (animals with inactivation of FAS in the liver) on a
chow diet have normal, rather than decreased, liver triglyceride content [69]. It thus appears
that the contribution of de novo lipogenesis to stored triglycerides is small in healthy liver.
In fatty liver, the contribution of FAS to intrahepatic triglycerides may be greater.
Ob/ob mice have increased hepatic FAS activity and fatty liver [94], but a mechanistic link
between the two has not been established. In humans with non-alcoholic fatty liver disease,
one group has reported that 26 ± 7% of hepatic triglycerides are derived from de novo
lipogenesis [95]. It is unknown how this compares to the triglyceride content of healthy
human liver. However, even in the setting of hepatic over-accumulation of fat, the
contribution of FAS appears to be less than that of fats derived from peripheral tissues or
dietary fat.

Functions of hepatic FAS: FAS-dependent ligand activation of PPARĮ
When liver-specific fatty acid synthase knockout (FASKOL) mice were generated,
they were surprisingly not protected against hepatic lipid accumulation, but instead developed
severe hepatic steatosis when on a zero-fat diet or with prolonged fasting [70]. The phenotype
of fasted or zero-fat diet-fed FASKOL mice is similar to that of PPARĮ-null mice:
hypoglycemia, low serum ketone levels, marked hepatic steatosis, and deficient hepatic fatty
acid oxidation [49, 70]. Much of this phenotype was corrected by administration of a known
PPARĮ agonist.
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The deficient PPARĮ activation in the absence of both FAS and dietary fat led to the
hypothesis that “new” fat, derived from de novo lipogenesis or dietary fat, can activate
PPARĮ, whereas “old” fat, derived from peripheral tissues or stored in the liver, cannot.
Hydrolysis of hepatic triglycerides has also been shown to mediate PPARĮ activation [96],
suggesting that triglycerides of different origins (de novo synthesis vs. free fatty acids
entering the liver following lipolysis in peripheral tissues) may occupy separate
compartments in the hepatocyte.
In addition to activating PPARĮ in liver, FAS has been shown to regulate PPARĮ in
macrophages [97] and hypothalamus [98] as well; knock-out of FAS in these tissues leads to
decreased expression of PPARĮ target genes which can be rescued by administration of a
PPARĮ agonist.
Further study of the FASKOL mouse led to the identification of an endogenous ligand
for hepatic PPARĮ: the phosphatidylcholine species 16:0/18:1-glycerophosphocholine [69],
also described above. The interaction of this species with PPARĮ is dependent on the activity
of FAS, and inactivation of choline/ethanolamine phosphotransferase 1 (CEPT1), the enzyme
catalyzing the final step in the Kennedy pathway for phosphatidylcholine biosynthesis,
mimics the FASKOL phenotype [69]. The dependency of PPARĮ activity on FAS is likely
mediated by its provision of substrate for CEPT1, ultimately producing ligand for PPARĮ:
long-chain fatty acids generated by FAS may be converted to acyl-CoA and then
diacylglycerol, which can combine with phosphocholine to form phosphatidylcholine in the
reaction catalyzed by CEPT1.
A summary of the impact of FAS on hepatic triglyceride metabolism is presented in
Figure 1.

Modulating hepatic FAS to treat disease
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Ob/ob mice have increased hepatic FAS gene expression as well as increased hepatic
FAS activity compared to lean mice [94]. Knockdown of the transcription factor
carbohydrate response element binding protein (ChREBP), which promotes the expression of
FAS as well as other genes, in ob/ob liver decreases hepatic lipid accumulation and decreases
hepatic lipogenesis, suggesting a link between de novo lipogenesis by FAS and fatty liver
[99]. However, in a gene expression profiling study of ob/ob animals separated into high
glucose and lower glucose groups, mice with lower sugars (and thus likely to be more insulin
sensitive) had higher hepatic expression levels of genes encoding lipogenic enzymes,
including FAS, as compared to mice with higher sugars [100]. This finding suggests that
while activation of lipogenic enzymes in the liver is associated with obesity, this effect is
unlikely to be mechanistically linked to insulin resistance.
FAS inhibitors have been tested in mouse models of obesity and diabetes. Treatment
of lean or obese mice with the FAS inhibitor C75 causes dramatic weight loss and
improvement of hepatic steatosis in obese mice. However, the effect is primarily mediated by
reduced food intake through inhibition of hypothalamic FAS (in addition to possible effects
of this particular agent that are independent of FAS), obscuring the potential effects of
modulating hepatic FAS [101].
The FAS inhibitor platensimycin is concentrated in the liver when administered orally
and does not affect food intake [102]. Treatment of high-fructose diet-fed db/db mice with
platensimycin reduces hepatic FAS activity, hepatic lipid accumulation, and hepatic fatty acid
oxidation [102]. These data are consistent with roles for hepatic FAS both as a producer of fat
that may accumulate in liver, and as a generator of lipid signals to nuclear receptors such as
PPARĮ.
These data also highlight a caveat when considering FAS inhibitors as therapy for
hepatic steatosis: inhibition of FAS can affect both lipid storage and lipid catabolism, and
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under conditions where baseline FAS activity is not particularly high, loss of FAS activity
might aggravate rather than ameliorate hepatic steatosis, as seen in the liver-specific FAS
knockout mice [70].

Regulation of FAS: Hormonal and nutritional regulation
Hepatic FAS is known to be regulated by insulin, glucagon, cyclic AMP, fructose,
glucose, and dietary fat. The long-term effects of hormones and nutrients on FAS expression
are clear, but their immediate effects are poorly understood.
Re-feeding mice or rats a high-carbohydrate diet following a prolonged fast causes a
robust induction of FAS expression as compared to the fasted or the ad lib-fed state [103106]. The effect of carbohydrate re-feeding is mediated by both insulin and glucose. Insulin
regulates FAS through transcriptional and non-transcriptional mechanisms. Under nutrientreplete conditions, de novo lipogenesis may promote storage of excess energy in the form of
hepatic triglycerides. Insulin promotes FAS expression through activation of the transcription
factors sterol regulatory element binding protein 1c (SREBP-1c) [107] and upstream
stimulatory factors 1 and 2 (USF1 and USF2) [108, 109]. Conversely, glucagon and cyclic
AMP inhibit the increase in FAS activity induced by carbohydrate re-feeding in rats [103,
110, 111].
The effect of fasting compared to ad lib feeding on the activity of hepatic FAS is less
clear. In mice, a 6 hour fast reduces FAS expression levels by 60% compared to ad lib
feeding [105], and in rats, a 24 hour fast reduces FAS expression by over 90% compared to
ad lib feeding [106]. However, a 14-hour fast in mice produces no change in FAS activity
compared to ad lib-fed mice [112]. One potential explanation for the lack of change in FAS
activity in some circumstance could be a relatively long half-life for the FAS protein. It is
possible that changes in FAS gene expression might have little effect on FAS enzyme activity
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in response to certain physiologically relevant periods of fasting as compared to the ad lib fed
condition.
While insulin promotes the expression of FAS, insulin also acutely inhibits the
enzymatic activity of hepatic FAS, causing a decrease in FAS activity within minutes [112].
This inhibition is dependent on the presence of the carcinoembryonic antigen-related cell
adhesion molecule 1 (CEACAM1), which is phosphorylated in response to insulin and
subsequently associates with FAS [112]. The acute inhibition of FAS by insulin is blunted in
hyperinsulinemic ob/ob mice [112]. While a clear physiological role for this acute inhibition
of FAS activity has not been determined, it is possible that the acute effect on FAS by insulin
primarily affects FAS lipid signals that impact PPARĮ. Acute inhibition of FAS in response
to insulin could then serve to halt the fasting response by PPARĮ and decrease fatty acid
oxidation when nutrients are abundant. Because the specific activity of FAS is affected, the
effect is likely post-translationally mediated. In contrast, the long-term effect of insulin on
FAS is transcriptionally mediated and promotes FAS expression, enabling increased storage
of energy as fat.
Carbohydrates directly promote the expression of hepatic FAS in the liver in addition
to having an indirect effect by stimulating insulin secretion. Feeding mice a high-glucose or
high-fructose diet for one week leads to 3-fold and 8-fold, respectively, increases in FAS
protein [113]. The effect of glucose on FAS expression is mediated by ChREBP [114-117].
Hepatic metabolism of glucose by glucokinase (GK) is necessary for the glucose-mediated
induction of FAS by ChREBP [118]. The insulin-induced activation of SREBP-1c and the
glucose-induced activation of ChREBP act synergistically to promote FAS expression [118].
A connection between lipid/carbohydrate sensing and metabolism is suggested by the finding
that stearoyl-CoA desaturase (Scd1), an enzyme catalyzing the synthesis of oleate, is
involved in the carbohydrate-induced induction of FAS and other lipogenic enzymes [113].
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Dietary fats inhibit FAS expression to decrease de novo lipogenesis when fats are
already abundant. Polyunsaturated fatty acids (PUFAs) may decrease FAS expression
through inhibition of SREBP-1c [119] and ChREBP [120] activity. Diets consisting of 10%
oil inhibit hepatic FAS activity when fed to rats of over the course of 4 weeks, with the
greatest reduction in rats fed fish oil [121]. Re-feeding rats a carbohydrate-free, high-fat diet
following fasting suppresses FAS gene expression to levels as low as those seen in rats fasted
for 24 hours [106].

Regulation of FAS: Transcription and the FAS promoter
Transcriptional regulation of FAS has been well characterized. Much of the work on
transcriptional regulation of FAS has been done in rats, but the FAS promoter is highly
conserved between species suggesting that studies of the rat FAS promoter are likely to be
relevant to mice and humans. Regulatory elements and transcription factor binding sites in
the proximal mouse FAS promoter are shown in Figure 2.
As noted above, SREBP-1c is activated by insulin and under appropriate conditions
promotes expression of lipogenic genes, including FAS. The FAS promoter contains a sterol
regulatory element (SRE) at -150 as well as tandem SREs at positions -72 and -62 that are
required for optimal SREBP-1c-mediated activation of FAS expression in rats [122-124].
An inverted CCAAT box at -94 is a binding site for nuclear factor Y (NF-Y) and is
necessary for inhibition of FAS expression by cyclic AMP [125, 126]. A binding site for the
transcription factor specificity factor 1 (Sp1) is located nearby at -91 [124]. NF-Y and Sp1
proteins interact [127] and mediate sterol-induced FAS expression synergistically with
SREBP-1c [124, 128]. Another transcription factor, X-box binding protein 1 (XBP1),
increases FAS promoter activity indirectly via SREBP-1c [129].
Also as noted above, ChREBP plays a central role in the glucose-induced
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transcriptional regulation of FAS as well as other lipogenic and glycolytic genes in the liver
[114-117]. Glucose promotes the nuclear translocation and activation of ChREBP, while
polyunsaturated fatty acids and cyclic AMP inhibit ChREBP activity [120, 130]. ChREBP
binds to a carbohydrate response element (ChRE) located at -7214 in the distal FAS promoter
in rats to activate FAS transcription [131]. ChREBP appears to be the main regulator of
glucose-induced FAS expression, as glucose fails to induce an increase in FAS expression in
ChREBP-null hepatocytes [114]. Mice fed a high-fructose diet have similar amounts of
nuclear ChREBP protein and ChRE-bound ChREBP protein compared to mice fed a highglucose diet, suggesting that dietary fructose and glucose have comparable effects on
ChREBP [132].
In addition to the ChRE, a direct repeat-1 (DR-1) element located between -7110 and
-7090 in the distal promoter of rat FAS is necessary for full glucose activation of FAS
expression [133]. Hepatic nuclear factor-4Į (HNF-4Į) binds to the DR-1 element and
interacts with ChREBP. Ablation of HNF-4Į produces a corresponding decrease in glucoseinduced FAS expression [133].
Liver X receptor (LXR), a transcription factor activated by oxysterols, upregulates
FAS expression through direct and indirect mechanisms. Indirectly, LXR can promote FAS
expression by binding to liver X receptor elements (LXREs) in the promoters of the SREBP
[134] and ChREBP [135] genes to promote their transcription. SREBP and ChREBP in turn
activate FAS transcription. The LXR-mediated activation of SREBP-1c is the primary
mechanism of insulin-induced SREBP activation [134]. The physiological relevance of LXRmediated transcriptional regulation of ChREBP is debated, as LXR is not necessary for the
glucose-induced activation of ChREBP [117]. LXR can also bind directly to LXREs located
at positions -686 to -672 of the mouse FAS promoter to activate FAS transcription [136].
An insulin response element (IRE) containing an E-box DNA binding motif is located
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at positions -71 to -50 of the FAS promoter, overlapping two tandem SREs. The IRE is
necessary for insulin-induced FAS expression [137]. USF1 and USF2 bind to the IRE [109].
Mutation of the E-box prevents USF binding and abolishes insulin-induced FAS expression.
However, the importance of USFs in insulin-stimulated FAS expression remains unclear,
because mutation of the E-box also prevented SREBP-1c binding [108].

Regulation of FAS: Post-translational regulation
While its transcriptional regulation has been well characterized, little has been known
about post-translational regulation of FAS activity.
Transcriptional regulation of FAS may require hours to affect protein levels since
both FAS mRNA and protein are fairly stable, buffering sudden changes due to increased
transcription and subsequent translation. There are several reports of FAS protein being
activated or inhibited in far shorter time frames, as well as reports of changes in FAS activity
that do not correlate with changes in FAS protein levels.
Insulin acutely decreases FAS enzyme activity. In hepatoma cells, FAS activity
decreases linearly from 2 to 15 minutes after insulin treatment, followed by an increase in
FAS activity for 75 minutes [112]. Peroxynitrate inhibits FAS activity in adipocytes within
10 minutes, without any effect on FAS protein levels [138]. Activation and inhibition of FAS
without corresponding changes in FAS protein levels have been reported in a variety of
cancer cell lines [139-141]. These data suggest the presence of post-translational regulation
of FAS.
Phosphorylation has been proposed as a mechanism of FAS regulation in cancer cells,
adipocytes, and liver. In livers from pigeons that were fasted and then re-fed, radiolabeled
phosphate was incorporated into FAS only in the cytosolic fraction of the liver (the
membrane fraction was not studied). The phosphorylation event was associated with low
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FAS activity, and dephosphorylation of FAS by incubation with phosphatases caused a 20fold increase in FAS activity [142]. Another inhibitory phosphorylation was demonstrated in
3T3L1 adipocytes, where FAS threonine phosphorylation was associated with inhibition of
FAS activity [138]. This phosphorylation event was shown to require AMP-activated kinase
(AMPK), likely through indirect effects since in vitro kinase assays failed to demonstrate any
incorporation of labeled phosphate into FAS in the presence of AMPK [138]. These findings
suggest the presence of an unidentified intermediate kinase step.
In human and mouse breast cancer cell lines, the finding that large differences in FAS
activity between cell lines did not correlate with FAS protein levels prompted an exploration
of FAS phosphorylation as an alternative mechanism of FAS regulation [140]. Phosphoserine
and phosphothreonine residues were detected in FAS in cell lines from both species, while
FAS phosphotyrosine residues were detected in human cells only. Phosphorylation of FAS in
these cell lines was associated with greater FAS activity [140]. Recently, tyrosine
phosphorylation of FAS was noted in two different human breast cancer cell lines. Both FAS
tyrosine phosphorylation and FAS activity were induced by overexpression of human
epidermal growth factor receptor 2 (HER2) and decreased by HER2 inhibition, and FAS was
phosphorylated when complexed with HER2 [141].
In addition to phosphorylation, FAS was one of a large number of hepatic metabolic
enzymes recently found to be lysine acetylated [143]. Acetylation was linked with diverse
effects on metabolic enzymes, including protein destabilization, activation, and inhibition,
suggesting that acetylation may play a major role in metabolic regulation. Acetylation of FAS
could represent a novel mechanism for controlling its activity.
Known examples of post-translational regulation of FAS are summarized in Table 1.

CONCLUSIONS AND DISSERTATION OBJECTIVES
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A physiological ligand for hepatic PPARĮ was identified in 16:0/18:1glycerophosphocholine, but is not known how activation of PPARĮ by this ligand is
regulated—by synthesis, delivery, or breakdown—such that PPARĮ is activated within the
first few hours of food withdrawal and inactivated as soon as nutrients and insulin become
abundant again. The role of FAS in synthesizing this ligand does little to aid our
understanding. FAS is thought to be primarily regulated transcriptionally and to be activated
after feeding. With the long half-life of the FAS protein, transcriptional regulation of FAS
would be irrelevant for the time frame of fasting-induced changes. The postprandial
activation of FAS is paradoxical—how can FAS be necessary for endogenous activation of
the fasting response, when lipogenesis by FAS supposedly occurs after re-feeding?
Regulation of ligand synthesis aside, how the poorly soluble 16:0/18:1glycerophosphocholine ligand would reach PPARĮ in the nucleus from its site of synthesis on
the cytoplasmic side of the ER and nuclear membranes is also unknown. The regulation of
ligand transport could be another node of regulation of PPARĮ in response to nutrient
availability or insulin/glucagon action.
The objective of the research presented in this dissertation is to define the regulation
of ligand-based PPARĮ activation in the liver. I have focused on two nodes of regulation: that
of ligand synthesis by FAS, and that of ligand delivery by a lipid-binding protein. Here, I
present research demonstrating subcellular compartmentalization of FAS protein for different
physiological functions; post-translational regulation of FAS in the form of compartmentspecific inhibitory phosphorylations of a FAS active site in response to insulin or feeding;
and nucleo-cytoplasmic transport of endogenously synthesized PPARĮ ligand by
phosphatidylcholine transfer protein (PCTP).
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FIGURES

Figure 1. The role of FAS in hepatic lipid metabolism. Fatty acid synthase controls fatty
acid catabolism through the synthesis of a ligand for PPARĮ, which activates fatty acid
oxidation genes. FAS makes a minor contribution of lipids to stored and secreted
triglycerides, with the major contributions coming from plasma free fatty acids and dietary
fats from chylomicron remnants. Abbreviations: 16:0/18:1 GPC, 16:0/18:1glycerophosphocholine; DAG, diacylglycerol; FAS, fatty acid synthase; FFA, free fatty acid;
PPARĮ, peroxisome proliferator-activated receptor alpha; RXR, retinoid X receptor; TAG,
triacylglycerol (triglyceride); VLDL, very low-density lipoprotein.
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Figure 2. The mouse proximal FAS promoter. Regulatory elements and nuclear factor
binding site nucleotides are highlighted in yellow. IRE, insulin response element; LXRE,
liver X receptor element; Nf-Y, nuclear factor Y binding site; Sp1, specificity factor 1
binding site; SRE, sterol regulatory element.
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TABLES
Type of post-translational
modification
Phosphorylation [142]
Threonine phosphorylation
[138]
Threonine and serine
phosphorylation [140]
Tyrosine phosphorylation [140,
141]
Acetylation [143]

Organism and tissue or cell type

Function

Pigeon liver
3T3-L1 adipocytes (mouse)

FAS inhibition
FAS inhibition

NMuMG (mouse mammary epithelial
cells), T1 (mouse mammary tumor
cells), SKBr3 (human breast
carcinoma cells)
SKBr3 (human breast carcinoma
cells)
Human liver

Unknown,
possibly FAS
activation

Table 1. Post-translational modifications of FAS.
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FAS activation
Unknown

REFERENCES
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.

11.
12.
13.
14.
15.
16.
17.
18.

Soeters, M.R., et al., Adaptive reciprocity of lipid and glucose metabolism in human
short-term starvation. Am J Physiol Endocrinol Metab, 2012. 303(12): p. E1397-407.
Liu, G.L., L.M. Fan, and R.N. Redinger, The association of hepatic apoprotein and
lipid metabolism in hamsters and rats. Comp Biochem Physiol A Comp Physiol,
1991. 99(1-2): p. 223-8.
Reaves, S.K., et al., Regulation of intestinal apolipoprotein B mRNA editing levels by
a zinc-deficient diet and cDNA cloning of editing protein in hamsters. J Nutr, 2000.
130(9): p. 2166-73.
Ducharme, N.A. and P.E. Bickel, Lipid droplets in lipogenesis and lipolysis.
Endocrinology, 2008. 149(3): p. 942-9.
Farese, R.V., Jr. and T.C. Walther, Lipid droplets finally get a little R-E-S-P-E-C-T.
Cell, 2009. 139(5): p. 855-60.
Francone, O.L., A.D. Kalopissis, and G. Griffaton, Contribution of cytoplasmic
storage triacylglycerol to VLDL-triacylglycerol in isolated rat hepatocytes. Biochim
Biophys Acta, 1989. 1002(1): p. 28-36.
Wiggins, D. and G.F. Gibbons, The lipolysis/esterification cycle of hepatic
triacylglycerol. Its role in the secretion of very-low-density lipoprotein and its
response to hormones and sulphonylureas. Biochem J, 1992. 284 ( Pt 2): p. 457-62.
Bar-On, H., et al., Contribution of floating fat triglyceride and of lecithin towards
formation of secretory triglyceride in perfused rat liver. Biochim Biophys Acta, 1971.
248(1): p. 1-11.
Lankester, D.L., A.M. Brown, and V.A. Zammit, Use of cytosolic triacylglycerol
hydrolysis products and of exogenous fatty acid for the synthesis of triacylglycerol
secreted by cultured rat hepatocytes. J Lipid Res, 1998. 39(9): p. 1889-95.
Pan, M., et al., The late addition of core lipids to nascent apolipoprotein B100,
resulting in the assembly and secretion of triglyceride-rich lipoproteins, is
independent of both microsomal triglyceride transfer protein activity and new
triglyceride synthesis. J Biol Chem, 2002. 277(6): p. 4413-21.
Cowie, C.C., et al., Full accounting of diabetes and pre-diabetes in the U.S.
population in 1988-1994 and 2005-2006. Diabetes Care, 2009. 32(2): p. 287-94.
Shaw, J.E., R.A. Sicree, and P.Z. Zimmet, Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010. 87(1): p. 4-14.
Ford, E.S., W.H. Giles, and W.H. Dietz, Prevalence of the metabolic syndrome
among US adults: findings from the third National Health and Nutrition Examination
Survey. JAMA, 2002. 287(3): p. 356-9.
Isomaa, B., et al., Cardiovascular morbidity and mortality associated with the
metabolic syndrome. Diabetes Care, 2001. 24(4): p. 683-9.
Kannel, W.B. and D.L. McGee, Diabetes and cardiovascular risk factors: the
Framingham study. Circulation, 1979. 59(1): p. 8-13.
Lozano, R., et al., Global and regional mortality from 235 causes of death for 20 age
groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet, 2012. 380(9859): p. 2095-128.
Balkau, B., et al., Proposed criteria for the diagnosis of diabetes: evidence from a
French epidemiological study (D.E.S.I.R.). Diabetes Metab, 1997. 23(5): p. 428-34.
Charles, M.A., et al., Revision of diagnostic criteria for diabetes. Lancet, 1996.
348(9042): p. 1657-8.

32

19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.

38.

Lazo, M., et al., Prevalence of Nonalcoholic Fatty Liver Disease in the United States:
The Third National Health and Nutrition Examination Survey, 1988-1994. Am J
Epidemiol, 2013.
Browning, J.D., et al., Prevalence of hepatic steatosis in an urban population in the
United States: impact of ethnicity. Hepatology, 2004. 40(6): p. 1387-95.
Marchesini, G., et al., Association of nonalcoholic fatty liver disease with insulin
resistance. Am J Med, 1999. 107(5): p. 450-5.
Argo, C.K. and S.H. Caldwell, Epidemiology and natural history of non-alcoholic
steatohepatitis. Clin Liver Dis, 2009. 13(4): p. 511-31.
Greten, T.F., et al., Survival rate in patients with hepatocellular carcinoma: a
retrospective analysis of 389 patients. Br J Cancer, 2005. 92(10): p. 1862-8.
Musso, G., et al., A meta-analysis of randomized trials for the treatment of
nonalcoholic fatty liver disease. Hepatology, 2010. 52(1): p. 79-104.
Shyangdan, D., et al., Insulin sensitisers in the treatment of non-alcoholic fatty liver
disease: a systematic review. Health Technol Assess, 2011. 15(38): p. 1-110.
Cohen, J.C., J.D. Horton, and H.H. Hobbs, Human fatty liver disease: old questions
and new insights. Science, 2011. 332(6037): p. 1519-23.
Sun, Z. and M.A. Lazar, Dissociating fatty liver and diabetes. Trends Endocrinol
Metab, 2013. 24(1): p. 4-12.
Chahil, T.J. and H.N. Ginsberg, Diabetic dyslipidemia. Endocrinol Metab Clin North
Am, 2006. 35(3): p. 491-510, vii-viii.
Curtin, A., et al., Alterations in apolipoprotein B-48 in the postprandial state in
NIDDM. Diabetologia, 1994. 37(12): p. 1259-64.
Rivellese, A.A., et al., Exogenous and endogenous postprandial lipid abnormalities in
type 2 diabetic patients with optimal blood glucose control and optimal fasting
triglyceride levels. J Clin Endocrinol Metab, 2004. 89(5): p. 2153-9.
Duez, H., et al., Hyperinsulinemia is associated with increased production rate of
intestinal apolipoprotein B-48-containing lipoproteins in humans. Arterioscler
Thromb Vasc Biol, 2006. 26(6): p. 1357-63.
Hogue, J.C., et al., Evidence of increased secretion of apolipoprotein B-48-containing
lipoproteins in subjects with type 2 diabetes. J Lipid Res, 2007. 48(6): p. 1336-42.
Mamo, J.C., et al., Postprandial dyslipidemia in men with visceral obesity: an effect
of reduced LDL receptor expression? Am J Physiol Endocrinol Metab, 2001. 281(3):
p. E626-32.
Morrish, N.J., et al., Mortality and causes of death in the WHO Multinational Study of
Vascular Disease in Diabetes. Diabetologia, 2001. 44 Suppl 2: p. S14-21.
Adiels, M., et al., Overproduction of very low-density lipoproteins is the hallmark of
the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol, 2008.
28(7): p. 1225-36.
Chan, D.C., et al., Nonalcoholic fatty liver disease as the transducer of hepatic
oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity.
Arterioscler Thromb Vasc Biol, 2010. 30(5): p. 1043-50.
Brinton, E.A., S. Eisenberg, and J.L. Breslow, Human HDL cholesterol levels are
determined by apoA-I fractional catabolic rate, which correlates inversely with
estimates of HDL particle size. Effects of gender, hepatic and lipoprotein lipases,
triglyceride and insulin levels, and body fat distribution. Arterioscler Thromb, 1994.
14(5): p. 707-20.
Brinton, E.A., S. Eisenberg, and J.L. Breslow, Increased apo A-I and apo A-II
fractional catabolic rate in patients with low high density lipoprotein-cholesterol
levels with or without hypertriglyceridemia. J Clin Invest, 1991. 87(2): p. 536-44.
33

39.
40.
41.
42.
43.
44.
45.
46.
47.

48.
49.

50.
51.
52.
53.
54.
55.
56.

Foger, B., et al., Relationship of plasma cholesteryl ester transfer protein to HDL
cholesterol. Studies in normotriglyceridemia and moderate hypertriglyceridemia.
Arterioscler Thromb Vasc Biol, 1996. 16(12): p. 1430-6.
Mann, C.J., et al., Mechanism of plasma cholesteryl ester transfer in
hypertriglyceridemia. J Clin Invest, 1991. 88(6): p. 2059-66.
Biddinger, S.B., et al., Hepatic insulin resistance is sufficient to produce dyslipidemia
and susceptibility to atherosclerosis. Cell Metab, 2008. 7(2): p. 125-34.
Duval, C., M. Muller, and S. Kersten, PPARalpha and dyslipidemia. Biochim
Biophys Acta, 2007. 1771(8): p. 961-71.
Watts, G.F., et al., Differential regulation of lipoprotein kinetics by atorvastatin and
fenofibrate in subjects with the metabolic syndrome. Diabetes, 2003. 52(3): p. 803-11.
Oosterveer, M.H., et al., Fenofibrate simultaneously induces hepatic fatty acid
oxidation, synthesis, and elongation in mice. J Biol Chem, 2009. 284(49): p. 3403644.
Henninger, C., et al., Effects of fenofibrate treatment on fatty acid oxidation in liver
mitochondria of obese Zucker rats. Biochem Pharmacol, 1987. 36(19): p. 3231-6.
Staels, B., et al., Mechanism of action of fibrates on lipid and lipoprotein metabolism.
Circulation, 1998. 98(19): p. 2088-93.
Bard, J.M., et al., A multicenter comparison of the effects of simvastatin and
fenofibrate therapy in severe primary hypercholesterolemia, with particular emphasis
on lipoproteins defined by their apolipoprotein composition. Metabolism, 1992.
41(5): p. 498-503.
Kersten, S., et al., Peroxisome proliferator-activated receptor alpha mediates the
adaptive response to fasting. J Clin Invest, 1999. 103(11): p. 1489-98.
Leone, T.C., C.J. Weinheimer, and D.P. Kelly, A critical role for the peroxisome
proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response:
the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl
Acad Sci U S A, 1999. 96(13): p. 7473-8.
Rakhshandehroo, M., et al., Peroxisome proliferator-activated receptor alpha target
genes. PPAR Res, 2010. 2010.
Danis, M., et al., Role of reducing equivalents from fatty acid oxidation in mixedfunction oxidation: studies with 2-bromooctanoate in the perfused rat liver. J
Pharmacol Exp Ther, 1981. 219(2): p. 383-8.
Xu, J., et al., Peroxisome proliferator-activated receptor alpha (PPARalpha)
influences substrate utilization for hepatic glucose production. J Biol Chem, 2002.
277(52): p. 50237-44.
Palou, M., et al., Sequential changes in the expression of genes involved in lipid
metabolism in adipose tissue and liver in response to fasting. Pflugers Arch, 2008.
456(5): p. 825-36.
Rasmussen, M., et al., Elevated beta2-adrenoceptor protein concentration in adipose
tissue from obese subjects is closely related to the body mass index and waist/hip
ratio. Clin Sci (Lond), 2003. 104(2): p. 93-102.
Mutel, E., et al., Control of blood glucose in the absence of hepatic glucose
production during prolonged fasting in mice: induction of renal and intestinal
gluconeogenesis by glucagon. Diabetes, 2011. 60(12): p. 3121-31.
Laskewitz, A.J., et al., Chronic prednisolone treatment reduces hepatic insulin
sensitivity while perturbing the fed-to-fasting transition in mice. Endocrinology, 2010.
151(5): p. 2171-8.

34

57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.
69.
70.
71.
72.
73.
74.
75.
76.

Hojlund, K., et al., Reference intervals for glucose, beta-cell polypeptides, and
counterregulatory factors during prolonged fasting. Am J Physiol Endocrinol Metab,
2001. 280(1): p. E50-8.
Boden, G., et al., Effect of fasting on serum leptin in normal human subjects. J Clin
Endocrinol Metab, 1996. 81(9): p. 3419-23.
Steyn, F.J., et al., GH does not modulate the early fasting-induced release of free fatty
acids in mice. Endocrinology, 2012. 153(1): p. 273-82.
Bergman, B.C., et al., Fasting decreases free fatty acid turnover in mice
overexpressing skeletal muscle lipoprotein lipase. Metabolism, 2006. 55(11): p. 14817.
Natalucci, G., et al., Spontaneous 24-h ghrelin secretion pattern in fasting subjects:
maintenance of a meal-related pattern. Eur J Endocrinol, 2005. 152(6): p. 845-50.
Huang, H., et al., Inhibitors of Fatty Acid Synthesis Induce PPAR alpha -Regulated
Fatty Acid beta -Oxidative Genes: Synergistic Roles of L-FABP and Glucose. PPAR
Res, 2013. 2013: p. 865604.
Haas, J.T., et al., Hepatic insulin signaling is required for obesity-dependent
expression of SREBP-1c mRNA but not for feeding-dependent expression. Cell Metab,
2012. 15(6): p. 873-84.
Longuet, C., et al., The glucagon receptor is required for the adaptive metabolic
response to fasting. Cell Metab, 2008. 8(5): p. 359-71.
Perfield, J.W., 2nd, et al., Altered hepatic lipid metabolism contributes to
nonalcoholic fatty liver disease in leptin-deficient Ob/Ob mice. J Obes, 2013. 2013: p.
296537.
Issemann, I., et al., The peroxisome proliferator-activated receptor:retinoid X
receptor heterodimer is activated by fatty acids and fibrate hypolipidaemic drugs. J
Mol Endocrinol, 1993. 11(1): p. 37-47.
Kliewer, S.A., et al., Convergence of 9-cis retinoic acid and peroxisome proliferator
signalling pathways through heterodimer formation of their receptors. Nature, 1992.
358(6389): p. 771-4.
Palmer, C.N., et al., Novel sequence determinants in peroxisome proliferator
signaling. J Biol Chem, 1995. 270(27): p. 16114-21.
Chakravarthy, M.V., et al., Identification of a physiologically relevant endogenous
ligand for PPARalpha in liver. Cell, 2009. 138(3): p. 476-88.
Chakravarthy, M.V., et al., "New" hepatic fat activates PPARalpha to maintain
glucose, lipid, and cholesterol homeostasis. Cell Metab, 2005. 1(5): p. 309-22.
Henneberry, A.L., M.M. Wright, and C.R. McMaster, The major sites of cellular
phospholipid synthesis and molecular determinants of Fatty Acid and lipid head
group specificity. Mol Biol Cell, 2002. 13(9): p. 3148-61.
Dreyer, C., et al., Positive regulation of the peroxisomal beta-oxidation pathway by
fatty acids through activation of peroxisome proliferator-activated receptors (PPAR).
Biol Cell, 1993. 77(1): p. 67-76.
Weisiger, R.A., When is a carrier not a membrane carrier? The cytoplasmic transport
of amphipathic molecules. Hepatology, 1996. 24(5): p. 1288-95.
Wakil, S.J., Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry,
1989. 28(11): p. 4523-30.
Chirala, S.S. and S.J. Wakil, Structure and function of animal fatty acid synthase.
Lipids, 2004. 39(11): p. 1045-53.
Smith, S., The animal fatty acid synthase: one gene, one polypeptide, seven enzymes.
FASEB J, 1994. 8(15): p. 1248-59.

35

77.
78.
79.
80.
81.
82.
83.
84.
85.
86.
87.
88.
89.
90.
91.
92.
93.
94.

95.
96.

Stoops, J.K., et al., Physicochemical studies of the rat liver and adipose fatty acid
synthetases. J Biol Chem, 1979. 254(15): p. 7418-26.
Stoops, J.K. and S.J. Wakil, Animal fatty acid synthetase. A novel arrangement of the
beta-ketoacyl synthetase sites comprising domains of the two subunits. J Biol Chem,
1981. 256(10): p. 5128-33.
Stoops, J.K., et al., Small-angle neutron-scattering and electron microscope studies of
the chicken liver fatty acid synthase. J Biol Chem, 1987. 262(21): p. 10246-51.
Maier, T., S. Jenni, and N. Ban, Architecture of mammalian fatty acid synthase at 4.5
A resolution. Science, 2006. 311(5765): p. 1258-62.
Maier, T., M. Leibundgut, and N. Ban, The crystal structure of a mammalian fatty
acid synthase. Science, 2008. 321(5894): p. 1315-22.
Asturias, F.J., et al., Structure and molecular organization of mammalian fatty acid
synthase. Nat Struct Mol Biol, 2005. 12(3): p. 225-32.
Witkowski, A., et al., Head-to-head coiled arrangement of the subunits of the animal
fatty acid synthase. Chem Biol, 2004. 11(12): p. 1667-76.
Witkowski, A., A.K. Joshi, and S. Smith, Coupling of the de novo fatty acid
biosynthesis and lipoylation pathways in mammalian mitochondria. J Biol Chem,
2007. 282(19): p. 14178-85.
Semenkovich, C.F., T. Coleman, and F.T. Fiedorek, Jr., Human fatty acid synthase
mRNA: tissue distribution, genetic mapping, and kinetics of decay after glucose
deprivation. J Lipid Res, 1995. 36(7): p. 1507-21.
Jayakumar, A., et al., Human fatty acid synthase: properties and molecular cloning.
Proc Natl Acad Sci U S A, 1995. 92(19): p. 8695-9.
Chirala, S.S., et al., Fatty acid synthesis is essential in embryonic development: fatty
acid synthase null mutants and most of the heterozygotes die in utero. Proc Natl Acad
Sci U S A, 2003. 100(11): p. 6358-63.
Wiegman, C.H., et al., Hepatic VLDL production in ob/ob mice is not stimulated by
massive de novo lipogenesis but is less sensitive to the suppressive effects of insulin.
Diabetes, 2003. 52(5): p. 1081-9.
Hudgins, L.C., et al., Human fatty acid synthesis is stimulated by a eucaloric low fat,
high carbohydrate diet. J Clin Invest, 1996. 97(9): p. 2081-91.
Hudgins, L.C., et al., Relationship between carbohydrate-induced
hypertriglyceridemia and fatty acid synthesis in lean and obese subjects. J Lipid Res,
2000. 41(4): p. 595-604.
Hudgins, L.C., et al., Human fatty acid synthesis is reduced after the substitution of
dietary starch for sugar. Am J Clin Nutr, 1998. 67(4): p. 631-9.
Parks, E.J., et al., Effects of a low-fat, high-carbohydrate diet on VLDL-triglyceride
assembly, production, and clearance. J Clin Invest, 1999. 104(8): p. 1087-96.
Delgado, T.C., et al., Sources of hepatic triglyceride accumulation during high-fat
feeding in the healthy rat. NMR Biomed, 2009. 22(3): p. 310-7.
Iizuka, K., B. Miller, and K. Uyeda, Deficiency of carbohydrate-activated
transcription factor ChREBP prevents obesity and improves plasma glucose control
in leptin-deficient (ob/ob) mice. Am J Physiol Endocrinol Metab, 2006. 291(2): p.
E358-64.
Donnelly, K.L., et al., Sources of fatty acids stored in liver and secreted via
lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest, 2005.
115(5): p. 1343-51.
Sapiro, J.M., et al., Hepatic triacylglycerol hydrolysis regulates peroxisome
proliferator-activated receptor alpha activity. J Lipid Res, 2009. 50(8): p. 1621-9.

36

97.
98.
99.
100.
101.
102.
103.
104.
105.
106.
107.
108.
109.
110.
111.
112.
113.

114.
115.

Schneider, J.G., et al., Macrophage fatty-acid synthase deficiency decreases dietinduced atherosclerosis. J Biol Chem, 2010. 285(30): p. 23398-409.
Chakravarthy, M.V., et al., Brain fatty acid synthase activates PPARalpha to maintain
energy homeostasis. J Clin Invest, 2007. 117(9): p. 2539-52.
Dentin, R., et al., Liver-specific inhibition of ChREBP improves hepatic steatosis and
insulin resistance in ob/ob mice. Diabetes, 2006. 55(8): p. 2159-70.
Lan, H., et al., Gene expression profiles of nondiabetic and diabetic obese mice
suggest a role of hepatic lipogenic capacity in diabetes susceptibility. Diabetes, 2003.
52(3): p. 688-700.
Loftus, T.M., et al., Reduced food intake and body weight in mice treated with fatty
acid synthase inhibitors. Science, 2000. 288(5475): p. 2379-81.
Wu, M., et al., Antidiabetic and antisteatotic effects of the selective fatty acid synthase
(FAS) inhibitor platensimycin in mouse models of diabetes. Proc Natl Acad Sci U S A,
2011. 108(13): p. 5378-83.
Nepokroeff, C.M., et al., Coordinate control of rat liver lipogenic enzymes by insulin.
Arch Biochem Biophys, 1974. 162(2): p. 340-4.
Clarke, S.D., M.K. Armstrong, and D.B. Jump, Nutritional control of rat liver fatty
acid synthase and S14 mRNA abundance. J Nutr, 1990. 120(2): p. 218-24.
Horton, J.D., et al., Regulation of sterol regulatory element binding proteins in livers
of fasted and refed mice. Proc Natl Acad Sci U S A, 1998. 95(11): p. 5987-92.
Sanchez, J., A. Palou, and C. Pico, Response to carbohydrate and fat refeeding in the
expression of genes involved in nutrient partitioning and metabolism: striking effects
on fibroblast growth factor-21 induction. Endocrinology, 2009. 150(12): p. 5341-50.
Foretz, M., et al., Sterol regulatory element binding protein-1c is a major mediator of
insulin action on the hepatic expression of glucokinase and lipogenesis-related genes.
Proc Natl Acad Sci U S A, 1999. 96(22): p. 12737-42.
Wang, D. and H.S. Sul, Upstream stimulatory factor binding to the E-box at -65 is
required for insulin regulation of the fatty acid synthase promoter. J Biol Chem, 1997.
272(42): p. 26367-74.
Wang, D. and H.S. Sul, Upstream stimulatory factors bind to insulin response
sequence of the fatty acid synthase promoter. USF1 is regulated. J Biol Chem, 1995.
270(48): p. 28716-22.
Lakshmanan, M.R., C.M. Nepokroeff, and J.W. Porter, Control of the synthesis of
fatty-acid synthetase in rat liver by insulin, glucagon, and adenosine 3':5' cyclic
monophosphate. Proc Natl Acad Sci U S A, 1972. 69(12): p. 3516-9.
Paulauskis, J.D. and H.S. Sul, Hormonal regulation of mouse fatty acid synthase gene
transcription in liver. J Biol Chem, 1989. 264(1): p. 574-7.
Najjar, S.M., et al., Insulin acutely decreases hepatic fatty acid synthase activity. Cell
Metab, 2005. 2(1): p. 43-53.
Miyazaki, M., et al., Stearoyl-CoA desaturase 1 gene expression is necessary for
fructose-mediated induction of lipogenic gene expression by sterol regulatory
element-binding protein-1c-dependent and -independent mechanisms. J Biol Chem,
2004. 279(24): p. 25164-71.
Ishii, S., et al., Carbohydrate response element binding protein directly promotes
lipogenic enzyme gene transcription. Proc Natl Acad Sci U S A, 2004. 101(44): p.
15597-602.
Yamashita, H., et al., A glucose-responsive transcription factor that regulates
carbohydrate metabolism in the liver. Proc Natl Acad Sci U S A, 2001. 98(16): p.
9116-21.

37

116.
117.
118.
119.
120.
121.
122.
123.

124.
125.
126.
127.
128.
129.
130.
131.
132.

Ma, L., L.N. Robinson, and H.C. Towle, ChREBP*Mlx is the principal mediator of
glucose-induced gene expression in the liver. J Biol Chem, 2006. 281(39): p. 2872130.
Denechaud, P.D., et al., ChREBP, but not LXRs, is required for the induction of
glucose-regulated genes in mouse liver. J Clin Invest, 2008. 118(3): p. 956-64.
Dentin, R., et al., Hepatic glucokinase is required for the synergistic action of
ChREBP and SREBP-1c on glycolytic and lipogenic gene expression. J Biol Chem,
2004. 279(19): p. 20314-26.
Moon, Y.S., et al., Suppression of fatty acid synthase promoter by polyunsaturated
fatty acids. J Lipid Res, 2002. 43(5): p. 691-8.
Dentin, R., et al., Polyunsaturated fatty acids suppress glycolytic and lipogenic genes
through the inhibition of ChREBP nuclear protein translocation. J Clin Invest, 2005.
115(10): p. 2843-54.
Kim, H.K., S. Choi, and H. Choi, Suppression of hepatic fatty acid synthase by
feeding alpha-linolenic acid rich perilla oil lowers plasma triacylglycerol level in rats.
J Nutr Biochem, 2004. 15(8): p. 485-92.
Magana, M.M. and T.F. Osborne, Two tandem binding sites for sterol regulatory
element binding proteins are required for sterol regulation of fatty-acid synthase
promoter. J Biol Chem, 1996. 271(51): p. 32689-94.
Latasa, M.J., et al., Nutritional regulation of the fatty acid synthase promoter in vivo:
sterol regulatory element binding protein functions through an upstream region
containing a sterol regulatory element. Proc Natl Acad Sci U S A, 2000. 97(19): p.
10619-24.
Bennett, M.K., et al., Sterol regulation of fatty acid synthase promoter. Coordinate
feedback regulation of two major lipid pathways. J Biol Chem, 1995. 270(43): p.
25578-83.
Rangan, V.S., B. Oskouian, and S. Smith, Identification of an inverted CCAAT box
motif in the fatty-acid synthase gene as an essential element for modification of
transcriptional regulation by cAMP. J Biol Chem, 1996. 271(4): p. 2307-12.
Roder, K., et al., NF-Y binds to the inverted CCAAT box, an essential element for
cAMP-dependent regulation of the rat fatty acid synthase (FAS) gene. Gene, 1997.
184(1): p. 21-6.
Roder, K., et al., Interaction between the two ubiquitously expressed transcription
factors NF-Y and Sp1. Gene, 1999. 234(1): p. 61-9.
Xiong, S., S.S. Chirala, and S.J. Wakil, Sterol regulation of human fatty acid synthase
promoter I requires nuclear factor-Y- and Sp-1-binding sites. Proc Natl Acad Sci U S
A, 2000. 97(8): p. 3948-53.
Ning, J., et al., Constitutive Role for IRE1{alpha}-XBP1 Signaling Pathway in the
Insulin-Mediated Hepatic Lipogenic Program. Endocrinology, 2011.
Kawaguchi, T., et al., Glucose and cAMP regulate the L-type pyruvate kinase gene by
phosphorylation/dephosphorylation of the carbohydrate response element binding
protein. Proc Natl Acad Sci U S A, 2001. 98(24): p. 13710-5.
Rufo, C., et al., Involvement of a unique carbohydrate-responsive factor in the
glucose regulation of rat liver fatty-acid synthase gene transcription. J Biol Chem,
2001. 276(24): p. 21969-75.
Koo, H.Y., et al., Replacing dietary glucose with fructose increases ChREBP activity
and SREBP-1 protein in rat liver nucleus. Biochem Biophys Res Commun, 2009.
390(2): p. 285-9.

38

133.
134.
135.
136.
137.
138.
139.
140.
141.
142.
143.

Adamson, A.W., et al., Hepatocyte nuclear factor-4alpha contributes to
carbohydrate-induced transcriptional activation of hepatic fatty acid synthase.
Biochem J, 2006. 399(2): p. 285-95.
Chen, G., et al., Central role for liver X receptor in insulin-mediated activation of
Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad
Sci U S A, 2004. 101(31): p. 11245-50.
Cha, J.Y. and J.J. Repa, The liver X receptor (LXR) and hepatic lipogenesis. The
carbohydrate-response element-binding protein is a target gene of LXR. J Biol Chem,
2007. 282(1): p. 743-51.
Joseph, S.B., et al., Direct and indirect mechanisms for regulation of fatty acid
synthase gene expression by liver X receptors. J Biol Chem, 2002. 277(13): p. 1101925.
Moustaid, N., R.S. Beyer, and H.S. Sul, Identification of an insulin response element
in the fatty acid synthase promoter. J Biol Chem, 1994. 269(8): p. 5629-34.
An, Z., et al., Nicotine-induced activation of AMP-activated protein kinase inhibits
fatty acid synthase in 3T3L1 adipocytes: a role for oxidant stress. J Biol Chem, 2007.
282(37): p. 26793-801.
Sabbisetti, V., et al., p63 promotes cell survival through fatty acid synthase. PLoS
One, 2009. 4(6): p. e5877.
Hennigar, R.A., et al., Characterization of fatty acid synthase in cell lines derived
from experimental mammary tumors. Biochim Biophys Acta, 1998. 1392(1): p. 85100.
Jin, Q., et al., Fatty acid synthase phosphorylation: a novel therapeutic target in
HER2-overexpressing breast cancer cells. Breast Cancer Res, 2010. 12(6): p. R96.
Qureshi, A.A., et al., Separation of two active forms (holo-a and holo-b) of pigeon
liver fatty acid synthetase and their interconversion by phosphorylation and
dephosphorylation. Biochem Biophys Res Commun, 1975. 66(1): p. 344-51.
Zhao, S., et al., Regulation of cellular metabolism by protein lysine acetylation.
Science, 2010. 327(5968): p. 1000-4.

39

Chapter 2:
Differential Subcellular Localization of FAS may be
Mediated by Interactions with Septin-2 and Septin-7

40

ABSTRACT
Fatty acid synthase (FAS) is a lipogenic enzyme functioning both in signaling, by
promoting synthesis of lipid ligands and signaling molecules, and in energy balance, by
synthesizing fat for storage of calories. In the liver, FAS exists in two distinct subcellular
pools: cytoplasmic FAS and membrane FAS. These two pools are differentially regulated and
appear to be specialized for different physiological functions.
Membrane FAS is associated with intracellular membranes through a strong
peripheral interaction, but the nature of this interaction—whether it is mediated by a lipid
anchor, by an interaction with another protein, or otherwise—is unknown. We hypothesized
that hepatic FAS associates with membranes through a protein-protein interaction with a
membrane-resident protein. To identify candidate proteins for localizing FAS to membranes,
we used a proteomics approach to comprehensively identify proteins co-precipitating with
FAS in the cytoplasmic and membrane fractions of two different liver model systems: Hepa16 immortalized hepatocytes and C57/BL6J mouse liver.
We identified three proteins—Septin-2, Septin-7, and 40S ribosomal protein S18—
that in two different liver model systems associate with fatty acid synthase exclusively in the
membrane fraction. Because the septins are involved in membrane structuring and
scaffolding, these proteins are possible mediators of FAS membrane localization.
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INTRODUCTION
The lipogenic enzyme fatty acid synthase (FAS) is highly expressed in liver and
involved in several aspects of hepatic metabolism. FAS synthesizes long-chain fatty acids
that can be incorporated into hepatic lipid droplets or secreted in lipoproteins. Additionally,
FAS is necessary for generating an endogenous ligand for peroxisome proliferator-activated
receptor Į (PPARĮ) in liver [1]. PPARĮ is a nuclear receptor and the primary mediator of the
fasting response, the adaptive changes in metabolism that occur during fasting or starvation.
The involvement of FAS in both synthesis of lipids for energy storage as well as the synthesis
of a lipid ligand to activate the fasting response during energy depletion is paradoxical.
FAS is localized to both the cytoplasm as well as to the ER and Golgi membranes [2].
The involvement of FAS in opposing processes (storage of excess energy and the fasting
response) is explained by the cytoplasmic FAS and the membrane-associated FAS having
distinct physiological functions; cytoplasmic FAS is active during starvation to generate
PPARĮ ligand, and membrane-associated FAS is active during feeding, probably to generate
lipids for incorporation into lipid droplets or VLDL [2].
The association of FAS with the ER and Golgi is mediated by a strong peripheral
membrane interaction [2], but the nature of this interaction is unknown. A peripheral
membrane association can be mediated by lipid anchoring, by ionic or electrostatic
interactions between the protein and membrane lipids, by an interaction between a
hydrophobic loop or amphipathic Į-helix and the membrane (the Į-helix being in-plane with
the membrane with the hydrophilic side facing the cytosol or organelle lumen), or by a
protein-protein association with another membrane-resident protein.
Mass spectrometric analysis failed to detect any lipid anchors or other posttranslational modifications of the FAS protein that could act as anchors [2]. There are
currently no known exposed hydrophobic loops or Į-helices in the FAS protein. Furthermore,
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if FAS were associated with membranes through a direct protein-membrane interaction, then
we would expect all FAS molecules to be membrane-associated, or the cytoplasmic FAS
molecules to have some sort of modification obscuring the membrane association domain.
However, FAS exists in both cytoplasmic and membrane-associated compartments, and no
post-translational modifications characteristic of all FAS in a specific compartment could be
identified [2].
Instead, we hypothesized that FAS associates with membranes through a proteinprotein interaction with a membrane-resident protein, likely an integral membrane protein
because of the strength of the interaction between FAS and membranes. If this membraneresident protein is less abundant than FAS in the cell, then the membrane-resident protein
would be saturated with FAS and be the limiting factor determining membrane residence of
FAS, thus explaining how the two distinct cytoplasmic and membrane pools of FAS can exist
despite the primary structure of the protein being identical between pools.
Here, we used a proteomic approach to identify FAS-associated proteins in the
cytoplasmic and membrane fractions of a liver cell line and of mouse liver. We identified
three proteins that are FAS-interactors exclusively in the membrane fraction and that were
found in both model systems. Out of these, two (Septin-2 and Septin-7) are members of the
septin class of proteins, which is known to be involved in membrane structuring, scaffolding,
and compartmentalization, marking these FAS-interacting proteins as potential mediators of
FAS membrane localization.
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MATERIALS AND METHODS
Animals. A six-month old female C57BL/6J mouse was used as a source of liver for
the mass spectrometric analysis of proteins.
Cell culture. Hepa1-6 cells were maintained in DMEM + 10% FBS until switching to
SILAC (see below) media. The SILAC media contained 10% dialyzed FBS.
SILAC labeling. Hepa1-6 cells were differentially labeled using the stable isotope
labeling with amino acids in cell culture (SILAC) technique [3, 4] by growing the cells for 6
passages in SILAC media containing “heavy” 13C6 L-lysine or “light” 12C6 L-lysine (Thermo
Scientific), ensuring over 99% incorporation of labeled amino acid into the cellular proteome.
Subcellular fractionation. To fractionate mouse liver, perfused liver from a
C57BL/6J mouse was homogenized in 20 mM HEPES buffer (pH 7.4) and centrifuged at
10,000 g for 45 min. The pellet was discarded and the supernatant spun at 179,000 g for 90
min at 4°C. The resulting supernatant (cytoplasm) was transferred to a fresh tube. Because
the association of FAS with membranes is resistant to high salt treatment [2], the pellet (crude
membrane fraction) was then resuspended in 20 mM HEPES buffer containing 1 M NaCl and
incubated for 30 min in order to dissociate irrelevant proteins from the membrane. After
spinning the sample again for 90 min, the supernatant was discarded and the pellet (crude
membrane fraction) was resuspended in a detergent-containing buffer. All spins were done at
4°C.
To fractionate Hepa1-6 cells, “light” and “heavy” cells were harvested in 20 mM
HEPES buffer and centrifuged at 10,000 g for 10 min. The pellets were discarded and the
supernatants centrifuged at 179,000 g for 2 h. The supernatants (cytoplasm) were removed
and the pellets (crude membrane fraction) were washed and resuspended.
Antibodies and immunoprecipitations. Rabbit polyclonal antibody against FAS
(ab22759) from Abcam was used to immunoprecipitated FAS. Non-immune rabbit serum
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from Jackson Immunoresearch was used for control immunoprecipitations.
For liver, FAS was immunoprecipitated from 1.2 mg of cytoplasmic or membrane
protein by overnight incubation using a polyclonal rabbit anti-FAS antibody. For Hepa1-6
cells, equal amounts of cytoplasmic protein from “light” and “heavy” cells and equal amounts
of membrane protein from “light” and “heavy” cells were used for immunoprecipitation of
FAS (“light” cells) using a polyclonal rabbit anti-FAS antibody or for a control
immunoprecipitation (“light” cells) with non-immune rabbit serum. After overnight
incubations at 4°C with antibodies or non-immune serum, IgG agarose beads were added and
the samples incubated for another 1 h.
Mass spectrometry. IP beads were washed, boiled in sample buffer, and subjected to
SDS-PAGE. The gel was stained with Coomassie, the gel segment corresponding to FAS was
excised and further cut into small pieces (1 mm2), destained with 50% CH3CN containing 25
mM NH4HCO3, dehydrated, reduced with 20 mM DTT for 1 h at 55°C, washed and
dehydrated, alkylated with 100 mM iodoacetamide for 1 h in the dark at room temperature,
then subjected to cycles of washing and dehydration followed by drying in a centrifugal
evaporator. In-gel digestion was performed with 0.02 mg/ml trypsin overnight at 37°C.
Peptides were extracted from the gel pieces using 5% TFA in 50% CH3CN and reconstituted
in 0.1% FA in 3% CH3CN.
Samples were then analyzed by LC-MS/MS with a NanoLC-LTQ-Orbitrap mass
spectrometer (Thermo Fisher Scientific) in data dependent mode. Acquired spectra were
searched against the Swiss-Prot database through the Mascot server to identify proteins.
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RESULTS
To identify candidate proteins localizing FAS to membranes, we comprehensively
surveyed FAS-associated proteins in the cytoplasmic and membrane fractions of mouse liver
and in a liver cell line by mass spectrometric analysis of proteins pulled down during
immunoprecipitation of FAS. To narrow the list of candidates, we looked for proteins that
were 1) exclusively found in the membrane fraction, 2) found in the membrane fractions of
both model systems, and, preferably, 3) known integral membrane proteins.
FAS-associated proteins in mouse liver cytoplasm and membrane. To identify FASassociated proteins in mouse liver, perfused liver was fractionated into a crude membrane
fraction and a cytoplasmic fraction. FAS was immunoprecipitated from both membrane and
cytoplasmic fractions using an anti-FAS antibody and the peptides pulled down were
analyzed by mass spectrometry. FAS interactors identified in cytoplasm and membrane of
mouse liver are listed in Table 1 and Table 2, respectively, along with the number of peptides
identified for each protein and the protein score (or Mascot score) for each protein. A cut-off
protein score of 100, reflecting a confidence level over 95% for protein identification, was
used to determine likely specific interactors. 49 likely FAS interactors were identified in the
cytoplasmic fraction and 50 likely interactors in the membrane fraction.
FAS-associated proteins in Hepa1-6 cell cytoplasm and membrane. To identify
FAS-associated proteins in Hepa1-6 cells, a murine immortalized liver cell line, and to
exclude as many non-specific interactions as possible, we used a combination of stable
isotope labeling with amino acids in cell culture (SILAC) and mass spectrometry. Hepa1-6
cells were labeled as “heavy” or “light” using stable isotope labeling with amino acids in cell
culture (SILAC) [3]. FAS was immunoprecipitated from “heavy” cells, while “light” cells
were immunoprecipitated using a control antibody. Peptides from both populations were
mixed and analyzed by mass spectrometry. The most likely FAS-interactors were found using
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the ratio of the intensity of peptides identified in the “heavy” cells versus the control “light”
cells, with a minimum ratio of 5 (meaning peak intensity is 5-fold higher for the “heavy”
peak than the “light” peak) and a minimum number of 2 peptides detected as the cut-off for
likely specific interactors.
FAS interactors in Hepa1-6 cytoplasm and membrane are listed in Table 3 and Table
4, respectively. Excluding FAS, 54 proteins were identified in the cytoplasmic fraction and
23 proteins were identified in the membrane fraction.
FAS-associated proteins exclusively found in the membrane fractions and in both
model systems. Three proteins were found that were exclusively present in the membrane
fraction and present in both Hepa1-6 cells and mouse liver (Table 5): Septin-2 (encoded by
Sept2), Septin-7 (encoded by Sept7), and 40S ribosomal protein S18 (encoded by Rps18).
Integral membrane proteins. None of the three proteins fulfilling the first two criteria
(exclusively present in the membrane fraction, and present in both model systems) are
integral membrane proteins; Septin-2 and Septin-7 are soluble cytoskeletal proteins while
40S ribosomal protein S18 is a component of ribosomes, which are cytoplasmic or associated
with ER membrane (rough ER).
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DISCUSSION
While none of the three candidate FAS-interacting proteins that were identified as
present exclusively in the membrane fractions in both Hepa1-6 cells and mouse liver were
integral membrane protein, the nature of the septin protein class marks Septin-2 and Septin-7
as viable candidates capable of mediating the strong interaction between FAS and
intracellular membranes.
The septin proteins are cytoskeletal GTP-binding proteins, forming hexameric and
octameric complexes that can assemble into filaments (reviewed in [5]). Functions of the
septins include scaffolding and membrane partitioning [5]. In phospholipid-based liposomes,
septins tubulate the liposome membrane, creating a membrane “brace” [6]. Septins can
regulate protein-protein associations [7] and protein-cytoskeleton interactions [8].
Unfortunately, there are no published studies to date on the function of Septin-2 or Septin-7
in liver or liver cells or in interactions with the ER membrane.
The identification of a ribosomal protein, 40S ribosomal protein S18, in the
membrane fraction of both model systems could indicate that FAS binds to the rough ER.
The presence of this protein may be a vestige of the abundance of ribosomes associated with
the rough ER membrane.
In conclusion, we have identified three proteins—40S ribosomal protein S18, Septin-2,
and Septin-7—that in two different liver model systems associate with fatty acid synthase
exclusively in the membrane fraction. Rigorous cut-offs for isotope ratio or protein scores
ensured a high confidence level for the candidate proteins being correctly identified and
specific interactors of FAS. The association of Septin-2 and Septin-7 with membrane-bound
FAS and the role of the septins in scaffolding and membrane structuring suggest that these
proteins could be important for the membrane localization of FAS. If that is true, these
proteins could potentially be modulated to change the proportion of FAS present in
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association with membranes and in the cytoplasm, which in turn could affect FAS-mediated
PPARĮ activation and lipid storage/secretion. Studies on FAS localization and function in
cells deficient in Septin-2 or Septin-7 are needed to elucidate the function of the FAS-septin
interactions.
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TABLES
Accession ID
FAS_MOUSE
ACACA_MOUSE
AL1L1_MOUSE
K2C5_MOUSE
PCCB_MOUSE
K2C6A_MOUSE
K1C14_MOUSE
ASSY_MOUSE
BHMT1_MOUSE
F16P1_MOUSE
ALDOB_MOUSE
PYC_MOUSE
SAHH_MOUSE
K1C17_MOUSE
SBP1_MOUSE
K1C42_MOUSE
K1C10_MOUSE
K2C75_MOUSE
GSTP1_MOUSE
IGG2B_MOUSE
HSP7C_MOUSE
HPPD_MOUSE
K1C16_MOUSE
K22E_MOUSE
K1C15_MOUSE
IGKC_MOUSE
K2C1B_MOUSE
K22O_MOUSE
K1C13_MOUSE
K2C73_MOUSE
K2C1_MOUSE
TBB4B_MOUSE
LDHA_MOUSE
K2C8_MOUSE
CAH3_MOUSE
K2C79_MOUSE
PLAK_MOUSE
K2C72_MOUSE
GSTA3_MOUSE
GPX1_MOUSE

Description
Fatty acid synthase
Acetyl-CoA carboxylase 1
Cytosolic 10-formyltetrahydrofolate dehydrogenase
Keratin, type II cytoskeletal 5
Propionyl-CoA carboxylase beta chain, mitochondrial
Keratin, type II cytoskeletal 6A
Keratin, type I cytoskeletal 14
Argininosuccinate synthase
Betaine--homocysteine S-methyltransferase 1
Fructose-1,6-bisphosphatase 1
Fructose-bisphosphate aldolase B
Pyruvate carboxylase, mitochondrial
Adenosylhomocysteinase
Keratin, type I cytoskeletal 17
Selenium-binding protein 1
Keratin, type I cytoskeletal 42
Keratin, type I cytoskeletal 10
Keratin, type II cytoskeletal 75
Glutathione S-transferase P 1
Ig gamma-2B chain C region
Heat shock cognate 71 kDa protein
4-hydroxyphenylpyruvate dioxygenase
Keratin, type I cytoskeletal 16
Keratin, type II cytoskeletal 2 epidermal
Keratin, type I cytoskeletal 15
Ig kappa chain C region
Keratin, type II cytoskeletal 1b
Keratin, type II cytoskeletal 2 oral
Keratin, type I cytoskeletal 13
Keratin, type II cytoskeletal 73
Keratin, type II cytoskeletal 1
Tubulin beta-4B chain
L-lactate dehydrogenase A chain
Keratin, type II cytoskeletal 8
Carbonic anhydrase 3
Keratin, type II cytoskeletal 79
Junction plakoglobin
Keratin, type II cytoskeletal 72
Glutathione S-transferase A3
Glutathione peroxidase 1

Protein
score
6979
3551
1469
729
706
678
669
617
614
612
596
560
520
515
512
495
456
448
418
397
370
363
358
331
327
326
306
305
301
295
286
282
276
221
185
154
147
142
134
113

# of
peptides
211
31
7
35
2
23
34
7
5
3
2
9
5
15
3
35
8
26
3
2
3
2
16
8
13
5
5
11
14
4
10
3
3
10
3
2
2
2
2
2

Table 1. FAS-associated proteins in mouse liver cytoplasm. A protein score of 100
(representing a confidence level over 95%) and a minimum number of two peptides was used
as the cut-off for likely FAS interactors.
50

Accession ID
FAS_MOUSE
ACACA_MOUSE
ATPA_MOUSE
MVP_MOUSE
GRP78_MOUSE
MCCB_MOUSE
K2C5_MOUSE
MCCA_MOUSE
K1C14_MOUSE
ENPL_MOUSE
PDIA1_MOUSE
S27A2_MOUSE
K2C6A_MOUSE
RS4X_MOUSE
K1C42_MOUSE
TPP2_MOUSE
IGG2B_MOUSE
K1C17_MOUSE
FMO5_MOUSE
CES3_MOUSE
K2C75_MOUSE
ATPB_MOUSE
RS3_MOUSE
UD11_MOUSE
K1C10_MOUSE
K1C16_MOUSE
K22E_MOUSE
ACSL5_MOUSE
S27A5_MOUSE
CP2DA_MOUSE
CP2DQ_MOUSE
SEPT2_MOUSE
K1C15_MOUSE
K22O_MOUSE
K2C1B_MOUSE
DHI1_MOUSE
K1C13_MOUSE
K2C1_MOUSE
K2C73_MOUSE
SEPT7_MOUSE
CMLO2_MOUSE
K2C8_MOUSE
PCCB_MOUSE
K2C79_MOUSE

Description
Fatty acid synthase
Acetyl-CoA carboxylase 1
ATP synthase subunit alpha, mitochondrial
Major vault protein
78 kDa glucose-regulated protein
Methylcrotonoyl-CoA carboxylase beta chain,
mitochondrial
Keratin, type II cytoskeletal 5
Methylcrotonoyl-CoA carboxylase subunit alpha,
mitochondrial
Keratin, type I cytoskeletal 14
Endoplasmin
Protein disulfide-isomerase
Very long-chain acyl-CoA synthetase
Keratin, type II cytoskeletal 6A
40S ribosomal protein S4, X isoform
Keratin, type I cytoskeletal 42
Tripeptidyl-peptidase 2
Ig gamma-2B chain C region
Keratin, type I cytoskeletal 17
Dimethylaniline monooxygenase [N-oxide-forming] 5
Carboxylesterase 3
Keratin, type II cytoskeletal 75
ATP synthase subunit beta, mitochondrial
40S ribosomal protein S3
UDP-glucuronosyltransferase 1-1 =2
Keratin, type I cytoskeletal 10
Keratin, type I cytoskeletal 16
Keratin, type II cytoskeletal 2 epidermal
Long-chain-fatty-acid-CoA ligase 5
Bile acyl-CoA synthetase
Cytochrome P450 2D10
Cytochrome P450 2D26
Septin-2
Keratin, type I cytoskeletal 15
Keratin, type II cytoskeletal 2 oral
Keratin, type II cytoskeletal 1b
Corticosteroid 11-beta-dehydrogenase isozyme 1
Keratin, type I cytoskeletal 13
Keratin, type II cytoskeletal 1
Keratin, type II cytoskeletal 73
Septin-7
Probable N-acetyltransferase CML2
Keratin, type II cytoskeletal 8
Propionyl-CoA carboxylase beta chain, mitochondrial
Keratin, type II cytoskeletal 79
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Protein
score
6296
3872
1548
1339
1223

# of
peptides
83
11
29
10
3

857
807

4
40

750
715
710
686
665
663
596
585
581
563
554
548
515
483
469
465
461
445
433
419
407
398
390
365
340
335
322
318
306
282
281
266
250
240
232
232
224

3
19
7
7
6
33
5
19
4
5
9
3
3
31
2
2
3
15
5
12
3
4
2
4
4
9
27
7
2
16
5
8
3
2
16
4
8

K1C19_MOUSE
KRT85_MOUSE
ALDOB_MOUSE
RS18_MOUSE
K2C7_MOUSE
HVM51_MOUSE
PYGL_MOUSE

Keratin, type I cytoskeletal 19
Keratin, type II cuticular Hb5
Fructose-bisphosphate aldolase B
40S ribosomal protein S18
Keratin, type II cytoskeletal 7
Ig heavy chain V region AC38 205.12
Glycogen phosphorylase, liver form

219
213
199
189
133
108
105

3
2
2
2
3
2
2

Table 2. FAS-associated proteins in mouse liver membrane. A protein score of 100
(representing a confidence level over 95%) and a minimum number of two peptides was used
as the cut-off for likely FAS interactors. Because the association of FAS with membranes is
resistant to high salt treatment [2], the pellet containing the crude membrane fraction was
resuspended in a buffer containing 1 M NaCl and incubated for 30 min in order to dissociate
irrelevant proteins from the membrane, after which the sample was re-centrifuged and the
supernatant discarded.
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Accession ID
FAS_MOUSE
ANR40_MOUSE
AP2A1_MOUSE
DTD1_MOUSE
SNX5_MOUSE
GFPT1_MOUSE
TWF1_MOUSE
ARL1_MOUSE
ARF1_MOUSE
ARF5_MOUSE
ARF4_MOUSE
UBC12_MOUSE
ATG3_MOUSE
MP2K1_MOUSE
SAR1A_MOUSE
CNN3_MOUSE
KTHY_MOUSE
UBE2Z_MOUSE
EF2_MOUSE
CXCR4_MOUSE
UBE2N_MOUSE
PYRG1_MOUSE
SAR1B_MOUSE
SAE2_MOUSE
CDK1_MOUSE
PUR6_MOUSE
RAB5A_MOUSE
MOL1A_MOUSE
RB11A_MOUSE
CDK18_MOUSE
PRS8_MOUSE
BLK_MOUSE
ATX10_MOUSE
PDC6I_MOUSE
TBB2A_MOUSE
TBB3_MOUSE
TBB5_MOUSE
TBB2C_MOUSE
TBB6_MOUSE
TBAL3_MOUSE
TBA1C_MOUSE
TBA1B_MOUSE
VILI_MOUSE
G3PT_MOUSE

Description
Fatty acid synthase
Ankyrin repeat domain-containing protein 40
AP-2 complex subunit alpha-1
D-tyrosyl-tRNA(Tyr) deacylase 1
Sorting nexin-5
Glucosamine--fructose-6-phosphate aminotransferase
[isomerizing] 1
Twinfilin-1
ADP-ribosylation factor-like protein 1
ADP-ribosylation factor 1
ADP-ribosylation factor 5
ADP-ribosylation factor 4
NEDD8-conjugating enzyme Ubc12
Ubiquitin-like-conjugating enzyme ATG3
Dual specificity mitogen-activated protein kinase
kinase 1
GTP-binding protein SAR1a
Calponin-3
Thymidylate kinase
Ubiquitin-conjugating enzyme E2 Z
Elongation factor 2
C-X-C chemokine receptor type 4
Ubiquitin-conjugating enzyme E2 N
CTP synthase 1
GTP-binding protein SAR1b
SUMO-activating enzyme subunit 2
Cyclin-dependent kinase 1
Multifunctional protein ADE2
Ras-related protein Rab-5A
Mps one binder kinase activator-like 1A
Ras-related protein Rab-11A
Cyclin-dependent kinase 18
26S protease regulatory subunit 8
Tyrosine-protein kinase Blk
Ataxin-10
Programmed cell death 6-interacting protein
Tubulin beta-2A chain
Tubulin beta-3 chain
Tubulin beta-5 chain
Tubulin beta-2C chain
Tubulin beta-6 chain
Tubulin alpha chain-like 3
Tubulin alpha-1C chain
Tubulin alpha-1B chain
Villin-1
Glyceraldehyde-3-phosphate dehydrogenase, testis-
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Heavy/light
ratio
32.87
25.48
22.59
12.76
11.36

# of
peptides
222
3
2
2
2

10.7
9.94
9.83
9.79
9.58
9.17
8.76
8.43

15
4
6
18
13
14
4
2

8.33
8.13
8.01
7.9
7.88
7.72
7.53
7.51
7.44
7.35
7.21
7.19
6.87
6.84
6.83
6.83
6.71
6.65
6.45
6.12
6.05
6.05
6.03
6
5.99
5.97
5.77
5.73
5.72
5.6
5.59

3
4
27
2
3
80
3
6
5
7
13
8
26
2
3
4
3
3
2
10
2
85
35
104
78
58
5
134
134
7
15

TBA4A_MOUSE
ACTBL_MOUSE
TBA1A_MOUSE
TLN1_MOUSE
KPYM_MOUSE
CHERP_MOUSE
IF4A1_MOUSE
EF1A1_MOUSE
G3P_MOUSE
RAB7A_MOUSE

specific
Tubulin alpha-4A chain
Beta-actin-like protein 2
Tubulin alpha-1A chain
Talin-1
Pyruvate kinase isozymes M1/M2
Calcium homeostasis endoplasmic reticulum protein
Eukaryotic initiation factor 4A-I
Elongation factor 1-alpha 1
Glyceraldehyde-3-phosphate dehydrogenase
Ras-related protein Rab-7a

5.58
5.54
5.54
5.53
5.48
5.445
5.37
5.33
5.33
5.27

92
51
134
3
61
2
28
24
77
3

Table 3. FAS-associated proteins in Hepa1-6 cytoplasm. A minimum heavy/light ratio of 5
and a minimum of two peptides was used as the cut-off for likely FAS interactors.
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Accession ID
FGF22_MOUSE
FAS_MOUSE
RG9D3_MOUSE
DTD1_MOUSE
SEPT2_MOUSE
SEPT9_MOUSE
G3P_MOUSE
SEPT7_MOUSE
TCPH_MOUSE
PCBP1_MOUSE
PCBP2_MOUSE
SC31A_MOUSE
TCPD_MOUSE
TCPZ_MOUSE
HAS1_MOUSE
TCPG_MOUSE
RS18_MOUSE
TCPB_MOUSE
EF1A1_MOUSE
NFH_MOUSE
ABCE1_MOUSE
SETB2_MOUSE
UGDH_MOUSE

Description
Fibroblast growth factor 22
Fatty acid synthase
RNA (guanine-9-)-methyltransferase domaincontaining protein 3
D-tyrosyl-tRNA(Tyr) deacylase 1
Septin-2
Septin-9
Glyceraldehyde-3-phosphate dehydrogenase
Septin-7
T-complex protein 1 subunit eta
Poly(rC)-binding protein 1
Poly(rC)-binding protein 2
Protein transport protein Sec31A
T-complex protein 1 subunit delta
T-complex protein 1 subunit zeta
Hyaluronan synthase 1
T-complex protein 1 subunit gamma
40S ribosomal protein S18
T-complex protein 1 subunit beta
Elongation factor 1-alpha 1
Neurofilament heavy polypeptide
ATP-binding cassette sub-family E member 1
Histone-lysine N-methyltransferase SETDB2
UDP-glucose 6-dehydrogenase

Heavy/light
# of
ratio
peptides
73.25
6
49.87
533
48.81
39.4
29.2
23.41
13.97
8.96
7.24
6.5
6.48
6.41
6.12
6.1
6.08
5.99
5.82
5.7
5.67
5.63
5.47
5.32
5.29

3
4
6
9
47
2
10
10
2
2
22
20
2
22
11
19
49
5
3
2
2

Table 4. FAS-associated proteins in Hepa1-6 membrane. A minimum heavy/light ratio of
5 and a minimum of two peptides was used as the cut-off for likely FAS interactors.
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Description
Septin-2
Septin-7
40S ribosomal protein S18

Protein
score
340
250
189

# of
peptides
4
3
2

Heavy/light
# of
ratio
peptides
29.2
6
8.96
2
5.82
11

Table 5. FAS-associated proteins exclusively present in the membrane fractions and
present in both mouse liver and Hepa1-6. Excluding FAS.
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Chapter 3:
Nutrient-Dependent Phosphorylation
Channels Lipid Synthesis to Regulate PPARĮ
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ABSTRACT
PPARĮ is a nuclear receptor that coordinates liver metabolism during fasting. Fatty
acid synthase (FAS) is an enzyme that stores excess calories as fat during feeding, but also
activates hepatic PPARĮ by promoting synthesis of an endogenous ligand. Here we show that
the mechanism underlying this paradoxical relationship involves the differential regulation of
FAS in at least two distinct subcellular pools: cytoplasmic and membrane-associated. In
mouse liver and cultured hepatoma cells, the ratio of cytoplasmic to membrane FAS specific
activity was increased with fasting, indicating higher cytoplasmic FAS activity under
conditions associated with PPARĮ activation. This effect was due to a nutrient-dependent and
compartment-selective covalent modification of FAS. Cytoplasmic FAS was preferentially
phosphorylated during feeding or insulin treatment at Thr-1029 and Thr-1033, which flank a
dehydratase domain catalytic residue. Mutating these sites to alanines promoted PPARĮ
target gene expression. Rapamycin-induced inhibition of mTORC1, a mediator of the
feeding/insulin signal to induce lipogenesis, reduced FAS phosphorylation, increased
cytoplasmic FAS enzyme activity, and increased PPARĮ target gene expression. Rapamycinmediated induction of the same gene was abrogated with FAS knockdown. These findings
suggest that hepatic FAS channels lipid synthesis through specific subcellular compartments
that allow differential gene expression based on nutritional status.
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INTRODUCTION
PPARĮ (peroxisome proliferator-activated receptor Į), one of three known members
of a nuclear receptor family targeted to treat lipid disorders, diabetes and obesity, is highly
expressed in the liver. Its induction by fasting promotes lipid uptake, fatty acid ȕ-oxidation,
ketogenesis, and gluconeogenesis [1, 2]. Ligand binding to PPARĮ causes it to
heterodimerize with RXRĮ, allowing activation of gene transcription at PPREs [3, 4].
Synthetic PPARĮ ligands such as fibrates, used for human lipid disorders [5], have been
known for decades, but potential endogenous ligands were identified only recently [6, 7].
Mice with liver-specific deletion of the lipogenic enzyme fatty acid synthase (FAS) have
impaired PPARĮ activity [8], and FAS activates PPARĮ by producing an endogenous
phospholipid ligand [6]. FAS also activates PPARĮ in brain and macrophages [9, 10].
Mammalian FAS synthesizes long chain fatty acids, primarily palmitate, through the
activities of seven functional domains: acyl carrier, acyl transferase, ȕ-ketoacyl synthase, ȕketoacyl reductase, ȕ-hydroxyacyl dehydratase, enoyl reductase, and thioesterase [11]. Like
PPARĮ, FAS is highly expressed in liver [12]. In times of nutrient excess, hepatic FAS
converts carbohydrate to lipid that is stored in lipid droplets or secreted in the form of VLDL
[13]. Nutrient excess is associated with elevated levels of insulin, known to induce FAS
expression.
These accepted physiological roles for PPARĮ and FAS appear to conflict with the
observation that inactivation of FAS impairs PPARα activation. How might FAS activate a
process stimulated by feeding such as insulin-responsive lipogenesis and yet also activate a
process stimulated by fasting such as the induction of PPARĮ-dependent gene expression?
We hypothesized that distinct subcellular pools of FAS mediate these disparate
effects. Compartmentalization would permit regulation of an FAS pool generating lipids for
signaling that would be distinct from an FAS pool generating lipids for energy storage. In
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support of this hypothesis, we demonstrate that FAS at two separate subcellular locations is
differentially regulated by nutrients and insulin, that this regulation involves preferential
dehydratase domain phosphorylation for the FAS pool that regulates PPARα, and that the
effects of the kinase mTORC1 on PPARα activity require FAS.
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MATERIALS AND METHODS
Animals. Male C57BL/6J mice at 8 weeks of age were provided ad libitum access to
chow diet (Purina #5053) or fasted for 18 h. All mice were kept on Aspen bedding and had
free access to water. Protocols were approved by the Washington University Animal Studies
Committee.
FAS enzyme activity assay. Using a modification of a previously described assay
[14], 20 μl of sample at 1 μg protein/μl was added to 70 μl of assay buffer (0.14 M potassium
phosphate buffer [pH 7.0], 1.4 mM EDTA [pH 8.0], 1.4 mM DTT, 0.24 mM NADPH, 0.1
mM acetyl-CoA). The rate of NADPH oxidation was monitored at 340 nm at baseline and
again after adding 10 μl of 0.85 mg/ml malonyl-CoA (Sigma). The substrate-dependent rate
was determined by subtracting the baseline NADPH oxidation rate from the rate after
addition of malonyl-CoA. The rate of NADPH oxidation was normalized to FAS protein
levels as determined by Western blotting and densitometry to determine specific activity.
Subcellular fractionation. Perfused liver from C57BL/6J mice was homogenized in
20 mM HEPES buffer (pH 7.4), centrifuged at 100 g for 30 min, and the pellet was discarded.
The supernatant was centrifuged at 500 g for 60 min; 1,200 g for 20 min; 10,000 g for 20
min; 20,000 g for 30 min; 40,000 g for 30 min; 70,000 g for 30 min; 100,000 g for 60 min;
and 179,000 g for 75 min. After each spin, the pellet was washed and resuspended, while the
supernatant was centrifuged again. All spins were done at 4°C. To obtain crude membrane
and cytoplasmic fractions from mouse liver, freshly isolated perfused liver was homogenized
in HEPES buffer and centrifuged at 10,000 g for 45 min at 4°C. The resulting pellet was
discarded and the supernatant centrifuged at 179,000 g for 180 min at 4°C. The supernatant
(cytoplasm) and pellet (crude membrane) were collected, and the pellet was washed and
resuspended in HEPES buffer. To obtain membrane and cytoplasmic extracts from Hepa1-6
cells, a Subcellular Protein Fractionation Kit for Cultured Cells (78840) from Thermo Fisher
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Scientific was used according to the manufacturer’s protocol.
Antibodies. Rabbit polyclonal antibodies against FAS (ab22759), PMP70 (ab3421),
and phosphothreonine (ab9337) were from Abcam. Mouse monoclonal antibody against Įtubulin (sc-5286) and rabbit polyclonal antibodies against Cav1 (sc-894) and ȕ-tubulin (sc9104, used to control for loading in Western blotting experiments) were from Santa Cruz
Biotechnology. Rabbit polyclonal antibodies against PDI (226), GM130 (2296), Na+/K+
ATPase (3010), Akt (9272), Phospho-Akt (S473) (9271), S6 ribosomal protein (2217), and
phospho-S6 ribosomal protein (Ser235/236) (2F9/4856) and rabbit monoclonal antibodies
against p70 S6 Kinase (2708) and CoxIV (4850) were from Cell Signaling Technology.
FAS solubility. Solubility assays were performed as previously described [15] with
minor modifications. Membranes were isolated from mouse liver by ultracentrifugation and
resuspended in buffer containing 20 mM HEPES buffer (pH 7.4), 1 mM EDTA, and 255 mM
sucrose. The membrane fraction was subjected to treatment with various solvents (1 M NaCl,
0.1 M Na2CO3 at pH 11.5, 1% SDS or 1% Triton X-100) and then centrifuged once more
(4°C, 180,000 g, 30 min). The resulting pellets and supernatants were analyzed by Western
blotting.
Cell culture. Hepa1-6 and Hek293T cells were maintained in DMEM + 10% FBS.
Prior to insulin treatment for FAS activity assays, Hepa1-6 cells were cultured in DMEM +
0.5% FBS for 6 h. All insulin treatments were performed in DMEM + 10% FBS.
Pulse-chase. Confluent Hepa1-6 cells in 6 cm dishes were incubated in methioninefree media for 30 min. The cells were then pulsed with 500 μCi of 35S-methionine per dish.
After 1 h cells for the “0” time point were harvested. For subsequent time points, cells were
washed with PBS, chased with non-radioactive complete media, and incubated for an
additional 45, 90, or 180 minutes before harvesting. Cells were fractionated into cytoplasm
and membrane as described above. FAS was immunoprecipitated from each fraction, samples
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were subjected to SDS-PAGE, the gel transferred onto PVDF membrane, and the bands
corresponding to labeled FAS visualized by autoradiography. Autoradiograms were then
analyzed by densitometry.
RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen) and reverse
transcribed using an iScript™ cDNA synthesis kit (Invitrogen). Semi-quantitative RT-PCR
was performed using SYBR® Green reagent (Applied Biosystems) with an ABI Prism 7700
PCR instrument.
Mutagenesis and plasmid construction. A retroviral plasmid, pBABE-Puro,
containing human FAS [16] generated by Max Loda (Dana Farber) was utilized to generate
FAS phosphosite mutants. A 3.4 kb fragment of FAS/pBABE-Puro including the two
putative phosphorylation sites (hFAS S1028 and T1032) and two flanking BsrGI sites was
amplified by PCR and subcloned into an intermediate Topo vector. Site-directed mutagenesis
of the Topo-FAS plasmid changed the codons corresponding to S1028 and T1032 to alanines,
yielding two single mutants. The S1028A/T1032A double mutant was made by sequential
mutagenesis, using the S1028A mutant as a template. Mutated FAS fragments were then
excised and cloned back into pBabe-Puro using the two BsrGI sites to generate mutant, full
length FAS cDNAs. Mutations as well as correct orientation of the re-inserted FAS fragments
were verified by DNA sequencing.
GFP-tagged FAS was generated by amplifying the cDNA encoding FAS from
pBabe-Puro-FAS by RT-PCR, adding restriction sites for XhoI and EcoRI on the 5’ and 3’
ends, respectively. The amplified product was cloned into pEGFP-C3 using the XhoI and
EcoRI sites, yielding an N-terminally GFP-tagged FAS construct.
Lentiviral shRNA-mediated knockdown and human FAS expression. A
plasmid encoding a mouse FAS shRNA (TRCN0000075703) was obtained from Open
Biosystems. The packaging vector psPAX2 (12260) and envelope vector pMD2.G (12259)
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were obtained from Addgene. Hek293T cells at 70% confluence in a 15 cm dish were
transfected using Lipofectamine 2000 with 8 μg psPAX2, 2.25 μg pMD2.G, and 9 μg shRNA.
After 48 h, media was collected and filtered through 0.45 μm syringe filters. Polybrene was
added and the media used to treat 50-70% confluent Hepa1-6 cells. After 24 h, the media was
aspirated and replaced with media containing retroviral particles encoding human FAS (see
below). Forty-eight h after addition of the retroviral media, cells were selected with
puromycin. After another 48 h, cells were harvested and knockdown of mouse FAS as well as
expression of human FAS were assessed.
To generate retroviral particles encoding human FAS, Hek293T cells in 10 cm
dishes were transfected using Lipofectamine 2000 with 3 μg FAS plasmid and 3 μg ȥA
helper plasmid. After 48 h, media were collected, filtered using 0.45 μM syringe filters,
polybrene was added, and the media was used to treat 50-70% confluent Hepa1-6 cells. After
48 h, 2 μg/ml puromycin was added, and after an additional 48 h, cells were harvested.
In experiments assessing PPARĮ target gene expression in cells expressing
mutant FAS, the endogenous murine FAS of Hepa1-6 cells was knocked down prior to
retroviral expression of human FAS as described above.
PPRE-luciferase reporter assay. Media containing lentiviral particles
encoding shRNA for murine FAS and media containing retroviral particles encoding wildtype or S1028A/T1032A double mutant human FAS were prepared as described above. 70%
confluent Hepa1-6 cells in 10 cm dishes were treated with lentiviral media for 24 h, after
which the media was aspirated and replaced with retroviral media for either wild type or
S1028A/T1032A FAS. After another 24 h, the media was again aspirated and replaced with
fresh media containing puromycin.
After two days of puromycin selection, the media was aspirated, replaced with
charcoal-stripped media (which is essentially fatty-acid free, minimizing PPAR activation by
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lipids in the growth media), and incubated for one hour. For all following steps, charcoalstripped media was used. Hepa1-6 cells were transfected with plasmids encoding 3x PPREluciferase and Renilla luciferase by electroporation. The electroporation for each 10 cm dish
of cells was done as follows: 5 μg of PPRE-luciferase plasmid and 5 μg of Renilla luciferase
plasmid were added to the bottom of a cuvette. Cells were harvested by trypsinization and
spun after adding media. The media was aspirated and cells were washed once with PBS. The
PBS was aspirated and cells resuspended in 0.5 ml PBS and transferred to the cuvette. The
cuvette containing cells and DNA was electroporated at 360 V and 250 μF (time constant of
4.5-5 sec-1). 1 ml of media was immediately added to the cuvette. Cells were transferred to a
15 ml tube and media containing puromycin was added up to 6 ml. Cells were allowed to
recover for 10 min, then plated.
One day following transfection, cells were harvested by scraping, washed with roomtemperature PBS three times, resuspended in PBS, and plated on a 96-well plate.
Luminescence from firefly luciferase and Renilla luciferase was then measured using DualGlo Luciferase Assay System (Promega) according to the manufacturer’s instructions. The
relative amounts of PPRE-luciferase activity were calculated as the ratio between firefly
luciferase to Renilla luciferase luminescence.
Mass spectrometry. To identify post-translational modifications in hepatic FAS,
perfused C57BL/6J mouse livers were homogenized in lysis buffer containing 1% Triton X100. The lysate was spun at 10,000 g for 45 min and the pellet discarded. FAS was
immunoprecipitated from 10 mg of the lysate by overnight incubation using a polyclonal
rabbit anti-FAS antibody. IP beads were washed, boiled in sample buffer, and subjected to
SDS-PAGE. The gel was stained with Coomassie, the gel segment corresponding to FAS was
excised and further cut into small pieces (1 mm2), destained with 50% CH3CN containing 25
mM NH4HCO3, dehydrated, reduced with 20 mM DTT for 1 h at 55°C, washed and
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dehydrated, alkylated with 100 mM iodoacetamide for 1h in the dark at room temperature,
then subjected to cycles of washing and dehydration followed by drying in a centrifugal
evaporator. In-gel digestion was performed with 0.02 mg/ml trypsin overnight or 0.02 mg/ml
chymotrypsin for 6 h at 37°C. Peptides were extracted from the gel pieces using 5% TFA in
50% CH3CN and reconstituted in 0.1% FA in 3% CH3CN.
Immobilized metal ion affinity chromatography (IMAC) was used to enrich the
sample for phosphopeptides. The sample was incubated with IMAC beads for 1 h at room
temperature. Peptides were eluted from the beads in IMAC buffer and the sample diluted
with 0.1% FA in 3% CH3CN. Samples were then analyzed by LC-MS/MS with a NanoLCLTQ-Orbitrap mass spectrometer (Thermo Fisher Scientific) in data dependent mode.
Acquired spectra were searched against Swiss-Prot database through Mascot server to
identify the protein and its post-translational modification. Non-enriched samples were also
run to allow a universal search for protein modifications as well as to search for acetyl
modifications.
To identify FAS modifications specific to membrane-associated FAS and cytoplasmic
FAS, membrane and cytoplasmic fractions were isolated from C57BL/6J mice as described
above. FAS was immunoprecipitated from equal amounts of membrane and cytoplasmic
lysates (1-10 mg/each) by overnight incubation using a polyclonal rabbit anti-FAS antibody.
The samples were then subjected to SDS-PAGE and analyzed as described above.
Statistics. Data are presented as mean ± standard error of the mean. Comparisons
between two groups were performed using an unpaired, two-tailed t-test. ANOVA was used
for comparisons involving more than two groups.
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RESULTS
Hepatic FAS is present in subcellular compartments. FAS synthesizes palmitate, and
FAS deficiency in liver decreases PPARĮ target genes. If the effect of FAS deficiency on
PPARĮ simply reflects palmitate availability, then exogenous palmitate should rescue the
effect. It did not. Treatment of Hepa1-6 cells with 50 μM palmitate failed to rescue
expression of the PPARĮ target gene ACO following FAS knockdown (Figure 1A). Higher
concentrations of palmitate (125-500 μM) were toxic (data not shown).
Since the FAS knockdown effect was not rescued with exogenous palmitate, it is
plausible that not only the product of the FAS reaction but also the location of its synthesis
mediates downstream effects. Dogma holds that FAS is a cytoplasmic enzyme. To determine
if FAS is also present at other sites, we fractioned mouse liver FAS by ultracentrifugation
(Figure 1B). FAS co-fractionated with the cytoplasmic marker S6K, but also with markers for
several organelles. Immunofluorescent staining for FAS in murine Hepa1-6 liver cells
demonstrated co-localization of FAS with ER and Golgi markers but not peroxisomal or
mitochondrial markers (Figure 1C). FAS did not appear in the nucleus (Figure 1C).
Membrane-associated and cytoplasmic FAS are differentially regulated. FAS is
induced by insulin and nutrients [12]. Surprisingly, the specific activity of mouse liver
cytoplasmic FAS was not increased in the fed state when insulin levels are high (Figure 2A).
Membrane-associated FAS specific activity was increased with feeding (Figure 2B). The
cytoplasmic/membrane activity ratio in liver was increased with fasting, when PPARα is
activated (Figure 2C). In Hepa1-6 cells, a transformed liver cell line, insulin significantly
decreased cytoplasmic FAS activity (Figure 2D), an effect that was not seen in the membrane
fraction (Figure 2E). As with mouse liver, the cytoplasmic/membrane activity ratio in Hepa16 cells was increased in the absence of added insulin (Figure 2F), a mimic of fasting.
To begin to address the possibility that membrane-associated FAS is an artifact of
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preparation, we treated isolated fractions with different solvents. Membrane-associated FAS
resisted solubilization by 1 M NaCl, remaining in the pelleted fraction, but was largely
solubilized by 0.1 M Na2CO3 (Figure 3A). Treatment with detergent (1% SDS or 1% Triton
X-100) solubilized most FAS protein (Figure 3A). These results suggest [17-19] that FAS
manifests a strong peripheral membrane interaction.
A pulse-chase study showed that radiolabelled FAS decreased over time in the
membrane-associated and cytoplasmic compartments (Figure 3B), suggesting that there is no
ordered flux of protein from one compartment to another over the time course of this
experiment. There was no discernible change in the distribution of FAS between membrane
and cytoplasm when cells were treated with insulin (Figure 3C).
Given the presence of a putative open reading frame (with a potential alternative start
codon) 5’ to the published first exon of both mouse and human FAS, we considered the
possibility that compartmentalized FAS represented differential splicing leading to nonidentical protein isoforms, only one of which is membrane-targeted. However, mass
spectrometric analysis of FAS in membrane and cytoplasm failed to detect the predicted
alternative amino acids at the N-terminus, and identified the published FAS protein sequence
as being N-terminally acetylated (Figure 3D). This modification, which marks the N-terminus
of most eukaryotic proteins [20], was present in membrane and cytoplasmic fractions of FAS,
precluding the existence of additional N-terminal sequence. All regions of the FAS protein
were similarly represented in each fraction, decreasing the possibility that compartment
location is determined by altered protein sequence due to a process such as exon exclusion
(data not shown).
Collectively, these results suggest that the enzyme activities of cytoplasmic and
membrane-associated FAS are differentially regulated, a phenomenon that does not appear to
be due to intracellular trafficking of the protein or differences in its primary structure.

69

Cytoplasmic FAS is preferentially phosphorylated. To address the possibility that
differential regulation of cytoplasmic and membrane-associated FAS is caused by a covalent
modification, we immunoprecipitated hepatic FAS from fasting and fed mice then tested
different fractions for the presence of phosphothreonine by Western blotting. Cytoplasmic
FAS in fed mice was strongly threonine phosphorylated, a modification that was almost
undetectable in fasted mice (Figure 4A). Phosphorylation of membrane-associated FAS was
low under both conditions (Figure 4A). In Hepa1-6 cells, insulin treatment (a mimic of
feeding) stimulated threonine phosphorylation of cytoplasmic but not membrane-associated
FAS (Figure 4B).
Analysis of FAS protein from unfractionated mouse liver by mass spectrometry
revealed only a single peptide that was threonine phosphorylated. This modification was
detected at two residues, Thr-1029 and Thr-1033 (a representative spectrum is shown in
Figure 5A). When liver FAS was separated into cytoplasmic and membrane-associated
fractions and subjected to the same analysis, the phosphorylated peptide was found
predominantly in the cytoplasm (Figure 5B) despite similar total amounts of the peptide in
both fractions (data not shown). These results suggest that the phosphorylated FAS species
detected in the cytoplasm with feeding or insulin (Figure 4A,B) is modified at Thr-1029 and
Thr-1033.
These residues are in the dehydratase domain of FAS. The function of this domain
requires two catalytic residues, His-878 and Asp-1032, and a third residue, Gln-1036, that
maintains the orientation of the catalytic residues [21]. The phosphorylated residues we
identified (denoted by * in Figure 5C) are in close proximity to the catalytic residue D1032
and the structural residue Q1036 (denoted by # in Figure 5C). Sequence alignment of the
dehydratase regions from different species revealed that in addition to strict conservation of
the active site residues D1032 and Q1036 (denoted by #), the phosphoresidues we identified
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are also conserved as either serines or threonines in humans, mice, rats, D. melanogaster, and
C. elegans (boxes, Figure 5D).
Since the evolutionary conservation of these phosphorylation sites suggests
involvement in FAS function, we mutated S1028 and T1032 in human FAS (corresponding to
the T1029 and T1033 in murine FAS) to alanines, generating two single mutants (S1028A
and T1032A) and one double mutant (S1028A/T1032A) (Figure 5E, mutated sites are
indicated by boxes and the active site residues by #). Wild type or mutant human FAS was
then expressed in Hepa1-6 cells following knockdown of endogenous mouse FAS. Compared
to cells expressing wild-type human FAS, cells expressing the S1028A mutation had
increased levels of the PPARĮ target gene CPT1 (Figure 5F), while cells expressing the
T1032A mutation did not show changes in PPARĮ target genes (Figure 5G). However,
expression of the double mutant S1028A/T1032A was associated with increased levels of
both ACO and CPT1 (Figure 5H). To test whether this effect could truly be mediated by
PPAR transcriptional activity, we performed a PPRE-luciferase reporter assay on Hepa1-6
cells. After expression of wild type or S1028A/T1032A double mutant FAS and knockdown
of endogenous mouse FAS, cells were transfected with plasmid encoding three tandem
peroxisome proliferator response elements (PPREs) fused to a firefly luciferase reporter gene.
Luciferase activity was five-fold increased in cells expressing S1028A/T1032A double
mutant FAS compared to wild type FAS (Figure 5I), indicating that the effect of FAS mutant
expression on the PPARĮ target genes ACO and CPT1 is indeed likely to be mediated by a
change in PPAR transcriptional activity. These data suggest that the inability to
phosphorylate FAS at these two sites disinhibits FAS enzyme activity to promote PPARĮ
target gene expression.
mTORC1 phosphorylates and inactivates FAS and inhibits PPARĮ activity. mTORC1
was recently identified as a physiologically important negative regulator of hepatic PPARĮ
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[22]. mTOR, the kinase component of mTORC1, is a serine/threonine kinase that
preferentially phosphorylates sites with hydrophobic residues at the +1 position [23]. Since
the phosphorylated residues we identified have the highly hydrophobic phenylalanine
(F1030) and methionine (M1034) at the +1 positions, we addressed a role for mTORC1 in
FAS phosphorylation. Treating Hepa1-6 cells with the mTORC1 inhibitor rapamycin for 30
min abolished the insulin-induced increase in cytoplasmic FAS threonine phosphorylation
(Figure 6A) and was associated with an increase in cytoplasmic FAS specific activity (Figure
6B). Treatment of these cells with Torin 1 at 250 nM also abolished insulin-induced FAS
phosphorylation (data not shown). Treating Hepa1-6 cells with rapamycin for 24 h (a
sufficient time to reach a new steady state for mRNA levels) decreased expression of the
PPARĮ target gene CPT1 (Figure 6C). These findings confirm those made in a different
system [22] and extend that work by implicating FAS in the mTORC1-PPARα axis.
To better define the interaction between mTORC1, FAS, and PPARα, FAS was
knocked down in Hepa1-6 cells followed by rapamycin treatment. FAS knockdown,
confirmed in the presence of rapamycin (Figure 6D), decreased CPT1 expression (Figure 6E).
The induction of CPT1 levels with rapamycin occurring with FAS expression (Figure 6C)
was lost with FAS knockdown (Figure 6E, solid bar). These results suggest that in this cell
line under these conditions, the induction of the PPARĮ target gene CPT1 caused by
inhibition of mTORC1 is FAS-dependent.
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DISCUSSION
FAS synthesizes lipid for energy storage and participates in the generation of a lipid
ligand involved in the activation of fatty acid oxidation. Energy storage occurs with feeding
and activation of fatty acid oxidation occurs with fasting. To clarify how the same enzyme
mediates both processes, we pursued the possibility that distinct pools of FAS are
differentially regulated in the liver.
We found FAS in the cytosol, but also localized FAS to organelles (Figure 1) through
a strong peripheral membrane interaction (Figure 3A). FAS specific activity was relatively
higher with feeding/insulin in membranes and relatively higher with fasting in the cytosol
(Figure 2). This effect did not appear to involve movement of FAS between compartments or
primary sequence differences between these pools of FAS. Instead, this activity difference
was associated with preferential phosphorylation of cytoplasmic (but not membrane) FAS
with feeding (Figure 4) at conserved sites within a catalytic domain (Figure 5). Mutation of
these sites increased endogenous PPARα target gene expression as well as activity of a
PPRE-dependent reporter gene (Figure 5) consistent with disinhibition of FAS in the absence
of phosphorylation. Inhibition of mTORC1 with rapamycin decreased FAS phosphorylation,
increased cytosolic FAS enzyme activity, and increased expression of the PPARα target gene
CPT1, an effect that was FAS-dependent (Figure 6). One interpretation of these findings is
that hepatic FAS exists in at least two differentially regulated subcellular pools, cytoplasmic
and membrane-associated (Figure 7). Cytoplasmic FAS is phosphorylated with feeding to
limit PPARĮ activation, and dephosphorylated with fasting to promote PPARĮ activation.
Our findings provide molecular definition and physiological context to an observation
made nearly four decades ago in birds. Using pigeon liver as a model and exclusively
studying FAS in the cytoplasm, Qureshi and colleagues found that feeding induced 32P
incorporation into FAS, which was associated with a loss of enzyme activity [24]. In vitro
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treatment with phosphatases dephosphorylated FAS and restored enzyme activity. The
authors of this study did not identify a physiological role for this covalent modification and it
is not known if the phosphosites we found are conserved in pigeon FAS due to the
unavailability of sequence data for this species. Regardless, our work suggests that the
phosphorylation state of cytoplasmic FAS may channel lipid flow to impact phospholipids
inducing gene expression in the nucleus.
Physiological, mass spectrometric, and crystal structure data indicate that
phospholipids interact with nuclear receptors [6, 25-29]. FAS appears to be linked to PPARα
through phosphatidylcholine synthesis mediated by the Kennedy pathway [6]. Viewed with
previous studies showing that phosphorylation regulates the CDP-choline branch of the
Kennedy pathway [30, 31], our identification of functionally relevant FAS phosphorylation
sites raises the possibility that phosphorylation at several nodes within a cascade of lipid
signaling from the cytoplasm to the nucleus coordinates FAS-mediated PPARα activation.
Palmitate is the direct product of the FAS reaction. If the mere availability of
palmitate were required to activate PPARα, exogenous palmitate would correct FAS
deficiency. However, the addition of palmitate to liver cells with FAS deficiency does not
restore defects in PPARα-dependent genes (Figure 1) and elevated serum palmitate levels
that accompany inactivation of liver FAS in mice does not rescue impaired activation of
PPARα-dependent genes [8]. Thus, palmitate produced by FAS appears to be
compartmentalized, a notion supported by our finding of preferential phosphorylation
depending on cellular location and nutritional state.
There is precedent for compartmentalization in metabolism. Exogenous
administration of T3, the active form of thyroid hormone that can be produced locally from
its precursor T4, does not rescue gene expression defects in the setting of hypothyroidism.
But administration of T4, which is metabolized to generate T3 locally, restores downstream
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effects [32]. There is also precedent for compartmentalization in lipid signaling. Phosphatidic
acid derived from glycerolipid synthesis has effects on mTORC2 that are opposite from those
induced by phosphatidic acid derived from membrane lipolysis [33]. These observations are
consistent with our model (Figure 7). In the fed state, cytoplasmic FAS is phosphorylated to
limit lipid production resulting in PPARα activation, while membrane FAS, less susceptible
to phosphorylation, likely produces lipids for energy storage or export. Given the rapid
demands of lipid synthesis prompted by transition from the fasting to the fed state, the
induction of membrane FAS may be predominantly substrate driven through allosteric
activation by the glycolytic intermediate fructose-1,6-bisphosphate [34].
mTORC1 may control the reciprocal activity of FAS in different compartments.
mTORC1 is activated by insulin and nutrients, prefers substrates like those we identified in
the dehydratase domain, and is known to suppress PPARĮ in the liver [22]. FAS and
mTORC1 appear to interact in the central nervous system where the physiological effects of
FAS inhibition are blunted by rapamycin [35], consistent with our model suggesting that
mTORC1 inhibition would increase FAS activity.
Our work provides evidence that hepatic FAS is in the cytoplasm as well as
peripherally associated with membranes. These two pools are differentially regulated by
nutrients and insulin, and differentially susceptible to phosphorylation, thus providing a
conceptual framework for understanding how FAS-mediated PPARĮ activation is linked to
the fasting state. Pharmacologically targeting modulators of FAS phosphorylation or
localization could allow the selective regulation of one pool of FAS. While complete
inhibition of FAS in liver leads to loss of PPARĮ activation and consequently fatty liver,
specifically targeting FAS-mediated lipid storage and avoiding the undesirable inhibition of
PPARĮ in this manner could, in theory, be an effective treatment for fatty liver and other
disorders associated with nutrient excess.
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FIGURES

Figure 1. Hepatic FAS is not exclusively cytoplasmic. (A) Expression levels of FAS (left)
and the PPARα-dependent gene ACO (right) in Hepa1-6 cells. Cells were treated with a
control (scrambled, sc) shRNA or an FAS shRNA in the presence of exogenous BSA76

conjugated palmitate or vehicle (BSA alone) for 8 h. *indicates P0.05. **indicates P0.005.
***indicates P0.0005. (B) Subcellular distribution of FAS protein in mouse liver by
differential centrifugation followed by Western blotting. Organelle markers: S6K = P70/S6
kinase (cytoplasmic marker), GM130 = Golgi Matrix protein 130 (Golgi marker), Cav1 =
Caveolin1 (caveolae marker), PDI = protein disulfide isomerase (endoplasmic reticulum
marker), Na+/K+ ATPase (plasma membrane marker), PMP70 = Peroxisomal Membrane
Protein 70 (peroxisomal marker), COXIV = Cytochrome C OXidase IV (mitochondrial
marker). (C) Immunofluorescent staining of FAS and expression of GFP-tagged organelle
markers in murine Hepa1-6 cells. Nuclei stained with DAPI are presented on the far left, GFP
images are presented second from left, FAS images are presented second from right, and
merged GFP/FAS images are presented on the far right.

77

Figure 2. Differential regulation of the activities of membrane-associated FAS and
cytoplasmic FAS. (A) Specific activity of FAS in the cytoplasmic fraction of mouse liver.
Mice were either fed ad lib (fed) or fasted for 18h (fasted). Activity was normalized to FAS
protein levels as measured by Western blotting. N=9/group. (B) Specific activity of FAS in
the membrane (Golgi/ER) fraction of mouse liver. Mice were either fed ad lib (fed) or fasted
for 18h (fasted). Activity was normalized to FAS protein levels as measured by Western
blotting. N=5/group. **indicates P0.005. (C) FAS specific activities shown in A and B
expressed as the ratio of FAS specific activity in cytoplasm to FAS specific activity in
membrane. *indicates P0.05. (D) Specific activity of FAS in the cytoplasmic fraction of
Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated times. Activity was
normalized to FAS protein levels as measured by Western blotting. N=3/group. *indicates
P0.05. (E) Specific activity of FAS in the membrane (Golgi/ER) fraction of Hepa1-6 cells.
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Cells were treated with 100 nM insulin for indicated times. Activity was normalized to FAS
protein levels as measured by Western blotting. N=3/group. (F) FAS specific activities shown
in D and E expressed as the ratio of FAS specific activity in cytoplasm to FAS specific
activity in membrane.
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Figure 3. Distinct characteristics of membrane and cytoplasmic FAS. (A) Detection of
FAS protein by Western blotting in pellets and supernatants of membrane fractions following
high-salt, carbonate, and detergent treatments. Mouse liver homogenate was fractionated by
differential centrifugation into cytoplasm (not shown) and membrane pellet (lane 1). The
pellet was resuspended, exposed to solvents as indicated, and again centrifuged to separate
pellet (P) from the new supernatant (S). (B) Pulse-chase analysis of FAS protein in
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membrane and cytoplasm of Hepa1-6 cells. Cells were pulsed with 35S-labeled methionine
for 1 h, then chased with media containing non-labeled methionine for the indicated times.
(C) Expression of GFP-tagged human FAS in Hepa1-6 cells treated with insulin for the
indicated times. Images demonstrate no detectable shifts of FAS between cytoplasmic and
membrane sites with insulin treatment. (D) Representative spectrum of N-terminally
acetylated peptide of FAS. N-terminal acetylation effectively marks the initial amino acid of
the protein, precluding the existence of additional expressed N-terminal exons that might
constitute distinct FAS isoforms.

81

Figure 4. Cytoplasmic FAS is threonine phosphorylated with feeding or insulin
treatment. (A) FAS threonine phosphorylation in response to feeding in mouse liver. FAS
was immunoprecipitated from cytoplasmic and membrane fractions and analyzed for
phosphothreonine by Western blotting. Mice were either fed ad lib (fed) or fasted for 18 h
(fasted). Representative blots are shown. Data are averages of two independent experiments.
*indicates P0.05. (B) FAS threonine phosphorylation in response to insulin in Hepa1-6 cells.
FAS was immunoprecipitated from Hepa1-6 cytoplasmic and membrane fractions and
analyzed for phosphothreonine by Western blotting. Cells were cultured in 0.5% FBS media
for 4 h prior to harvest (starved), or in 0.5% FBS media for 4 hours, then treated with 1 nM
insulin in 10% FBS media for 15 min (refed/insulin). Representative blots are shown. Data
are averages of two independent experiments. *indicates P0.05.
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Figure 5. Phosphorylation of cytoplasmic FAS at the dehydratase domain catalytic site
controls downstream PPARĮ target gene expression. (A) Representative spectrum of the
FAS P-T1029/P-T1033 phosphopeptide from wild type mouse liver. (B) Distribution of PT1029/P-T1033 phosphopeptides identified by mass spectrometry in cytoplasm and
membrane fractions of mouse liver. While the proportion of phosphorylation differed based
on fraction, peptide abundances (phosphorylated + non-phosphorylated) were similar for the
membrane and cytoplasm fractions (not shown). (C) Position of P-T1029 and P-T1033 amino
acid residues in relation to the FAS dehydratase domain active site residues. D1032 is one of
two dehydratase domain catalytic residues in FAS. (D) Sequence alignment of the FAS
putative phospho-amino acids and dehydratase domain active sites in several species. (E)
Diagram of the FAS phosphosite mutants in human FAS. (F) RT-PCR analyses of PPARĮ
target gene expression in Hepa1-6 cells expressing wild type or S1028A mutant FAS.
Endogenous FAS was knocked down using lentiviral shRNA for murine FAS. Wild type or
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mutant human FAS was expressed using retroviruses. Data are averages of three independent
experiments. *indicates P0.05. (G) RT-PCR analyses of PPARĮ target gene expression in
Hepa1-6 cells expressing wild type or T1032A mutant FAS. Assay performed as in (F). Data
are averages of three independent experiments. (H) RT-PCR analyses of PPARĮ target gene
expression in Hepa1-6 cells expressing wild type or S1028A/T1032A mutant FAS. Assay
performed as in (F). Data are averages of three independent experiments. *indicates P0.05.
(I) PPRE-luciferase activity in Hepa1-6 cells expressing wild type or S1028A/T1032A
mutant FAS. Wild type or mutant human FAS was expressed using retroviruses. Endogenous
FAS was knocked down using lentiviral shRNA for murine FAS. Cells were co-transfected
with plasmids encoding 3xPPRE-firefly luciferase and Renilla luciferase. PPRE-luciferase
activity is reported as the ratio of firefly/Renilla luciferase luminescence. N=3-6/group.
***indicates P0.0005.
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Figure 6. FAS phosphorylation is inhibited by rapamycin and impacts CPT1 expression.
(A) Cytoplasmic FAS phosphorylation in response to rapamycin in Hepa1-6 cells. Hepa1-6
cells were treated with vehicle, 100 nM insulin, or 100 nM insulin + 100 nM rapamycin for
30 min. The cytoplasmic fractions were isolated, then FAS was immunoprecipitated and
analyzed for phosphothreonine by Western blotting. *indicates P0.05. (B) Cytoplasmic FAS
activity in response to rapamycin in Hepa1-6 cells. Cells were treated with 100 nM insulin
and vehicle (DMSO) or 100 nM insulin + 100 nM rapamycin for 30 min and FAS enzyme
activity was assayed. Activity was normalized to FAS protein levels as measured by Western
blotting. Data are averages of two independent experiments. *indicates P 0.05. (C) CPT1
expression levels in response to rapamycin in Hepa1-6 cells. Cells were treated with vehicle
(DMSO) or 100 nM rapamycin for 24 h. Data are averages of two independent experiments.
*indicates P0.05. (D) FAS expression levels following FAS knockdown in Hepa1-6 cells.
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N=3-5/group. ***indicates P0.0005. (E) CPT1 expression levels in response to rapamycin
following FAS knockdown in Hepa1-6 cells. N=3-5/group. *indicates P0.05. NS indicates
not significant.
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Figure 7. Schematic depiction of insulin/feeding-regulated FAS phosphorylation and
FAS-mediated PPARĮ activation. In the fed state, mTORC1 promotes phosphorylation of
FAS, thus limiting downstream generation of a phosphatidylcholine ligand that activates
PPARα-dependent gene expression. In the fasting state, dephosphorylated FAS in the
cytoplasm is permissive for the generation of the ligand activating PPARα-dependent gene
expression. Abbreviations: PC = phosphatidylcholine, RXR = retinoid X receptor, TAG =
triacylglycerol.
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Chapter 4:
Phosphatidylcholine Transfer Protein Activates PPARĮ
in the Liver by Nucleo-Cytoplasmic Ligand Shuttling
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ABSTRACT
The nuclear receptor PPARĮ is a key regulator of lipid metabolism in the liver and the
target of the fibrate drugs, used to treat dyslipidemia. Hepatic PPARĮ is activated by an
endogenous phosphatidylcholine (PC) ligand, the production of which is dependent on fatty
acid synthase (FAS) and choline-ethanolamine phosphotransferase-1 (CEPT1), the latter
catalyzing the final step in PC synthesis. It is not known how this lipid reaches the nuclear
PPARĮ from the extranuclear CEPT1. Here, we provide evidence that phosphatidylcholine
transfer protein (PCTP) shuttles PC ligand to PPARĮ in liver.
PCTP knockdown in Hepa1-6 hepatocytes caused dramatic reductions in expression
of PPARĮ target genes, and PCTP co-immunoprecipitated with PPARĮ, suggesting this
effect may be due to a direct interaction. Immunofluorescent imaging showed that PCTP is
found in both cytoplasm and nucleus, and starvation of cells caused an accumulation of PCTP
in the nucleus, consistent with a shuttling function controlled by nutrition.
Using mass spectrometry, we demonstrated that PCTP binds 16:0/18:1-GPC. We
further showed that the binding of this ligand to PCTP is FAS-dependent: in mice with liverspecific knockout of FAS, the amount of 16:0/18:1-GPC bound to PCTP in the nucleus was
significantly reduced. In the cytoplasm, there was no significant difference in binding. In
mice with whole-body knockout of Pctp, the amount of 16:0/18:1-GPC bound to PPARĮ in
the nucleus may be reduced compared to wild type mice.
Taken together, these data suggest that PCTP activates PPARĮ in the liver by
promoting delivery of endogenously synthesized lipid ligand to PPARĮ in the nucleus.
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INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of liver disease
in the Western world and a common comorbidity of the metabolic syndrome [1]. In the
United States, 10–35% of Americans are believed to have fatty liver [2]. While fatty liver in
itself can be benign, it often progresses into nonalcoholic steatohepatitis (NASH), which in
turn can lead to liver cirrhosis and hepatocarcinoma. As of 2013, there are no therapies for
NAFLD that are approved by the FDA in the United States or the EMA in the European
Union. A pharmacological treatment for fatty liver could thus benefit a large fraction of the
population.
One of the major pathways for modulating fat metabolism and transport in the liver is
through the nuclear receptor peroxisome proliferator-activated receptor Į (PPARĮ). In the
liver, PPARĮ is essential for the fasting response and regulates gluconeogenesis, fatty acid
oxidation, and lipoprotein metabolism in response to changes in nutrient availability [3, 4].
Mice lacking PPARĮ are fasting-intolerant and develop hepatosteatosis [3, 4].
PPARĮ is ligand-activated, and in the liver, the phosphatidylcholine (PC) species
16:0/18:1-glycerophoshocholine (16:0/18:1-GPC) functions as an endogenous ligand
activating PPARĮ during periods of fasting or starvation [5]. Synthesis of this ligand and
activation of PPARĮ is dependent on the presence of fatty acid synthase (FAS) and of
choline/ethanolamine phosphotransferase-1 (CEPT1), which catalyzes the final step in
phosphatidylcholine synthesis by the Kennedy pathway [5, 6].
How, then, does ligand synthesized by CEPT1 reach PPARĮ? CEPT1 is located at the
ER and the nuclear membranes [7] with the active site facing the cytoplasm [8], precluding a
direct interaction with the nuclear PPARĮ. Because the cytoplasmic movement of
amphipathic molecules such as phosphatidylcholine is extremely inefficient [9], simple
diffusion of the ligand is an unlikely mechanism of transport. A more likely possibility is that
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phosphatidylcholine ligand is transported to PPARĮ in association with a protein.
Phosphatidylcholine transfer protein (PCTP) is a small, soluble lipid-binding protein
of unclear physiological function. It is also known as StARd2 as it contains a StART (StARrelated lipid-transfer) domain. PCTP binds phosphatidylcholine exclusively, at a 1:1 ratio
[10]. It is highly expressed in the liver [11] and found both in cytoplasm and in the nucleus
[11]. Mice with whole-body knock-out of PCTP have decreased mRNA expression of
PPARĮ target genes in the liver [12]. These characteristics make PCTP an ideal candidate for
a ligand-delivering chaperone for hepatic PPARĮ.
Here, we present evidence that PCTP activates PPARĮ in the liver through the
endogenous FAS-CEPT1 pathway by promoting ligand delivery to PPARĮ in the nucleus.
Any of the nodes of the FAS-PCTP-CEPT1 pathway of PPARĮ activation could potentially
represent novel targets for treatment of fatty liver.
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RESULTS
Loss of PCTP decreases hepatic PPARĮ target gene expression. Gene-chip analysis
of hepatic mRNA in full-body PCTP knock-out mice (Pctp-/- mice) indicates that the mice
have decreased PPARĮ target gene expression compared to controls [12]. We tested the
effect of PCTP ablation in Hepa1-6 cells, a murine hepatoma cell line. Following knockdown
of Pctp with shRNA, expression of the PPARĮ targets ACO and CEPT1 was dramatically
reduced, suggesting a similar role for PCTP with respect to PPARĮ in this in vitro system
(Figure 1A). If the effect of PCTP on PPARĮ is due to PCTP delivering ligand to PPARĮ, it
would be expected that the two proteins physically interact. To test this, we expressed Myctagged PCTP in Hek293T cells and did a pull-down using an anti-Myc antibody. PPARĮ coimmunoprecipitated with Myc (Figure 1B), suggesting a physical interaction between these
proteins.
PCTP shuttles between cytoplasm and PPARĮ in the nucleus in a nutrient-dependent
manner. As PPARĮ is activated under conditions of low nutrients, we hypothesized that the
movement of PCTP would be regulated by nutritional stimuli such that there are greater
amounts of PCTP available to PPARĮ in the nucleus during starvation. To test this, we
imaged Myc-tagged PCTP in Hepa1-6 cells under control or serum-starved conditions using
an antibody against the Myc epitope. Under control conditions, PCTP was evenly distributed
throughout the cell (Figure 2A, left). Under serum-starved conditions, the majority of cells
remained unchanged; however, we found that in a significant proportion of cells, Myc-PCTP
distinctly accumulated in the nucleus (Figure 2A, right). The reason for the heterogeneous
PCTP distribution between cells is unclear.
To confirm the nuclear localization of PPARĮ in this cell line and under these
conditions, we imaged FLAG-tagged PPARĮ in Hepa1-6 cells under control or serum-starved
conditions. FLAG-PPARĮ was exclusively nuclear under either condition (Figure 2B).
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Nuclear PCTP binds 16:0/18:1-GPC in vivo in liver in a FAS-dependent manner. To
determine which phosphatidylcholine (PC) species bind to hepatic PCTP in vivo and their
dependence on FAS, we administrated adenovirus encoding FLAG-tagged PCTP (Ad-PCTPFLAG) or, as a control, untagged GFP to wild type or FASKOL mice. Four days after
adenovirus injection and after fasting the mice for 18 h, the livers were harvested and
fractionated into cytoplasm and nucleus under conditions unlikely to disturb the
ligand/protein interaction. We immunoprecipitated FLAG-tagged PCTP using an antibody
directed at the FLAG epitope. Immunoprecipitate eluates showed a dominant band the size of
PCTP during immunoblotting with an anti-FLAG antibody (representative blot shown in
Figure S1).
Lipids from the eluates were analyzed by mass spectrometry. There was no detectable
PC signal for eluates from mice injected with GFP adenovirus (data not shown). Several
peaks corresponding to PC species were detected in wild type Ad-PCTP-FLAG mice
(representative spectra shown in Figure 3A and 3D), the most abundant being the peaks with
mass to charge ratio (m/z) of 758.6 and 760.6. M/z 758.6 corresponds to 16:1/18:1-GPC or
16:0/18:2-GPC, while m/z 760.6 corresponds to the PPARĮ ligand 16:0/18:1-GPC. These
peaks were detected in both the cytoplasmic and the nuclear eluates. As a control, the
samples were also analyzed for phosphatidylethanolamine (PE). There was no detectable PE
signal (data not shown), consistent with the highly selective PC-binding by PCTP.
Since activation of PPARĮ by 16:0/18:1-GPC is dependent on the lipogenic pathway
including FAS and CEPT1 [5], we tested whether the presence of 16:0/18:1-GPC in the
FLAG-PCTP eluates is dependent on the presence of FAS using mice with liver-specific
ablation of FAS (FASKOL mice). Representative spectra for PC are shown in Figure 3B and
3E. In the cytoplasm, there was no difference in the amount of 16:0/18:1-GPC bound to
FLAG-PCTP (normalized to FLAG protein levels) between wild type and FASKOL mice
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(Figure 3F). In the nucleus, however, the amount of 16:0/18:1-GPC ligand in the FLAG
eluate was significantly reduced in mice lacking FAS (Fig. 3E). M/z 758.6 (corresponding to
16:1/18:1-GPC or 16:0/18:2-GPC) was likewise reduced in the nucleus of mice lacking FAS
(see representative spectra in Figure 3A-B; not quantified).
One interpretation of these data is that FAS participates in the biosynthesis of a lipid
ligand that is delivered to the nucleus by PCTP. The lack of change in cytoplasmic 16:0/18:1GPC levels in the FLAG eluates could reflect participation of cytoplasmic PCTP in additional
functions that involve its binding to dietary or membrane phosphatidylcholine as well,
obscuring any difference solely from loss of FAS.
PPARĮ may bind 16:0/18:1-GPC in vivo in liver in a PCTP-dependent manner. To
test whether the binding of the 16:0/18:1-GPC ligand to PPARĮ is dependent on PCTP, we
administered adenovirus encoding FLAG-tagged PPARĮ (Ad-FLAG-PPARĮ) to Pctp-/- mice
or wild type littermates, then analyzed lipids in the FLAG immunoprecipitate eluate as above.
Immunoblotting with anti-FLAG antibody showed a band the size of PPARĮ in the nuclear
fraction (representative blot shown in Figure S2). There was no detectable FLAG-tagged
protein in the cytoplasmic fraction, as expected from the nuclear localization of PPARĮ (data
not shown).
We analyzed FLAG-PPARĮ eluates for phospholipids by mass spectrometry. No
phosphatidylethanolamine or phosphatidylserine was detected (data not shown). Similar to
PCTP, the dominant peaks for PC were m/z 758.6 and 760.6, corresponding to 16:1/18:1GPC/16:0/18:2-GPC and 16:0/18:1-GPC, respectively (Figure 4A). The relative amounts of
this lipid were over 60% lower in Pctp-/- mice than wild types (representative spectra are
shown in Figure 4A and 4B); however, this difference was not statistically significant
(quantification in Figure 4C; p = 0.20).
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DISCUSSION
The final enzyme in the biosynthesis of an endogenous ligand for PPARĮ, CEPT1, is
exclusively extranuclear, while hepatic PPARĮ is exclusively nuclear. We pursued the
hypothesis that the phosphatidylcholine-binding protein PCTP functions as a transport protein
for the 16:0/18:1-GPC PPARĮ ligand in the liver, shuttling between the cytoplasm and
PPARĮ in the nucleus to deliver ligand and thereby activate PPARĮ during periods of
starvation.
We found that PCTP moved between cytoplasm and nucleus in a nutrient-dependent
manner, tending to accumulate in the nucleus under periods of starvation (Figure 2A). PCTP
co-precipitated with PPARĮ (Figure 1B), suggesting a physical association between the two
proteins that could serve to transfer lipid. PCTP bound 16:0/18:1-GPC, and in the nucleus, it
did so in a manner dependent on FAS (Figure 3), indicating that the ligand delivered to the
nucleus by PCTP is indeed derived from the FAS-catalyzed de novo lipogenic pathway
previously described [5]. Binding of the 16:0/18:1-GPC ligand to PPARĮ may in turn be
dependent on the presence of PCTP (Figure 4), supporting a role for PCTP in delivering this
ligand to hepatic PPARĮ.
Because of the capacious ligand-binding domain of PPARĮ, there are likely several
endogenous ligands with varying transactivation capabilities and tissue distribution. It
follows, then, that there may be several ligand-binding chaperones with varying specificities
and distributions for transport of lipid ligands with poor solubility, both for PPARĮ and for
the other PPARs. It will be of interest to characterize the transport mechanisms for
endogenous PPAR ligands in other tissues as well, as this could potentially provide new ways
of selectively or concomitantly modulating desired sets of PPARs to achieve a therapeutic
effect.
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MATERIALS AND METHODS
Animals. Pctpí/í mice (gift from David Cohen, Brigham and Women’s Hospital,
generated as described [13]) and littermate control mice were on an FVB/NJ genetic
background. Pctpí/í mice were genotyped using Klentaq and the following primer sets: 5’CCCTTCTTGCCGTCACTC-3’ and 5’- TACGTCTACACCCGCCAG-3’ resulting in a 162
bp PCTP fragment and 5’-TGTCAAGACCGACCTGTCCG-3’ and 5’-TATTCGGCAAGCAGGCATCG-3’ resulting in a 447 bp fragment of the Neomycin resistance gene replacing
the Pctp gene in knock-out alleles. Liver-specific FAS knock-out mice (FASKOL mice) and
littermate controls were on a C57BL/6J background and were genotyped using previously
described primer sets [6].
Mice were provided ad libitum access to chow diet (Purina #5053) or fasted for 18 h.
All mice were kept on Aspen bedding during fasting/feeding experiments and had free access
to water. Protocols were approved by the Washington University Animal Studies Committee.
Antibodies. Rabbit monoclonal antibody against p70 S6 Kinase (2708) was from Cell
Signaling Technology (Danvers, MA). Rabbit polyclonal antibody against Myc (sc789) and
rabbit polyclonal antibody against PPARĮ (sc9000) were from Santa Cruz Biotechnology
(Santa Cruz, CA). Mouse monoclonal antibody against FLAG (F1804) was from Sigma (St.
Louis, MO).
Cell culture. Hepa1-6 cells, Hek293, and Hek293T cells were maintained in DMEM
+ 10% FBS.
Lentiviral shRNA-mediated knockdown. Plasmid encoding shRNA for mouse
PCTP (TRCN0000105217) was obtained from Open Biosystems (Huntsville, AL). Packaging
vector psPAX2 (12260) and envelope vector pMD2.G (12259) were obtained from Addgene
(Cambridge, MA). 70% confluent Hek293T cells in a 15 cm dish were transfected using
Lipofectamine 2000 with 8 μg psPAX2, 2.25 μg pMD2.G, and 3 μg mouse PCTP shRNA.
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After 48 h, media was collected and filtered through 0.45 μm syringe filters. Polybrene was
added and the media was used to treat 50-70% confluent Hepa1-6 cells. After 24 h, the media
was aspirated and replaced with fresh media. 48 h after addition of retroviral media, cells
were selected with puromycin. After another 48 h, cells were harvested and knockdown of
PCTP was assessed.
RT-PCR. Total RNA was extracted with TRIzol reagent (Invitrogen, Carlsbad, CA)
and reverse transcribed using iScript™ cDNA synthesis kit (Invitrogen). Quantitative RTPCR was performed using SYBR® Green reagent (Applied Biosystems, Carlsbad, CA) with
an ABI Prism 7700 PCR instrument.
Plasmid constructs. Plasmid encoding Myc-tagged PCTP was a gift from David
Cohen (Brigham and Women’s Hospital).
Transfection. Hepa1-6 cells were transfected by electroporation. 25 μg plasmid DNA
was used per confluent 10 cm dish of Hepa1-6 cells (or ~1x107 cells). Plasmid DNA was
added to the bottom of a cuvette. Cells were trypsinized and spun down after adding regular
media. Media was aspirated and the cells washed in PBS and spun again. PBS was aspirated
and cells were resuspended in 0.5 ml PBS and transferred to the cuvette. The cuvette with
cells and DNA was electroporated at 360 V and 250 μF (time constant of 4.5-5 sec-1) and 1
ml of media was immediately added to the cuvette. Cells were transferred to a 15 ml tube and
media was added up to 5-10 ml. Cells were allowed to recover for 10 min after which they
were plated. For immunofluorescent imaging, cells were plated directly onto fibronectincovered glass coverslips (BD Biosciences) in 6-well dishes and imaged 2 days following
transfection.
Hek293T cells were transfected using Lipofectamine 2000 (Invitrogen) according to
the manufacturer’s instructions. 10 μg of plasmid was used per 10 cm dish of ~90% confluent
Hek293T cells. Cells were harvested for immunoprecipitation the following day.
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Myc immunoprecipitation. 0.5 mg protein lysate from Hek293T cells in 1 ml of
buffer containing 0.5% NP-40 was incubated with 20 μl anti-Myc antibody on a rocker at
4°C overnight. 50 μl agarose beads were then added and the sample incubated for another 1 h
on a rocker at 4°C. The beads were spun down, the supernatant aspirated, and the beads were
washed with HNTG buffer 3 times before boiling the beads in 2X loading buffer for Western
blotting and loading the entire volume onto a protein gel.
Adenoviruses. Adenovirus encoding FLAG-tagged wild type mouse PPARĮ and
adenovirus encoding a GFP marker only were gifts from T. C. Leone and D. P. Kelly. To
make adenovirus encoding FLAG-tagged wild type mouse PCTP, murine Hepa1-6 cell
cDNA was used as template to amplify full-length Pctp by PCR with primers adding a 5’
BamHI site followed by a FLAG tag on the 5’ side and an XhoI site on the 3’ side:
5’-ACAACAGGATCCACCATGGATTACAAGGATGACG- 3’ and 5’-ACAACACTCGAGTTAGGTTTTCTTGTGGTAGTTC-3’. The amplified Pctp was cut using BamHI and
XhoI, ligated with pAdTrack-CMV vector (encoding a GFP marker) that had been cut with
BglII and XhoI, and recombined with Ad-Easy1 vector.
Adenoviruses were packaged in Hek293 cells and purified with cesium chloride
ultracentrifugation. Optimal dosing of the adenoviruses was determined by assaying for
adenoviral protein expression by Western blotting and the survival of mice injected with
varying doses of adenovirus. Adenovirus was injected in 100 μl total volume. Livers were
harvested four days following injection for nuclear extraction and FLAG
immunoprecipitation for mass spectrometry.
Nuclear extraction. Perfused liver from Pctpí/í mice, FASKOL mice, or appropriate
control mice was harvested and ~100 mg liver was added directly into a glass homogenizing
tube on ice containing 1 ml of cold non-detergent-containing hypotonic buffer (10 mM
HEPES [pH 7.9], 1.5 mM MgCl2, 10 mM KCl, 1 mM DTT, protease and phosphatase
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inhibitors). After 5 min incubation on ice, the liver was manually homogenized using a glass
pestle. After an additional 10 min incubation, the homogenate was centrifuged at 8000 g at
4°C for 20 min. The supernatant (cytoplasmic fraction) was removed to a fresh tube. The
pellet was resuspended in nuclear extraction buffer (10 mM HEPES, 0.42 M NaCl, 25%
glycerol, 1.5 mM MgCl2, 0.5 mM EDTA, 1 mM DTT, protease and phosphatase inhibitors),
placed on a rotating shaker at 4°C for 1 h, then centrifuged at 18,000 g for 10 min. The
supernatant (nuclear fraction) was removed to a fresh tube.
FLAG immunoprecipitation. Cytoplasmic or nuclear extract (~3 mg of cytoplasmic
protein or ~600 μg nuclear protein in a total volume of 750 μl) was incubated with 50 μl antiFLAG M2-Agarose affinity gel beads (A2220, Sigma) overnight at 4°C on a rotating shaker.
Five washes (wash buffer: 50 mM Tris HCl [pH 7.4], 100 mM NaCl, protease and
phosphatase inhibitor cocktail) were followed by elution by competition with excess 3x
FLAG peptide (F4799, Sigma; 150 ng/ml). A 25 μl aliquot of the eluted sample was
processed for immunoblotting. The remainder was transferred to glass tubes along with 1 ml
of chloroform per sample and processed for mass spectrometry.
Mass spectrometry. Lipids were extracted from the samples, mixed with 14:0/14:0GPC as an internal standard for PC, and analyzed as [M+H]+ ions by positive ion ESI/MS.
Statistics. Data are shown as mean ± SEM. Comparisons between two groups were
performed using un unpaired, two-tailed t-test. Comparisons between more than two groups
were performed using ANOVA.
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FIGURES

Figure 1. PCTP promotes hepatic PPARĮ target gene expression and physically
associates with PPARĮ. (A) mRNA expression of Pctp, Aco, and Cpt1 as measured by realtime RT-PCR in Hepa1-6 cells with or without knock-down of Pctp using shRNA.
Expression levels are normalized to the ribosomal gene L32. *indicates P0.05. (B) Coimmunoprecipitation of PPARĮ and Myc-tagged PCTP. Myc-PCTP was overexpressed in
Hek293T cells and immunoprecipitated using anti-Myc antibody. The immunoprecipitate
eluates were analyzed by Western blotting as shown for PPARĮ and Myc (PCTP).
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Figure 2. PCTP shuttles between cytoplasm and the nucleus in a nutrient-dependent
manner. (A) Representative images of immunofluorescent staining of Myc-tagged PCTP in
Hepa1-6 cells during control or serum-starved conditions. Hepa1-6 cells were transfected
with Myc-PCTP by electroporation two days prior to experiment. Cells pictured on the left
were kept in media containing 10% FBS (fresh at 6 h prior to fixation). Cells pictured on the
right were starved in media containing 0.5% FBS for 6 h prior to fixation. BF denotes brightfield. Insets show cells stained with secondary antibody only. (B) Representative images of
immunofluorescent staining of FLAG-tagged PPARĮ in Hepa1-6 cells under control or
serum-starved conditions (as described for panel A). Cells were treated with FLAG- PPARĮ
adenovirus two days prior to harvest. There were no cells under either condition where extranuclear PPARĮ staining was visible.
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Figure 3. Nuclear PCTP binds 16:0/18:1-GPC in vivo in liver in a FAS-dependent
manner. (A-B) and (D-E) Representative mass spectra of phosphatidylcholine bound to
FLAG-PCTP immunoprecipitated from nuclear and cytoplasmic fractions of liver from
FASKOL mice or wild type littermates. The insets show magnification of peaks including
that corresponding to 16:0/18:1-GPC. (C) Quantification of 16:0/18:1-GPC abundance in
nuclear PCTP expressed as percentage of wild type, as measured by mass spectrometry.
*indicates P0.05. (F) Quantification of 16:0/18:1-GPC abundance in cytoplasmic PCTP
expressed as percentage of wild type, as measured by mass spectrometry.
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Figure 4. PPARĮ binds 16:0/18:1-GPC in vivo in liver in a PCTP-dependent manner.
(A-B) Representative mass spectra of phosphatidylcholine bound to FLAG-PPARĮ
immunoprecipitated from nuclear fractions of liver from Pctp-/- mice and wild type
littermates. The insets show magnification of peaks including that corresponding to
16:0/18:1-GPC. (C) Quantification of 16:0/18:1-GPC abundance in nuclear PPARĮ
expressed as percentage of wild type, as measured by mass spectrometry.
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Figure 5. Proposed model of PCTP-mediated ligand delivery to PPARĮ. In the fasting
state, FAS is active and promotes synthesis of an endogenous PC ligand for PCTP, which can
then enter the nucleus and deliver the ligand to PPARĮ. PPARĮ then promotes transcription
of genes involved in fatty acid oxidation and ketogenesis. Abbreviations: CEPT1,
choline/ethanolamine phosphotransferase 1; FAS, fatty acid synthase; PC,
phosphatidylcholine; PCTP, phosphatidylcholine transfer protein, PPARĮ, peroxisome
proliferator-activated receptor alpha; RXR = retinoid X receptor.
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Figure S1. FLAG protein levels in liver from mice injected with PCTP-FLAG or GFP
adenovirus. “KO” refers to FASKOL mice. “Wt” refers to wild type, FAS lox+/+ mice not
expressing Cre.
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Figure S2. FLAG protein levels in liver from mice injected with PPARĮ-FLAG
adenovirus. “KO” refers to a Pctp-/- mouse. “Wt” refers to a wild type littermate.
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Chapter 5:
Conclusions
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The studies presented in this dissertation demonstrate how the post-translational
regulation of a signaling lipid—16:0/18:1-glycerophosphocholine—ensures appropriate
metabolic responses to changes in nutrient and hormone levels.
This lipid activates the hepatic fasting response via PPARĮ, and we have shown that
its activity is regulated both at the level of its synthesis and by its subcellular location. In
Chapter 2 and 3, we demonstrated that PPARĮ activation by 16:0/18:1-GPC is controlled by
multiple modes of post-translational regulation of its biosynthesis by fatty acid synthase
(FAS). In Chapter 4, we demonstrated that the nucleo-cytoplasmic transport of 16:0/18:1GPC by phosphatidylcholine transfer protein (PCTP) regulates PPARĮ activation.
Here, I will briefly discuss these findings in the context of four things I learned from
my graduate research.

1.

The cytoplasm is a big place
In Chapter 3, I presented evidence that FAS protein in the liver is compartmentalized

into two separate subcellular locations, each with its own distinct pattern of regulation and
physiological function. In Chapter 2, a possible mechanism for the membrane localization of
FAS was provided by identifying two cytoskeletal proteins, Septin-2 and Septin-7, that
associate with FAS exclusively in the membrane fraction.
The dual location of FAS was surprising, as FAS is a cytoplasmic protein according
to textbooks (the term “cytosolic FAS” is used to distinguish it from mitochondrial type II
FAS in some sources [1]). The discovery that liver FAS concentrates at the ER and Golgi was
a chance observation. But the textbooks are correct: FAS is not a membrane-spanning protein
or a secreted protein and does not exist within any intracellular organelles. “Cytoplasmic” is
simply too broad a term to be useful in describing location. As exemplified by FAS, a protein
freely floating in the cytoplasm can be very different in function and regulation from the
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same protein peripherally associated with the cytoplasmic side of a membrane—even though
they are both, technically, cytoplasmic proteins.
2.

Some things are not new, just forgotten
Even more surprising was the discovery that cytoplasmic FAS is active during fasting,

while membrane FAS is active during feeding; our hypothesis for months had been that the
unexpected membrane-bound FAS would be responsible for the correspondingly unexpected
role of FAS in PPARĮ activation. Actually measuring FAS activity in mouse liver after ad lib
feeding or fasting, however, disrupted this hypothesis (Chapter 3, Figure 2).
I found it worrisome that the “classical,” cytoplasmic pool of FAS was regulated in
the opposite direction of how it was supposed to be regulated—let alone that the changes in
specific activity by necessity involved post-translational regulation, another feature that FAS
was not thought to possess. However, a careful literature search revealed that we were not the
first to observe feeding-induced inhibition of FAS activity nor post-translational regulation of
FAS activity. In fact, some of the earliest studies on FAS demonstrated changes in FAS
specific activity, allosteric regulation, and post-translational modifications of FAS. In 1968,
Salih Wakil’s group demonstrated allosteric regulation of FAS specific activity by 1,6fructose-bisphosphate, a glycolytic intermediate [2], and in 1975, John Porter’s group
published an account of inhibitory phosphorylation of FAS during feeding in pigeon liver [3].
These were rigorously performed studies on the biochemistry of the FAS protein,
something of a rarity today when FAS mRNA levels are far easier to measure and so a
common proxy for FAS activation. They also provided completely novel and, in the case of
the Porter study, unexpected information about the regulation of FAS. In spite of this, neither
study had ever been cited in a review article; rather, reviews on FAS tend to focus on the
studies showing induction of FAS mRNA by re-feeding following starvation and to define
FAS regulation as transcriptional and feeding-induced [4-6]. The lack of impact of these
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studies can in part be attributed to their age; they used the term “fatty acid synthetase” which
has become less common, and may so be missed during literature searches for “fatty acid
synthase.” But it also emphasizes the importance of reading primary literature, even (or
especially) when it is relatively old. As a side note, I was delighted to find the 1975 article on
inhibition of FAS by phosphorylation; it set my mind at ease that our results were real, yet the
study was old enough that our work would still be considered novel. Sometimes old is new
again.
3.

Housekeeping gene  unregulated gene
In Chapter 3, we demonstrated rapid, post-translational regulation of FAS, a

housekeeping gene. FAS enzymatic activity was controlled through two phosphorylations on
threonines 1029 and 1033 of murine FAS, flanking a crucial catalytic residue. These
phosphorylations were found exclusively in cytoplasmic FAS, where insulin or feeding
induced phosphorylation of FAS by mTORC1 leading to an inhibition of FAS-mediated
PPARĮ activation.
In the textbook Molecular Biology of the Cell, a housekeeping gene is defined as a
“[g]ene serving a function required in all the cell types of an organism, regardless of their
specialized role” [7]. These include genes involved in transcription and translation (such as
ribosomal proteins and heat shock proteins), metabolism (such as genes involved in in lipid
and glucose metabolism), and cell structure (such as actin and myosin). The term is useful
and accurate to indicate genes and proteins that are ubiquitous and necessary for life, but
becomes problematic when it is assumed that “constitutive” expression is equivalent to
“unregulated” expression. If a protein is necessary for life, would that diminish the likelihood
of its regulation by physiological or pathophysiological stimuli, or, by extension, of its
involvement in signaling cascades requiring some manner of regulation? There is no reason
to believe that to be the case.
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An example of this misconception is the use of certain housekeeping genes as internal
standards or loading controls for protein or mRNA levels, such as the the glycolytic enzyme
GAPDH, when the levels of many housekeeping genes and proteins are in fact regulated in
response to various drugs, experimental conditions, cell cycle stages, age etc. (reviewed and
studied in [8]). But more importantly, this misconception puts a damper on interest in
research on housekeeping proteins. A gene assumed not to be regulated is simply not as
interesting for studying dynamic signaling processes.
The “housekeeping” attribute of a protein or gene does make it difficult to study:
unless compensatory mechanisms are at play, a mouse with full-body knock-out of a
housekeeping gene by definition cannot be generated, as the housekeeping protein fulfills a
function required for life. The embryonic lethality resulting from knock-out of many
housekeeping genes obscures more subtle functions and any physiological or
pathophysiological regulation that would occur in adult mice. In the case of FAS, whole-body
knock-out causes early embryonic lethality (probably due to an inability to synthesize cell
membranes), but tissue-specific knock-outs have revealed a number of signaling functions of
FAS specific for different tissues that are sometimes finely regulated [9-14]. How many other
important signaling roles and levels of regulation of housekeeping proteins are unexplored
simply because they are assumed not to exist, or too difficult to study?

4. Not all lipids are the same
Just like not all proteins are the same, there is a staggering variety of lipids in nature
and not all lipids are functionally equivalent. Rather, different lipids (or the same lipid in
different places) play a variety of roles in cell signaling, structure, and energy storage, such as
the function of 16:0/18:1-GPC in activating PPARĮ (and not just 16:0/18:1-GPC, but FASderived 16:0/18:1-GPC specifically). While the variety of functions of such a diverse class of
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biomolecules shouldn’t come as a big surprise, the importance of lipids in signaling has only
gained attention in the past fifteen years. As an illustration of this, the phrases “lipid signaling”
and “signaling lipid” appeared 584 times in articles in the PubMed database over the past
fifteen years (as of 6/20/2013), and prior to that only 44 times since the first usage of “lipid
signaling” in the literature in 1988.
The increasing interest in signaling lipids partly results from improvements in mass
spectrometry, allowing for rapid identification of low-abundance lipid molecules. It also
represents a recognition that the abundance of distinct lipid species may reflect a
corresponding variety in functions. To me, this recognition ties in with the third point in
emphasizing just how much we still do not know about cell biology, even in research fields
that have been studied for decades, such as lipids and housekeeping genes. Thanks to the
enormous increase in our knowledge of biology over the past century, a textbook in
molecular biology may make it seem as if most cell biology has already been worked out.
The challenge lies in seeing the gaps in our knowledge.
The most important classes of larger biomolecules in living organisms are proteins,
nucleic acids, lipids and polysaccharides. It would be easy to dismiss any of the latter classes
as simply “fats” and “sugars” meant for storing and transporting energy, yet the sheer number
of unique lipid species and polysaccharide modifications suggest that there is much we do not
yet know. Developments in mass spectrometry have improved our ability to fill these gaps in
knowledge.
Establishing lipid-protein relationships for signaling lipids will be crucial, as the
existence of protein targets facilitate pharmacological and genetic manipulation for research
or therapeutic purposes. For all the lipid species of yet unknown function, there will be
known and novel proteins involved in their synthesis, transport, and catabolism. Identification
of signaling lipids may provide novel pathways that can be targeted to treat human disease,
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and knowledge of these proteins would provide feasible pharmacological targets to treat
metabolic disease.
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a b s t r a c t
Fatty acid synthase (FAS) catalyzes the de novo synthesis of fatty acids. In the liver, FAS has long been categorized as a housekeeping protein, producing fat for storage of energy when nutrients are present in excess.
Most previous studies of FAS regulation have focused on the control of gene expression. However, recent
ﬁndings suggest that hepatic FAS may also be involved in signaling processes that include activation of peroxisome proliferator-activated receptor α (PPARα). Moreover, reports of rapid alterations in FAS activity as well
as ﬁndings of post-translational modiﬁcations of the FAS protein support the notion that dynamic events in addition to transcription impact FAS regulation. These results indicate that FAS enzyme activity can impact liver
physiology through signaling as well as energy storage and that its regulation may be complex. This article is
part of a Special Issue entitled Triglyceride Metabolism and Disease.
© 2011 Elsevier B.V. All rights reserved.

1. Introduction
The liver is involved in the uptake, synthesis, storage, secretion,
and catabolism of fatty acids and triglycerides. Fatty acid synthase
(FAS), the enzyme catalyzing de novo synthesis of fatty acids, is traditionally thought of as a housekeeping protein, producing fatty acids
that can be used for energy storage, membrane assembly and repair,
and secretion in the form of lipoprotein triglycerides. However, the
contribution by FAS to secreted triglycerides appears to be negligible
compared to other sources of fat under common dietary conditions.
An unexpected role for FAS as a signaling enzyme emerged with the
ﬁnding that FAS can affect fatty acid oxidation through PPARα, the
main mediator of the fasting response in the liver.
The possibility that FAS may be involved in promoting fat catabolism in addition to its known function of synthesizing fat raises new
questions regarding the regulation of FAS. Are there multiple pools
of FAS with distinct functions, allowing separate control of FASmediated signaling and FAS-mediated energy storage? How is FASPPARα signaling regulated in response to nutritional and hormonal
stimuli, and how is it possible for FAS to be activated or inhibited rapidly? FAS has been thought to be regulated mostly at the transcriptional
level, which might preclude an immediate response by FAS to changes
in nutritional or hormonal stimuli since FAS mRNA is fairly stable. A
role for FAS in signaling suggests the presence of rapid, posttranslational mechanisms of FAS regulation. This review will address

☆ This article is part of a Special Issue entitled Triglyceride Metabolism and Disease.
⁎ Corresponding author. Tel.: +1 314 362 7617.
E-mail address: csemenko@wustl.edu (C.F. Semenkovich).
1388-1981/$ – see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbalip.2011.09.017

physiological functions of hepatic FAS, its regulation by nutrients and
hormones, and mechanisms of regulation.
FAS may be a therapeutic target for treating fatty liver and dyslipidemia [1]. Both are common features of the metabolic syndrome
[2,3], which affects ~ 1 in 4 Americans [4]. Both are also independent
risk factors for coronary artery disease [5–7], the most common
cause of death worldwide. Identiﬁcation of regulatory proteins and
pathways distinguishing housekeeping FAS from signaling FAS could
potentially lead to novel therapeutics that selectively target FAS
function.
1.1. Hepatic triglyceride metabolism
Under nutrient-replete conditions, the primary fuel of the liver is
glucose rather than fat. Fatty acids are not subjected to β-oxidation
and instead are incorporated into triglycerides for storage in lipid
droplets or secretion in very low-density lipoproteins (VLDL). Dietary
fat in the form of chylomicron remnants is taken up by the liver; de
novo synthesis of fatty acids by FAS may make a modest contribution
to storing energy as fat when nutrients are present in excess.
During fasting, lipolysis in peripheral tissues (primarily adipose
tissue) increases the levels of plasma free fatty acids (FFAs), which
are taken up by the liver. Activation of the transcription factor peroxisome proliferator-activated receptor α (PPARα) mediates the adaptive
response to fasting by promoting the transcription of genes involved in
the uptake and catabolism of fatty acids [8–11]. Fatty acids derived from
peripheral tissues or intrahepatic lipid droplets are catabolized through
β-oxidation to produce ketone bodies, which are used as fuel when glucose is scarce.
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In insulin resistance, insulin fails to suppress lipolysis in peripheral
tissues even when nutrients are abundant, resulting in high circulating
levels of FFAs that are taken up by the liver. Increased FFA uptake and
perhaps increased de novo synthesis of fat in the liver overwhelms
the capacity for fatty acid oxidation, leading to fat accumulation and
eventually the development of hepatosteatosis or fatty liver.
There are thus three main sources of FFAs that contribute to liver
triglyceride: plasma, de novo synthesis, and dietary fat delivered by
chylomicron remnants. Triglycerides are secreted in VLDL, stored in
lipid droplets, or catabolized through the action of lipases and βoxidation. Fatty acid synthase appears to participate in liver triglyceride
metabolism both by contributing de novo synthesized lipids for storage
and secretion under nutrient-replete conditions and by promoting βoxidation of fatty acids through activation of PPARα under nutrientdeﬁcient conditions.
1.2. Fatty acid synthase
Fatty acid synthase (FAS, encoded by Fasn) catalyzes the biosynthesis of saturated fatty acids from simple precursors (de novo lipogenesis). The primary product of the FAS reaction is palmitate
(C16:0), but stearate (C18:0) and shorter fatty acids may also be produced. FAS substrates are acetyl-CoA, malonyl-CoA, and NADPH.
Acetyl-CoA functions as a primer for the reaction, while NADPH provides reducing equivalents. The fatty acid is elongated from the initial
acetyl-CoA by repeated condensations with malonyl-CoA, which donates two carbons in each cycle of condensation. Palmitate synthesis
thus requires seven cycles of malonyl-CoA addition to an acetyl-CoA
primer to yield a saturated, 16-carbon fatty acid.
The FAS protein exists as a homodimer of 273 kDa subunits. Each
monomer contains seven protein domains required for fatty acid synthesis: acyl carrier, acyl transferase, β-ketoacyl synthase, β-ketoacyl
reductase, β-hydroxylacyl dehydratase, enoyl reductase, and thioesterase [12] (reviewed in Refs. [13–15]). However, FAS is only enzymatically active in the dimeric form [12]. The monomers were
initially thought to be oriented head-to-tail to form the dimer
[16,17], but recent structural data demonstrate a head-to-head orientation of the monomers that are intertwined at their middle to form
an X-shape [18–21]. Mammalian FAS is a type I FAS complex with
the domains consolidated in a single peptide; prokaryotes and yeast
have a type II FAS with separate proteins catalyzing the individual reactions. Type II FAS complexes capable of synthesizing short-chain
(up to 14 carbons) fatty acids are also found in mammalian mitochondria [22].
FAS is a soluble protein and thought to be localized in the cytoplasm, although the speciﬁcs of its subcellular localization are largely
unexplored. Its tissue distribution is broad with highest levels in the
liver, adipose tissue, and lungs [23,24]. Whole-body knockout of FAS
causes embryonic lethality in mice, suggesting that de novo lipogenesis
is necessary early during development [25]. A likely possibility is that
FAS is required to provide lipids for cell membranes of the growing embryo. Viable tissue-speciﬁc FAS knockout mice have been generated, including a liver-speciﬁc knockout (discussed below).
2. Function of FAS in hepatic lipid metabolism
2.1. Contribution of de novo synthesized lipids to stored and secreted
hepatic triglycerides
Hepatic FAS synthesizes lipids that are stored as lipid droplets or
secreted in VLDL in the fed state. In mice, the contribution of liver
FAS to secreted VLDL is minor. Ob/ob mice have 10-fold increased hepatic de novo lipogenesis compared to lean mice, but no signiﬁcant
differences in serum triglycerides [26]. In mice with liver-speciﬁc
knockout of FAS (FASKOL mice), serum triglycerides are normal on
a chow diet [27].

The contribution of de novo lipogenesis to secreted triglycerides
has been studied in humans in the setting of various diets. On diets
low in fat and high in carbohydrate (10% of calories as fat and 75%
as carbohydrate), de novo lipogenesis makes a signiﬁcant contribution to circulating lipids as almost half of VLDL triglyceride is derived
from de novo lipogenesis under these conditions [28]. However, a
typical Western diet is high in fat as well as carbohydrates. In similar
studies using diets higher in fat (30% fat, 55% carbohydrate or 40% fat,
45% carbohydrate), the contribution of de novo lipogenesis to VLDL
triglycerides is undetectable or minor, at 0–10% [28,29]. These diets
are more representative of the high fat, high carbohydrate content
of a typical Western diet, indicating that under common dietary conditions, de novo lipogenesis is not a signiﬁcant contributor to VLDL
triglycerides. Substituting starch for sugar in a high-carbohydrate
diet also decreases the contribution of de novo lipogenesis to 0–1%
or 5% [30,31]. Obese individuals do not appear to have increased
FAS-derived VLDL triglycerides compared to lean individuals [29].
Under the high-fat, high-carbohydrate dietary conditions common
in the Western world today, hepatic FAS thus appears to be a minor
contributor to VLDL triglycerides.
FAS may contribute to triglycerides stored in hepatic lipid droplets. In rats fed a chow diet, 11 ± 1% of hepatic triglycerides are derived from de novo lipogenesis [32]. On a high-fat diet, de novo
lipogenesis is suppressed and only 1.0 ± 0.2% of hepatic triglycerides
are derived from FAS [32]. FASKOL mice on a chow diet have normal,
rather than decreased, liver triglyceride content [27]. It thus appears
that the contribution of de novo lipogenesis to stored triglycerides
is small in healthy liver.
In fatty liver, the contribution of FAS to intrahepatic triglycerides
may be greater. Ob/ob mice have increased hepatic FAS activity and
fatty liver [33], but a mechanistic link between the two has not
been established. In humans with non-alcoholic fatty liver disease,
one group has reported that 26 ± 7% of hepatic triglycerides are derived from de novo lipogenesis [34]. It is unknown how this compares
to the triglyceride content of healthy human liver. However, even in
the setting of hepatic over-accumulation of fat, the contribution of
FAS appears to be less than that of fats derived from peripheral tissues
or dietary fat.

2.2. Regulation of triglyceride metabolism through signaling lipids: ligand
activation of PPARα
PPARα is a member of a family of ligand-activated nuclear receptors important for modulating metabolism and inﬂammation. During
fasting, PPARα promotes lipid uptake and catabolism of fatty acids
through β-oxidation to produce ketone bodies [9–11].
When liver-speciﬁc fatty acid synthase knockout (FASKOL) mice
were generated, they were surprisingly not protected against hepatic
lipid accumulation, but instead developed severe hepatic steatosis
when on a zero-fat diet or with prolonged fasting [35]. The phenotype
of fasted or zero-fat diet-fed FASKOL mice is similar to that of PPARα
null mice: hypoglycemia, low serum ketone levels, marked hepatic
steatosis, and deﬁcient hepatic fatty acid oxidation [10,35]. Much of
this phenotype was corrected by administration of a known PPARα ligand. The deﬁcient PPARα activation in the absence of both FAS and
dietary fat led to the hypothesis that “new” fat, derived from de
novo lipogenesis or dietary fat, can activate PPARα, whereas “old”
fat, derived from peripheral tissues or stored in the liver, cannot. Hydrolysis of hepatic triglycerides has also been shown to mediate
PPARα activation [36], suggesting that triglycerides of different origins (de novo synthesis vs. free fatty acids entering the liver following
lipolysis in peripheral tissues) may occupy separate compartments in
the hepatocyte. In addition to activating PPARα in liver, FAS has been
shown to regulate PPARα in macrophages [37] and hypothalamus
[38] as well.
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Further study of the FASKOL mouse led to the identiﬁcation of an
endogenous ligand for hepatic PPARα: the phosphatidylcholine species 16:0/18:1-glycerophosphocholine [27]. The interaction of this
species with PPARα is dependent on the activity of FAS, and inactivation of choline/ethanolamine phosphotransferase 1 (CEPT1), an enzyme catalyzing the ﬁnal step in phosphatidylcholine biosynthesis,
mimics the FASKOL phenotype [27]. FAS thus appears to contribute
to PPARα activity by promoting the synthesis of one of its ligands.
A summary of the impact of FAS on hepatic triglyceride metabolism is presented in Fig. 1.
2.3. Modulating hepatic FAS to treat disease
Ob/ob mice have increased hepatic FAS gene expression as well as
increased hepatic FAS activity compared to lean mice [33]. Knockdown of the transcription factor carbohydrate response element
binding protein (ChREBP), which promotes the expression of FAS as
well as other genes, in ob/ob liver decreases hepatic lipid accumulation and decreases hepatic lipogenesis, suggesting a link between de
novo lipogenesis by FAS and fatty liver [39]. However, in a gene expression proﬁling study of ob/ob animals separated into high glucose
and lower glucose groups, mice with lower sugars (and thus likely to
be more insulin sensitive) had higher hepatic expression levels of
genes encoding lipogenic enzymes, including FAS, as compared to
mice with higher sugars [40]. This ﬁnding suggests that while activation of lipogenic enzymes in the liver is associated with obesity, this
effect is unlikely to be mechanistically linked to insulin resistance.
FAS inhibitors have been tested in mouse models of obesity and
diabetes. Treatment of lean or obese mice with the FAS inhibitor
C75 causes dramatic weight loss and improvement of hepatic steatosis in obese mice. However, the effect is primarily mediated by reduced food intake through inhibition of hypothalamic FAS (in
addition to possible effects of this particular agent that are independent of FAS), obscuring the potential effects of inhibiting hepatic
FAS [41].
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The FAS inhibitor platensimycin is concentrated in the liver when
administered orally and does not affect food intake [1]. Treatment of
high-fructose diet-fed db/db mice with platensimycin reduces hepatic
FAS activity, hepatic lipid accumulation, and hepatic fatty acid oxidation [1]. These data are consistent with roles for hepatic FAS both as a
producer of fat that may accumulate in liver, and as a generator of
lipid signals to nuclear receptors such as PPARα.
These data also highlight a caveat when considering FAS inhibitors
as therapy for hepatic steatosis: inhibition of FAS can affect both lipid
storage and lipid catabolism, and under conditions where baseline
FAS activity is not particularly high, loss of FAS activity might aggravate rather than ameliorate hepatic steatosis, as seen in the liverspeciﬁc FAS knockout mice [35].
3. Regulation of FAS activity
Transcriptional regulation of FAS has been well characterized, but
little is known about the post-translational regulation of FAS activity.
Similarly, long-term effects of hormones and nutrients on FAS expression are clear but their immediate effects are poorly understood.
3.1. Hormonal and nutritional regulation of FAS
Hepatic FAS is known to be regulated by insulin, glucagon, cyclic
AMP, fructose, glucose, and dietary fat.
Re-feeding mice or rats a high-carbohydrate diet following a prolonged fast causes a robust induction of FAS expression as compared
to the fasted or the ad lib-fed state [42–45]. The effect of carbohydrate
re-feeding is mediated by both insulin and glucose. Insulin regulates
FAS through transcriptional and non-transcriptional mechanisms.
Under nutrient-replete conditions, de novo lipogenesis may promote
storage of excess energy in the form of hepatic triglycerides. Insulin
promotes FAS expression through activation of the transcription factors sterol regulatory element binding protein 1c (SREBP-1c) [46]
and upstream stimulatory factors 1 and 2 (USF1 and USF2) [47,48].

Fig. 1. The role of FAS in hepatic triglyceride metabolism. Fatty acid synthase controls fatty acid catabolism through the synthesis of a ligand for PPARα, which activates fatty acid
oxidation genes. FAS makes a minor contribution of lipids to stored and secreted triglycerides, with the major contributions coming from plasma free fatty acids and dietary fats
from chylomicron remnants. 16:0/18:1 GPC, 16:0/18:1-glycerophosphocholine; DAG, diacylglycerol; FAS, fatty acid synthase; FFA, free fatty acid; PPARα, peroxisome
proliferator-activated receptor alpha; RXR, retinoid X receptor; TAG, triacylglycerol (triglyceride); VLDL, very low-density lipoprotein.
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Conversely, glucagon and cyclic AMP inhibit the increase in FAS activity
induced by carbohydrate re-feeding in rats [42,49,50].
The effect of fasting compared to ad lib feeding on the activity of
hepatic FAS is less clear. In mice, a 6 hour fast reduces FAS expression
levels by 60% compared to ad lib feeding [44], and in rats, a 24 hour
fast reduces FAS expression by over 90% compared to ad lib feeding
[45]. However, a 14 hour fast in mice produces no change in FAS activity compared to ad lib-fed mice [51]. One potential explanation
for the lack of change in FAS activity in some circumstances could
be a relatively long half-life for the FAS protein. It is possible that
changes in FAS gene expression might have little effect on FAS enzyme activity in response to certain physiologically relevant periods
of fasting as compared to the ad lib fed condition.
While insulin promotes the expression of FAS, insulin also acutely
inhibits the enzymatic activity of hepatic FAS, causing a decrease in
FAS activity within minutes [51]. This inhibition is dependent on the
presence of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1), which is phosphorylated in response to insulin
and subsequently associates with FAS [51]. This acute inhibition of
FAS by insulin is blunted in hyperinsulinemic ob/ob mice [51]. While a
clear physiological role for this acute inhibition of FAS activity has not
been determined, it is possible that the acute effect on FAS by insulin
primarily affects FAS lipid signals that impact PPARα. Acute inhibition
of FAS in response to insulin could then serve to halt the fasting response by PPARα and decrease fatty acid oxidation when nutrients
are abundant. Because this acute change alters the speciﬁc activity
of FAS, the effect is likely post-translationally mediated. In contrast,
the long-term effect of insulin on FAS is transcriptionally mediated
and promotes FAS expression, enabling increased storage of energy
as fat.
Carbohydrates directly promote the expression of hepatic FAS in
the liver in addition to having an indirect effect by stimulating insulin
secretion. Feeding mice a high-glucose or high-fructose diet for
1 week leads to 3-fold and 8-fold, respectively, increases in FAS protein [52]. The effect of glucose on FAS expression is mediated by
ChREBP [53–56]. Hepatic metabolism of glucose by glucokinase (GK)
is necessary for the glucose-mediated induction of FAS by ChREBP [57].
The insulin-induced activation of SREBP-1c and the glucose-induced activation of ChREBP act synergistically to promote FAS expression [57]. A
connection between lipid/carbohydrate sensing and metabolism is suggested by the ﬁnding that stearoyl-CoA desaturase (SCD1), an enzyme
catalyzing the synthesis of oleate, is involved in the carbohydrateinduced induction of FAS and other lipogenic enzymes [52].
Dietary fats inhibit FAS expression to decrease de novo lipogenesis
when fats are already abundant. Polyunsaturated fatty acids (PUFAs)
may decrease FAS expression through inhibition of SREBP-1c [58] and
ChREBP [59] activity. Diets consisting of 10% oil inhibit hepatic FAS activity when fed to rats of over the course of 4 weeks, with the greatest
reduction in rats fed ﬁsh oil [60]. Re-feeding rats a carbohydrate-free,
high-fat diet following fasting suppresses FAS gene expression to
levels as low as those seen in rats fasted for 24 h [45].

3.2. Transcription and the FAS promoter
Much of the work on transcriptional regulation of FAS has been
done in rats, but the FAS promoter is highly conserved between species
suggesting that studies of the rat FAS promoter are likely to be relevant
to mice and humans. Regulatory elements and transcription factor
binding sites in the proximal mouse FAS promoter are shown in Fig. 2.
As noted above, SREBP-1c is activated by insulin and under appropriate conditions promotes expression of lipogenic genes, including
FAS. The FAS promoter contains a sterol regulatory element (SRE) at
−150 as well as tandem SREs at positions −72 and −62 that are required for optimal SREBP-1c-mediated activation of FAS expression in
rats [61–63].
An inverted CCAAT box at −94 is a binding site for nuclear factor Y
(NF-Y) and is necessary for inhibition of FAS expression by cyclic AMP
[64,65]. A binding site for the transcription factor speciﬁcity factor 1
(Sp1) is located nearby at −91 [63]. NF-Y and Sp1 proteins interact
[66] and mediate sterol-induced FAS expression synergistically with
SREBP-1c [63,67]. Another transcription factor, X-box binding protein
1 (XBP1), increases FAS promoter activity indirectly via SREBP-1c [68].
Also as noted above, ChREBP plays a central role in the glucoseinduced transcriptional regulation of FAS as well as other lipogenic
and glycolytic genes in the liver [53–56]. Glucose promotes the nuclear
translocation and activation of ChREBP, while polyunsaturated fatty
acids and cyclic AMP inhibit ChREBP activity [59,69]. ChREBP binds to
a carbohydrate response element (ChRE) located at −7214 in the distal
FAS promoter in rats to activate FAS transcription [70]. ChREBP appears
to be the main regulator of glucose-induced FAS expression, as glucose
fails to induce an increase in FAS expression in ChREBP-null hepatocytes
[53]. Mice fed a high-fructose diet have similar amounts of nuclear
ChREBP protein and ChRE-bound ChREBP protein compared to mice
fed a high-glucose diet, suggesting that dietary fructose and glucose
have comparable effects on ChREBP [71].
In addition to the ChRE, a direct repeat-1 (DR-1) element located
between −7110 and −7090 in the distal promoter of rat FAS is necessary for full glucose activation of FAS expression [72]. Hepatic nuclear
factor-4α (HNF-4α) binds to the DR-1 element and interacts with
ChREBP. Ablation of HNF-4α produces a corresponding decrease in
glucose-induced FAS expression [72].
Liver X receptor (LXR), a transcription factor activated by oxysterols,
upregulates FAS expression through direct and indirect mechanisms.
Indirectly, LXR can promote FAS expression by binding to liver X receptor elements (LXREs) in the promoters of the SREBP [73] and ChREBP
[74] genes to promote their transcription. SREBP and ChREBP in turn activate FAS transcription. The LXR-mediated activation of SREBP-1c is the
primary mechanism of insulin-induced SREBP activation [73]. The physiological relevance of LXR-mediated transcriptional regulation of
ChREBP is debated, as LXR is not necessary for the glucose-induced activation of ChREBP [56]. LXR can also bind directly to LXREs located at
positions −686 to −672 of the mouse FAS promoter to activate FAS
transcription [75].

Fig. 2. The mouse proximal FAS promoter. Regulatory elements and nuclear factor binding site nucleotides are highlighted in yellow. IRE, insulin response element; LXRE, liver X
receptor element; Nf-Y, nuclear factor Y binding site; Sp1, speciﬁcity factor 1 binding site; SRE, sterol regulatory element.
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An insulin response element (IRE) containing an E-box DNA binding
motif is located at positions −71 to −50 of the FAS promoter, overlapping two tandem SREs. The IRE is necessary for insulin-induced FAS expression [76]. USF1 and USF2 bind to the IRE [48]. Mutation of the E-box
prevents USF binding and abolishes insulin-induced FAS expression.
However, the importance of USFs in insulin-stimulated FAS expression
remains unclear, because mutation of the E-box also prevented
SREBP-1c binding [47].
3.3. Post-translational regulation of FAS
Transcriptional regulation of FAS may require hours to affect protein
levels since both FAS mRNA and protein are fairly stable, buffering sudden changes due to increased transcription and subsequent translation.
There are several reports of FAS protein being activated or inhibited
in far shorter time frames, as well as reports of changes in FAS activity
that do not correlate with changes in FAS protein levels. Insulin acutely
decreases FAS enzyme activity. In hepatoma cells, FAS activity decreases
linearly from 2 to 15 min after insulin treatment, followed by an increase in FAS activity for 75 min [51]. Peroxynitrate inhibits FAS activity
in adipocytes within 10 min, without any effect on FAS protein levels
[77]. Activation and inhibition of FAS without corresponding changes
in FAS protein levels have been reported in a variety of cancer cell
lines [78–80]. These data suggest the presence of post-translational regulation of FAS.
Phosphorylation has been proposed as a mechanism of FAS regulation in cancer cells, adipocytes, and liver. In livers from pigeons
that were fasted and then re-fed, radiolabeled phosphate was incorporated into FAS in the cytosolic fraction. The phosphorylation
event was associated with low FAS activity, and dephosphorylation
of FAS by incubation with phosphatases caused a 20-fold increase in
FAS activity [81]. Another inhibitory phosphorylation was demonstrated in 3T3-L1 adipocytes, where FAS threonine phosphorylation
was associated with inhibition of FAS activity [77]. This phosphorylation event was shown to require AMP-activated kinase (AMPK), likely
through indirect effects since in vitro kinase assays failed to demonstrate any incorporation of labeled phosphate into FAS in the presence
of AMPK [77]. These ﬁndings suggest the presence of an unidentiﬁed intermediate kinase step.
In human and mouse breast cancer cell lines, the ﬁnding that large
differences in FAS activity between cell lines did not correlate with
FAS protein levels prompted an exploration of FAS phosphorylation
as an alternative mechanism of FAS regulation [79]. Phosphoserine
and phosphothreonine residues were detected in FAS in cell lines
from both species, while FAS phosphotyrosine residues were detected
in human cells only. Phosphorylation of FAS in these cell lines was associated with greater FAS activity [79]. Recently, tyrosine phosphorylation of FAS was noted in two different human breast cancer cell
lines. Both FAS tyrosine phosphorylation and FAS activity were induced by overexpression of human epidermal growth factor receptor
2 (HER2) and decreased by HER2 inhibition, and FAS was phosphorylated when complexed with HER2 [80].
In addition to phosphorylation, FAS was one of a large number of
hepatic metabolic enzymes recently found to be lysine acetylated
[82]. Acetylation was linked with diverse effects on metabolic enzymes, including protein destabilization, activation, and inhibition,
suggesting that acetylation may play a major role in metabolic regulation. Acetylation of FAS could represent a novel mechanism for controlling its activity.
Known examples of post-translational regulation of FAS are summarized in Table 1.
4. Conclusions and future directions
Hepatic FAS is generally thought to be a housekeeping protein,
synthesizing fatty acids for the partitioning and storage of excess
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Table 1
Post-translational modiﬁcations of FAS.
Type of
post-translational
modiﬁcation

Organism and tissue or cell type

Function

Phosphorylation [81]
Threonine
phosphorylation [77]
Threonine and serine
phosphorylation [79]

Pigeon liver
3T3-L1 adipocytes (mouse)

FAS inhibition
FAS inhibition

NMuMG (mouse mammary
epithelial cells), T1 (mouse
mammary tumor cells), SKBr3
(human breast carcinoma cells)
Tyrosine
SKBr3 (human breast
phosphorylation [79,80] carcinoma cells)
Acetylation [82]
Human liver

Unknown,
possibly FAS
activation
FAS activation
Unknown

energy. However, the contribution of FAS to stored and secreted triglycerides is minor under most physiological conditions. Studies of
mice deﬁcient in hepatic FAS have demonstrated that FAS also serves
as a signaling protein, controlling the activation of PPARα under
nutrient-deﬁcient conditions to promote the adaptive response to
fasting.
FAS is regulated in part through effects on gene expression. However,
rapid changes in enzyme activity associated with alterations in nutritional status suggest that post-translational mechanisms underlie enzymatic responses to external stimuli. An approach to understanding
these dynamic effects might include identifying post-translational
modiﬁcations of FAS, characterizing FAS subcellular localization,
searching for FAS-interacting proteins, and pursuing other mechanisms that enable immediate control of FAS activity.
The existence of separate physiological functions for FAS implies
that it might be possible to develop function-speciﬁc therapies. Exclusively modulating the cellular FAS pool that promotes fatty acid oxidation or exclusively modulating the pool that promotes synthesis
of lipids for storage could provide new treatment options for fatty
liver and other serious obesity-related conditions.
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SUMMARY

De novo lipogenesis in adipocytes, especially with
high fat feeding, is poorly understood. We demonstrate that an adipocyte lipogenic pathway encompassing fatty acid synthase (FAS) and PexRAP
(peroxisomal reductase activating PPARg) modulates endogenous PPARg activation and adiposity.
Mice lacking FAS in adult adipose tissue manifested
increased energy expenditure, increased brown fatlike adipocytes in subcutaneous adipose tissue,
and resistance to diet-induced obesity. FAS knockdown in embryonic ﬁbroblasts decreased PPARg
transcriptional activity and adipogenesis. FASdependent alkyl ether phosphatidylcholine species
were associated with PPARg and treatment of
3T3-L1 cells with one such ether lipid increased
PPARg transcriptional activity. PexRAP, a protein
required for alkyl ether lipid synthesis, was associated with peroxisomes and induced during adipogenesis. PexRAP knockdown in cells decreased
PPARg transcriptional activity and adipogenesis.
PexRAP knockdown in mice decreased expression of
PPARg-dependent genes and reduced diet-induced
adiposity. These ﬁndings suggest that inhibiting
PexRAP or related lipogenic enzymes could treat
obesity and diabetes.
INTRODUCTION
A relentless increase in mean global body weight since 1980
has resulted in an estimated 1.5 billion overweight people worldwide, of which a half billion are obese (Finucane et al., 2011).
Obesity leads to diabetes, which is associated with premature
death from many causes (Seshasai et al., 2011). Obesity is
caused by positive energy balance leading to expansion of
adipocyte mass. However, adipocytes possess functional pathways that might be targeted to complement therapies altering
energy balance. De novo lipogenesis, an adipocyte function

that requires the multifunctional enzyme fatty acid synthase
(FAS) (Semenkovich, 1997), is one such potential target since
adipose tissue FAS has been implicated in obesity and insulin
resistance in humans (Moreno-Navarrete et al., 2009; Roberts
et al., 2009; Schleinitz et al., 2010).
Fatty acid synthase catalyzes the ﬁrst committed step in
de novo lipogenesis. The magnitude of de novo lipogenesis is
different in rodents and people. Lipogenesis is thought to be
a relatively minor contributor to whole body lipid stores in
a present-day human consuming a typical high fat diet (Aarsland
et al., 1996; Letexier et al., 2003; McDevitt et al., 2001). However,
pharmacologic or genetic manipulation of enzymes in the lipogenic pathway can have profound metabolic consequences
(Postic and Girard, 2008), suggesting that de novo lipogenesis
might serve a signaling function independent of the generation
of lipid stores (Lodhi et al., 2011). Consistent with this concept,
FAS in liver is part of a lipogenic pathway involved in the generation of a ligand for peroxisome proliferator-activated receptor
a (PPARa) (Chakravarthy et al., 2009), a key transcriptional regulator of fatty acid oxidation.
PPARs, consisting of PPARa, PPARd and PPARg, are ligand
activated transcription factors that form obligate heterodimers
with the retinoid X receptor (RXR) and regulate metabolism
(Wang, 2010). Ligand binding results in a conformational change
in the receptor, promoting dissociation of repressors, recruitment of coactivators, and subsequent activation of target gene
expression. This nuclear receptor family was identiﬁed and
named based on activation by chemicals that promote proliferation of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990).
Peroxisomes participate in the oxidation of certain fatty acids
as well as the synthesis of bile acids and ether lipids (Wanders
and Waterham, 2006). These single membrane-enclosed organelles are present in virtually all eukaryotic cells. In adipocytes
they tend to be small and were referred to as microperoxisomes
by Novikoff and colleagues, who documented a large increase in
peroxisome number during the differentiation of 3T3-L1 adipocytes (Novikoff and Novikoff, 1982; Novikoff et al., 1980).
We sought to evaluate the role of de novo lipogenesis in adipocyte function and metabolism. Here we show that a lipogenic
pathway encompassing FAS and PexRAP (peroxisomal reductase activating PPARg), an enzyme localized to peroxisomes
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Figure 1. Targeted Deletion of Adipose Tissue FAS Decreases Adiposity
(A) FAS protein by western blot in brown (BAT) and white (WAT) adipose tissue of Lox/Lox control (without Cre), adiponectin-Cre control (without ﬂoxed alleles),
and FASKOF mice.
(B) Tissue distribution of FAS protein by western blot. An apparent increased expression of hepatic FAS protein in FASKOF mice was not consistently observed.
(C) FAS enzyme activity assay. *p = 0.031. N = 4/genotype.
(D) Body weight of HFD-fed control and FASKOF male mice. Similar results were also obtained in two additional feeding experiments with different cohorts of
male mice. *p = 0.03. **p = 0.0068 at 16 weeks, 0.0028 at 20 weeks. N = 6-8/genotype. Additional data including females are provided in Table S1.
(E) MRI analysis of body composition in HFD-fed mice. **p < 0.0001. N = 6/genotype.
(F) Tissue weights of HFD-fed control and FASKOF mice. **p = 0.005. N = 6/genotype.
(G) Histologic appearance of WAT harvested from chow-fed or HFD-fed mice.
(H) Adipocyte size distribution determined with the NIH Image J program. Error bars in (C)–(F) represent SEM.

and encoded by a previously unidentiﬁed mammalian gene,
contributes to the endogenous activation of PPARg and modulates adiposity with high fat feeding.
RESULTS
Targeted Deletion of Adipose Tissue FAS
We generated FAS knocked out in fat (FASKOF) mice by
crossing FASlox/lox mice (Chakravarthy et al., 2005) with adiponectin-Cre transgenic mice (Eguchi et al., 2011). FASKOF
mice, born at the expected Mendelian frequency, were overtly
normal. FAS protein was decreased in white and brown adipose
tissue of FASKOF relative to Cre only (without lox sites) and lox/
lox (without Cre) control mice (Figures 1A and 1B). FAS protein
content was not decreased in whole brain extracts of FASKOF
2 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.

mice (Figure 1B). FAS mRNA assayed by quantitative RT-PCR
was the same in the hypothalamus of FASKOF and lox/lox
mice (not shown), suggesting that phenotypes are not likely to
be due to CNS effects (Lu et al., 2011; Ryan et al., 2011). FAS
enzyme activity was decreased in fat but not liver of FASKOF
mice (Figure 1C). Hepatic FAS enzyme activity was not signiﬁcantly increased in the setting of decreased adipose tissue
FAS activity (Figure 1C).
Chow-fed FASKOF and control mice weighed the same.
However, feeding a high fat diet (HFD) elicited a phenotypic
difference. HFD-fed FASKOF mice weighed less (Figure 1D)
and had less adiposity as well as more lean tissue compared
to controls (Figure 1E). The adiposity effect was seen in both
sexes and also in the setting of high carbohydrate/zero fat diet
feeding (Table S1). Epididymal fat pads (white adipose tissue,
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WAT), but not other tissues, from HFD-fed FASKOF mice
weighed less than those from control mice (Figure 1F). White
adipocytes isolated from FASKOF mice were smaller than adipocytes from control mice with HFD feeding (Figures 1G and 1H),
but there was no effect with chow feeding. Genotype and diet
had no effect on adipocyte cell number (not shown), perhaps
reﬂecting induction of adiponectin-Cre expression following adipose tissue development.
The weight of brown adipose tissue (BAT) was not different in
mice fed HFD. However, when adult mice were fed a high carbohydrate/zero fat diet, which maximizes effects due to FAS deﬁciency, the BAT depot in FASKOF mice weighed signiﬁcantly
less than that of control mice (Figure S1A). The histologic
appearance of BAT was not different between genotypes in
mice fed HFD, but lipid stores were depleted (Figure S1B) and
the PPARg target genes CD36, HSL, and ATGL were decreased
(Figure S1C) in the BAT depot from FASKOF mice fed a high
carbohydrate/zero fat diet.
Hepatic histologic appearance (Figure S1D) and lipid content
(Figure S1E) were not different between control and FASKOF
animals.
Altered Thermogenesis in FASKOF Mice
Food intake was not different between FASKOF and control
mice on any diet (Table S1). When studied on a HFD prior to development of statistically signiﬁcant differences in body weight,
FASKOF mice had increased energy expenditure compared to
controls (Figure 2A). Systemic glucose tolerance and insulin
sensitivity were enhanced in HFD-fed FASKOF mice (notable
for less adiposity) compared to controls (Figures 2B and 2C),
but with chow feeding (a condition associated with similar
degrees of adiposity in each genotype) there was no difference
in glucose tolerance between FASKOF and control mice (Figure S1F). Consistent with the observation that decreased
adiposity improves insulin sensitivity in numerous animal models
(Elchebly et al., 1999; Masuzaki et al., 2001; Yang et al., 2005;
Yuan et al., 2001), levels of phospho-Akt relative to total Akt
were increased in skeletal muscle of HFD-fed FASKOF mice
(data not shown). Serum leptin was lower (perhaps reﬂecting
decreased adiposity) but adiponectin was unaffected in HFDfed FASKOF mice (Table S1). Given effects of FAS deletion on
other PPARg genes (see below), it is possible that not all targets
of PPARg, including adiponectin, are affected by FAS deletion.
Monitored physical activity was not increased in FASKOF animals (Figure S1G).
Body temperature was not different between control and
FASKOF mice at room temperature, there were no apparent
brown fat-like adipocytes in the epididymal fat of FASKOF
mice, and FASKOF epididymal fat did not have increased
expression of the brown fat gene UCP1 (not shown). However,
UCP1 expression was strikingly increased in inguinal fat from
HFD-fed FASKOF mice as compared to controls (Figure 2D).
Expression of PRDM16, a transcriptional coregulator involved
in the development of classic BAT as well as brown fat-like
adipocytes in subcutaneous white adipose tissue (WAT) (Seale
et al., 2011), was also increased as were levels of the brown
fat genes Cidea and PGC1a (Figure 2D). PPARa is known to
induce UCP1 expression (Barbera et al., 2001), and mRNA levels
for PPARa as well as the PPARa-dependent genes CPT1 and

ACO were increased in inguinal fat (Figure 2D). Since PPARa
promotes fatty acid oxidation, we assayed this process in
homogenates of WAT as the release of CO2 from radiolabelled
palmitate. In HFD-fed mice, fatty acid oxidation was increased
in FASKOF as compared to control mice in inguinal but not
epididymal WAT (Figure 2E). To maximize effects due to
FAS deﬁciency, we fed mice a high carbohydrate/zero fat diet
and analyzed inguinal fat. Under these conditions, inguinal fat
mRNA levels for UCP1, Cidea, and PGC1a were increased (Figure S1H). UCP1 protein was increased in inguinal fat from
FASKOF as compared to control mice by both western blotting
(Figure 2F) and immunocytochemistry (Figure 2G). With cold
exposure, FASKOF mice maintained their body temperature at
a signiﬁcantly higher level than control mice (Figure 2H), suggesting that increased brown fat-like cells in subcutaneous WAT of
FASKOF are physiologically relevant.
FAS Promotes PPARg Activation and Adipogenesis
PPARg is necessary and sufﬁcient for adipogenesis (Tontonoz
and Spiegelman, 2008) but also mediates HFD-induced hypertrophy of adipocytes (Hosooka et al., 2008; Kubota et al., 1999).
Moreover, PPARg is thought to promote fat development at
the expense of myogenesis (Hu et al., 1995; Seale et al., 2008).
Previous studies suggested that lipogenic pathways may be
required for activating PPARg by generating its endogenous
ligand (Kim and Spiegelman, 1996; Kim et al., 1998) and inﬂuencing adipogenesis (Schmid et al., 2005).
Since HFD-fed FASKOF mice have decreased adiposity and
reduced adipocyte hypertrophy (Figure 1), we explored the possibility that FAS is involved in PPARg activation and adipogenesis using mouse embryonic ﬁbroblasts (MEFs) from FASlox/lox
animals. Expression of Cre using an adenovirus (Ad-Cre) in these
cells decreased FAS protein and impaired adipogenesis (Figures
3A and 3B). Defective adipogenesis induced by FAS deﬁciency
was rescued by treatment with the PPARg activator rosiglitazone
(Figure 3B, bottom panels), likely due to induction of processes
(involving CD36, LPL, and other proteins) that facilitate uptake
of lipids from the culture media.
We next transfected HEK293 cells with cDNAs for PPARg
and a PPAR-dependent luciferase reporter in the presence
or absence of FAS knockdown. FAS deﬁciency decreased
luciferase reporter activity, an effect that was rescued with
rosiglitazone, suggesting that FAS regulates PPARg transcriptional activity (Figure 3C). To address possible contributions of
ligand-independent effects of FAS knockdown on PPARg transactivation, we performed luciferase reporter assays using cells
transfected with constitutively active PPARg (VP16-PPARg) or
wild-type PPARg. FAS knockdown reduced luciferase reporter
activity in cells transfected with WT PPARg, and the effect was
signiﬁcantly greater than in cells transfected with VP16-PPARg
(Figure 3D). Knockdown of FAS in primary MEFs decreased
expression of the PPARg target genes aP2 and CD36 but
increased expression of the early myogenesis markers MyoD
and myogenin, effects that were reversed with rosiglitazone (Figure 3E). Consistent with induction of myogenic markers, FAS
inactivation was associated with myotube formation under
promyogenic culture conditions (Figure 3F). FAS knockdown
decreased levels of proteins regulated by PPARg in 3T3-L1
adipocytes (Figure 3G). PPARg target gene expression was
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Figure 2. Altered Metabolism in Mice with Adipose-Speciﬁc Knockout of FAS
(A) Oxygen consumption (VO2) by indirect calorimetry in HFD-fed mice. Indicated p value by ANOVA. N = 8–10/genotype.
(B) Glucose tolerance testing in HFD-fed mice. p = 0.0477 at 0 min, 0.0415 at 60 min. N = 6–8/genotype. Serum insulin values at 30 min point shown in the inset.
(C) Insulin tolerance testing in the mice of (B). *p = 0.039.
(D) RT-PCR analysis of gene expression in inguinal WAT of HFD-fed control and FASKOF male mice. Gene expression analysis in inguinal WAT of ZFD-fed mice is
presented in Figure S1H. **p = < 0.0001 for UCP1, 0.0017 for Cidea, 0.0001 for PRDM16, 0.0008 for PGC1a, 0.0012 for PPARa, and 0.0001 for CPT1; *p = 0.042
for ACO.
(E) Measurement of fatty acid oxidation in epididymal (eWAT) and inguinal (iWAT) fat of control and FASKOF mice fed HFD. *p = 0.0355 for HFD iWAT. N = 3
animals/genotype for each diet.
(F) Western blot analysis in inguinal WAT of ZFD-fed control and FASKOF male mice. Each lane represents a separate mouse.
(G) Immunocytochemical analysis of UCP1 expression in inguinal WAT of ZFD-fed control and FASKOF mice. Images are from two separate mice per genotype.
(H) Rectal temperature of ZFD-fed control and FASKOF mice at room temperature (23 C) and after 1 hr exposure to 4 C. N = 6–8 animals/genotype. *p = 0.011.
Error bars in (A)–(E) and (H) represent SEM.

restored in these murine cells with FAS knockdown by expressing human FAS (Figure 3H). PPARg target genes were also
decreased in the adipose tissue of FASKOF mice (Figure 3I).
To determine if FAS deﬁciency is affecting PPARg expression
as opposed to its transcriptional activity, we fed mice a high
carbohydrate/zero fat diet to maximize effects due to FAS deﬁciency and subjected gonadal WAT to western blotting. There
was no effect on PPARg protein mass while protein levels of
the PPARg target aP2 were decreased in FASKOF as compared
to control mice (Figure 3J). One plausible interpretation of these
4 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.

results is that FAS is part of a lipogenic pathway that regulates
adipogenesis at the expense of myogenesis by generating
endogenous ligands for PPARg that promote its transcriptional
activity.
Identiﬁcation of FAS-Dependent Diacyl and Alkyl Ether
Lipid Species Bound to PPARg
There are probably numerous PPARg endogenous ligands that
may be generated under conditions requiring alterations in
adipocyte function, but ligands are initially produced early during
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Figure 3. FAS Is Required for Adipogenesis and PPARg Activation
(A) Western blot analysis of FAS knockdown in primary MEFs from FASlox/lox mice treated with an adenovirus expressing GFP or Cre at the indicated multiplicity of
infection (moi).
(B) Oil red O staining of FASlox/lox MEFs treated with Ad-GFP or Ad-Cre and differentiated to adipocytes in the presence or absence of rosiglitazone.
(C) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg in the
presence or absence of rosiglitazone. **p < 0.0001 versus control, #p < 0.0001 versus FAS siRNA basal. N = 3/condition.
(D) HEK293 cells treated with control or FAS siRNA were transfected with plasmids encoding PPRE-luciferase, Renilla luciferase and wild-type PPARg or VP16PPARg DBD (an N-terminal fragment of PPARg encompassing the DNA binding domain fused to the VP16 transactivation domain). **p < 0.0001 versus control,
#p < 0.0001 versus FAS siRNA/WT PPARg. N = 3/condition.
(E) RT-PCR analysis of gene expression in FAS-deﬁcient (Ad-Cre-treated) or control (Ad-GFP-treated) MEFs subjected to the adipogenesis protocol. **versus AdGFP, p = 0.0060 for aP2, 0.0010 for CD36, 0.0051 for MyoD, 0.0007 for Myogenin. #versus Ad-Cre, p = 0.0015 for aP2, 0.0013 for CD36, 0.0099 for MyoD, 0.0019
for Myogenin.
(F) FAS-deﬁcient (Ad-Cre-treated) or control (Ad-GFP-treated) MEFs cultured to promote myogenesis and stained with a skeletal muscle myosin heavy chain
antibody.
(G) Detection of proteins induced by PPARg in 3T3-L1 ﬁbroblasts and adipocytes treated with control or FAS shRNA.
(H) Restoration of PPARg target gene expression with human FAS using 3T3-L1 adipocytes with endogenous knockdown of FAS. 3T3-L1 cells stably expressing
retrovirally encoded human FAS were infected with a lentivirus expressing scrambled control (SC) or mouse FAS shRNA. The cells were induced to differentiate
into adipocytes. The upper panel shows real-time PCR analysis of aP2 expression and the bottom panel shows a western blot with antibodies against FAS, HA,
and actin. *p = 0.0224 (versus SC shRNA, empty vector). #p < 0.0001 (versus FAS shRNA, empty vector).
(I) RT-PCR analysis of gene expression in control and FASKOF gonadal WAT. **p = 0.007. *p = 0.0493 for C/EBPa, 0.010 for LPL, 0.039 for CD36. N = 4/genotype.
(J) Western blot analysis in gonadal WAT of ZFD-fed control and FASKOF female mice. Each lane represents a separate mouse. Error bars in (C)–(E), (H), and (I)
represent SEM.

adipocyte differentiation (Tzameli et al., 2004). To isolate such
putative FAS-dependent ligands, we used mass spectrometry
after infecting MEFs with an adenovirus encoding FLAG-tagged
PPARg and inducing differentiation (Figure 4A). PPARg was iso-

lated by afﬁnity from cells in the presence or absence of FAS
knockdown (Figure 4B) and associated lipids were analyzed by
mass spectrometry (Figure 4C). We identiﬁed several phosphatidylcholine species with diacyl (ester bond-linked) or 1-O-alkyl
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Figure 4. Isolation of FAS-Dependent Diacyl and 1-O-alkyl Ether Phosphatidylcholine Species Associated with PPARg
(A) Strategy for detection of PPARg-associated lipids.
(B) Detection of FLAG-PPARg protein immunoprecipitated from adipocytes treated with control or FAS shRNA.
(C) Mass spectrometric analyses of [M+Li]+ ions of glycerophosphocholine (GPC) lipids bound to FLAG-PPARg or control protein (GFP) immunoprecipitated from
control and FAS knockdown adipocytes. Ions of m/z 752 and 780 represent 1-O-alkyl GPC species.
(D) CV-1 cells were transfected with plasmids encoding UAS-luciferase, Renilla luciferase and Gal4-PPARg LBD (a C-terminal fragment of PPARg encompassing
the ligand binding domain fused to the Gal4 DNA binding domain) or Gal4 alone. The cells were treated with 18:1e/16:0-GPC (corresponding to m/z 752 in C),
rosiglitazone, or DMSO. After 48 hr, UAS-luciferase reporter activity was measured and normalized to Renilla luciferase reporter activity. **p = 0.0001. *p = 0.018
(10 mM), 0.024 (20 mM), 0.019 (80 mM).
(E) 3T3-L1 cells were induced to differentiate in DMEM+10% FBS with supplemental dexamethasone, insulin and IBMX in the presence of 20 mM 18:1e/16:0-GPC
or DMSO. After 3 days, the cells were retreated with the GPC in media containing supplemental insulin alone. The next day, the cells were harvested for RNA
extraction and real-time PCR analysis. The data are representative of 3 separate experiments. *p = 0.0147 (aP2), 0.0006 (LPL), 0.0102 (CD36). Error bars in (D) and
(E) represent SEM.

(ether bond-linked) side chains associated with PPARg that were
competitively displaced by rosiglitazone (not shown). Alkyl ether
lipids were particularly enriched in PPARg samples compared to
controls (Table S2). The species at m/z 752 [M+Li]+ was most
frequently associated with PPARg and tandem mass spectrometry identiﬁed it as 1-O-octadecenyl-2-palmitoyl-3-glycerophosphocholine (18:1e/16:0-GPC) (Figure S2). We synthesized this
alkyl ether lipid and used it to treat cultured cells. 18:1e/16:0GPC increased PPARg-dependent luciferase reporter activity
6 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.

in a dose-dependent fashion (Figure 4D) but was less potent
than rosiglitazone. We found that 20 mM 18:1e/16:0-GPC significantly increased the expression of PPARg target genes in differentiating 3T3-L1 adipocytes (Figure 4E).
In order to provide insight into the interaction between
18:1e/16:0-GPC and the PPARg ligand binding domain (LBD),
we developed a GST-pulldown assay of PPARg ligand binding based on the ligand-dependent interaction between an
N-terminal region of CBP1 and the PPARg LBD (Gelman et al.,
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1999). 18:1e/16:0-GPC increased the interaction between the
GST-tagged PPARg LBD and the myc-tagged CBP1 N terminus
in a dose-dependent manner (Figure S3A). However, 18:1e/16:0GPC did not increase the interaction between the GST-tagged
LBD of a different nuclear receptor, PPARa, and the myc-tagged
CBP1 N terminus (Figure S3B). To provide additional evidence
that this ether lipid enhances PPARg transcription due to agonism, we added 18:1e/16:0-GPC to terminally differentiated
3T3-L1 adipocytes. Both 18:1e/16:0-GPC and rosiglitazone
increased LPL gene expression in differentiated adipocytes
that were treated with a control shRNA prior to induction of differentiation (Figure S3C). In cells prevented from differentiating into
adipocytes by FAS knockdown, treatment with either 18:1e/
16:0-GPC or rosiglitazone after completion of the differentiation
protocol (with dexamethasone, IBMX, and insulin followed by
additional insulin treatment) did not restore full LPL expression
(Figure S3C). FAS deﬁciency decreased expression of PPARgdependent genes (Figure 3I) while increasing expression of
PPARa-dependent genes (Figure 2D). When FAS expression
was knocked down in 3T3-L1 cells that were subsequently
induced to differentiate into adipocytes, the FAS-deﬁciencyassociated increase in ACO gene expression was signiﬁcantly
decreased when cells were differentiated in the presence of
the selective PPARa antagonist GW6471 (Figure S3D). These
results suggest that an FAS-dependent ether lipid interacts
with PPARg but not PPARa and that FAS deﬁciency is associated with decreased activation of PPARg and increased activation of PPARa.
Cloning and Characterization of PexRAP
Ether lipid synthesis in mammals occurs through the peroxisomal acyl dihydroxyacetone phosphate (DHAP) pathway, allowing synthesis of lysophosphatidic acid as an alternative to
direct acylation of glycerol 3-phosphate. This pathway is obligatory for synthesis of ether lipids including platelet activating
factors and plasmalogens (Hajra and Das, 1996; Hajra et al.,
2000; McIntyre et al., 2008) (Figure 5A). The terminal enzyme
activity in this pathway, acyl/alkyl DHAP reductase, was puriﬁed
and characterized from guinea pig liver (LaBelle and Hajra,
1974), but the gene encoding this protein has not been identiﬁed
in mammals (McIntyre et al., 2008). Since a yeast enzyme (Ayr1p)
(Athenstaedt and Daum, 2000) that catalyzes this reaction has
been cloned and characterized, we used this sequence to identify DHRS7b, a protein of unknown function, as a mammalian ortholog (Figure 5B). We renamed this protein PexRAP. Gradient
fractionation of 3T3-L1 adipocytes showed that PexRAP is
enriched in fractions containing peroxisomal markers, such as
PMP70 and catalase (Figure 5C). Myc-tagged PexRAP coimmunoprecipitated with Pex19 (peroxisomal biogenesis factor 19, an
import receptor for peroxisomal membrane proteins) (Figure 5D),
and this interaction was conﬁrmed in pulldown experiments
using GST-PexRAP (Figure 5E).
To demonstrate that PexRAP mediates its predicted enzyme
activity, we knocked down PexRAP expression in MEFs (Figure 5F) and found decreased levels of 1-O-alkyl ether phospholipids as well as certain diacyl phospholipids (Figure 5G), some of
which also arise from the DHAP pathway. 18:1e/16:0-GPC was
detected in these experiments as m/z 746 [M+H]+ since these
experiments were performed with protonated species; 18:1e/

16:0-GPC was detected as m/z 752 using lithiated species in
Figure 4C. PexRAP protein was detected in multiple tissues,
but levels were low in skeletal muscle (Figure 5H). The overall
expression of PexRAP in BAT was relatively low and BAT
primarily expressed a shorter isoform (which lacks 9 amino
acid residues at the N terminus), suggesting that PexRAP may
have a different role in BAT compared to WAT. Both PexRAP
and FAS proteins markedly increase early during differentiation of 3T3-L1 adipocytes, prior to similar increases in proteins
such as C/EBPa and aP2 known to be induced by PPARg activation (Figure 5I). Thus, PexRAP is peroxisomal, its inactivation
decreases lipids associated with PPARg, and its temporal relationship during differentiation with other adipocyte proteins
suggests that it could be involved in adipogenesis.
PexRAP Is Required for Adipogenesis
To address the role of PexRAP in adipogenesis, we knocked
down its expression in 3T3-L1 cells. Adipogenesis (assessed
by both Nile red staining and triglyceride content) was abrogated with PexRAP knockdown and rescued with rosiglitazone
(Figures 6A and 6B), suggesting that PexRAP, like FAS (Figure 3B), affects PPARg activation. Knockdown of PexRAP or
DHAP acyltransferase (DHAPAT, the enzyme immediately upstream of PexRAP, Figure 5A) in 3T3-L1 adipocytes decreased
expression of PPARg target genes (Figure 6C). Rosiglitazone
treatment rescued the effect of PexRAP or DHAPAT knockdown
on PPARg target genes (Figure 6D).
PexRAP Knockdown in Mice Alters Body Composition
and Metabolism
We translated these observations to HFD-fed C57BL/6J mice,
characterized by increased adiposity and insulin resistance.
A series of PexRAP antisense oligonucleotides (ASOs) were
screened for effectiveness (not shown) and results of PexRAP
knockdown for two of the most promising are shown in Figure 7A
using Hepa1-6 cells. ASO2 was selected for use in mice. Intraperitoneal administration of ASO2 at up to 20 mg/kg twice
a week for three weeks resulted in a dose-dependent decrease
in PexRAP protein in WAT and liver (but not in brain or skeletal
muscle, Figures 7B and S4A). Mice were fed a HFD for four
weeks to increase adiposity and then animals were injected
twice a week with 20 mg/kg of ASO2 or the control ASO for
24 days while HFD was continued. ASO treatment had no
effect on liver function tests or liver histology (not shown). Liver
fat content was nearly signiﬁcantly lower (p = 0.072) with ASO
treatment. Food intake was unaffected (Table S3). However,
this intervention decreased expression of PexRAP as well as
PPARg target genes (including PPARg itself) in WAT (Figure 7C).
PexRAP knockdown in HFD-fed mice also decreased adiposity,
increased leanness, and decreased fasting glucose (Figure 7D
and Table S3). Glucose tolerance was improved and insulin
levels were lower in HFD-fed mice treated with the PexRAP
ASO (Figures 7E and 7F).
DISCUSSION
These studies suggest that depletion of FAS in adipose tissue
suppresses HFD-induced obesity. FAS is a minor contributor
to cellular lipid stores with high fat feeding (Aarsland et al.,
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Figure 5. Cloning and Characterization of the Terminal Component in the Mammalian Peroxisomal Ether Lipid Synthetic Pathway
(A) The peroxisomal acyl-DHAP pathway of lipid synthesis. FAS, fatty acid synthase; ACS, acyl CoA synthase; G3PDH, glycerol 3-phosphate dehydrogenase;
DHAP, dihydroxyacetone phosphate; DHAPAT, DHAP acyltransferase; FAR1, fatty acyl CoA reductase 1; ADHAPS, alkyl DHAP synthase; ADHAP Reductase,
acyl/alkyl DHAP reductase activity; LPA, lysophosphatidic acid; AGP, 1-O-alkyl glycerol 3-phosphate.
(B) Mouse DHRS7b is homologous to yeast acyl DHAP reductase, Ayr1p. TMD, transmembrane domain; Adh_short, short chain dehydrogenase/reductase
domain.
(C) PexRAP (peroxisomal reductase activating PPARg, detected using anti-DHRS7b antibody) is enriched in peroxisomal fractions isolated from 3T3-L1
adipocytes. S, supernatant; P, pellet after sedimentation.
(D) Pex19 coimmunoprecipitates with Myc-tagged PexRAP. WCL, whole cell lysates.
(E) Pex19 interacts with PexRAP in GST pull-down experiments using 3T3-L1 adipocytes.
(F) RT-PCR analysis of PexRAP expression with PexRAP knockdown in MEFs. **p = 0.0084.
(G) Mass spectrometric analyses of [M+H]+ ions of GPC lipids in MEFs after PexRAP knockdown. Quantiﬁcation of the 1-O-alkyl ether GPC lipid peak at m/z 746
[M+H]+ (identical to the lithium adduct at m/z 752 in Figure 4C) is shown in the inset. **p = 0.0009.
(H) Mouse tissue distribution of PexRAP protein by western blotting.
(I) Protein abundances of PexRAP and FAS increase prior to increases in C/EBPa and aP2 during differentiation of 3T3-L1 adipocytes. Error bars in (F) and (G)
(inset) represent SEM.

1996; Letexier et al., 2003; McDevitt et al., 2001); HFD feeding
decreases FAS expression (Coupe et al., 1990; Kersten, 2001).
Thus, it is unlikely that the reduced adiposity observed in the
HFD-fed FASKOF mice was due to the inability to synthesize
fatty acids per se. Rather, our results suggest that inhibiting
a lipogenic pathway initiated by FAS increases thermogenesis
and reduces activation of PPARg. Increased energy expenditure
comes not from effects on classic BAT but instead by inducing
8 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.

the formation of brown fat-like (‘‘brite’’) cells in subcutaneous
adipose tissue (Seale et al., 2011).
In addition to inducing brown fat-like cells in subcutaneous
fat, FAS deletion decreased PPARg transcriptional activity. It is
possible that these transcriptional effects are unrelated or only
partially related to the phenotype of resistance to diet-induced
obesity caused by increased brite cells. PPARg agonism can
induce UCP1 gene expression and produce small adipocytes in
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Figure 6. PexRAP Is Required for Adipogenesis and PPARg Activation
(A) Nile red staining of 3T3-L1 adipocytes treated with control or PexRAP shRNA in the presence or absence of rosiglitazone.
(B) Triglyceride content for the cells of (A). **p = 0.0066 versus control, #p = 0.0071 versus PexRAP shRNA vehicle. N = 3/condition.
(C) RT-PCR analysis of gene expression following PexRAP or DHAPAT knockdown. P versus control: DHAPAT, *0.0278, **0.007; PexRAP, *0.040; aP2, **0.0060
for PexRAP shRNA and 0.0058 for DHAPAT shRNA; C/EBPa, *0.0160 for PexRAP shRNA and 0.0165 for DHAPAT shRNA; LPL, **0.0014, *0.0450; CD36, *0.0113
for PexRAP shRNA and 0.0132 for DHAPAT shRNA. N = 3–5/condition.
(D) Rosiglitazone treatment rescues the effect of PexRAP or DHAPAT knockdown on PPARg target gene expression. 3T3-L1 cells infected with lentivirus expressing control, PexRAP, or DHAPAT shRNA were induced to differentiate into adipocytes and then treated with 2.5 mM rosiglitazone. Expression of PPARg
target genes was analyzed by quantitative RT-PCR. For aP2, exact p values from left to right = 0.0038, 0.0119, 0.0024, 0.0032. For CD36, p values = 0.0022,
0.0015, 0.0110, < 0.0001.
Error bars in (B)–(D) represent SEM.

WAT (de Souza et al., 2001; Fukui et al., 2000; Tiraby et al., 2003),
similar to the FASKOF mouse phenotype, and yet FASKOF mice
have decreased PPARg activation. However, pharmacologic
agonism of PPARg promotes adiposity, while FASKOF mice
have less adiposity. Effects on PPARa with FAS deletion could
provide a plausible explanation. PPARa and its targets are
induced in FASKOF adipose tissue (Figure 2D). PPARa inhibition
decreases induction of the PPARa target gene ACO with FAS
knockdown in 3T3-L1 cells (Figure S3D). PPARa agonism can
also induce UCP1 gene expression (Barbera et al., 2001) as

well as decrease adipocyte size (Tsuchida et al., 2005), and the
acute effects of PPARa activation on UCP1 gene expression
may exceed those of PPARg (Pedraza et al., 2001). Decreased
PPARg transcriptional activity could reﬂect the lack of an FASassociated lipid ligand, allowing increased PPARa activity and
induction of UCP1. In support of this notion, induction of UCP1
and the development of brown fat-like cells by FNDC5 (cleaved
to form irisin) occurs in part through PPARa (Boström et al., 2012).
Our data point to a pathway (Figure 7G, left) in which lipids
synthesized by FAS serve as substrate for PexRAP, which
Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc. 9
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Figure 7. Knockdown of PexRAP in Mice Alters Body Composition and Metabolism
(A) PexRAP knockdown using antisense oligonucleotides (ASOs) in Hepa1-6 cells.
(B) Western blot analysis using epididymal WAT of C57BL/6J mice treated intraperitoneally with the indicated doses of control or PexRAP ASO twice a week for
3 weeks.
(C) RT-PCR analysis of epididymal WAT expression following ASO treatment. P versus control: PexRAP **0.0078; PPARg **0.0051; CD36 *0.0420; LPL **0.0030.
N = 4/condition.
(D) Body composition by MRI following 4 weeks of HFD feeding (baseline) and after 3.5 weeks of ASO treatment while still eating a HFD. **p = 0.0098 for fat, 0.0071
for lean. N = 4/condition.
(E) Glucose tolerance testing in HFD-fed mice following ASO treatment. *p = 0.0220 at 15 min and 0.0434 at 120 min. **p = 0.0019.
(F) Insulin levels at the 30 min point from (E). *p = 0.0363.
(G) Models of PPARg and PPARa gene expression in WT and FAS-deﬁcient adipocytes. Error bars in (C)–(F) represent SEM.

generates alkyl ether lipids that are potential endogenous
PPARg ligands. Disruption of FAS (Figure 7G, right) decreases
these ether lipids, altering the coactivator milieu to favor
PPARa-dependent gene expression.
Several lines of evidence support the concept that a lipogenic
pathway localized to peroxisomes is important for endogenous
activation of PPARg. The PPAR family was named because of
the ability to be activated by agents that increase the number
of peroxisomes (Dreyer et al., 1992; Issemann and Green,
1990). The number of peroxisomes is dramatically increased
during differentiation of 3T3-L1 adipocytes (Novikoff and Novikoff, 1982; Novikoff et al., 1980), a PPARg-dependent process.
Consistent with our observation that PexRAP expression is
10 Cell Metabolism 16, 1–13, August 8, 2012 ª2012 Elsevier Inc.

induced during adipogenesis, previous studies suggest that
the activities of various enzymes in the peroxisomal ether lipid
synthetic pathway increase during differentiation of 3T3-L1 adipocytes (Hajra et al., 2000).
There is precedent for PPARg activation by alkyl ether lipids.
Azelaoyl PAF (1-O-hexadecyl-2-O-(9-carboxyoctanoyl)-sn-glyceryl-3-phosphocholine), reported to be equipotent to rosiglitazone (Davies et al., 2001), and 1-O-alkyl glycerol 3-phosphate
(McIntyre et al., 2003; Tsukahara et al., 2006), synthesized
directly by PexRAP (see Figure 5A), are thought to be PPARg
ligands. Because PPARg has a capacious ligand binding pocket
(Schupp and Lazar, 2010), it is possible that instead of a single
authentic endogenous ligand, multiple lipids are recruited to
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the receptor depending on the physiological context, with variable effects on transcriptional activity (Lodhi et al., 2011; Schupp
and Lazar, 2010).
ASO-mediated inhibition of PexRAP decreased adiposity and
improved glucose metabolism, probably by activating thermogenesis in subcutaneous WAT. In studies to be reported elsewhere, we have observed that PexRAP deﬁciency in adipose
tissue achieved by crossing adiponectin-Cre mice with ﬂoxed
PexRAP animals robustly induces UCP1 expression in subcutaneous but not epididymal WAT.
Adipose-speciﬁc knockout of PPARg in mice has yielded
conﬂicting results: one group reported lipodystrophy and insulin
resistance (He et al., 2003), while another found enhanced insulin sensitivity (Jones et al., 2005). Certain human PPARg mutations cause lipodystrophy and insulin resistance, likely through
a dominant-negative effect to disrupt interaction with coactivators (Agostini et al., 2006). In our studies, neither ASO-mediated
PexRAP knockdown in mice nor Cre-mediated adipose-speciﬁc
FAS knockout in mice produced lipodystrophy. Both decreased
adiposity and improved glucose metabolism. PPARg haploinsufﬁciency in mice (Kubota et al., 1999; Miles et al., 2000) also
decreases adiposity and increases insulin sensitivity, but this
genetic effect is not limited to adipose tissue. A Pro12Ala
PPARg mutation in mice (Heikkinen et al., 2009) and humans
(Huguenin and Rosa, 2010) decreases (but does not abolish)
PPARg transcriptional activity and results in decreased adiposity
and increased insulin sensitivity, although this mutation is not
adipose-speciﬁc.
Inhibiting FAS or the peroxisomal enzyme PexRAP in adipose
tissue alters body composition and improves glucose metabolism in the setting of a high fat diet. Both represent attractive
targets for novel diabetes and obesity therapies.
EXPERIMENTAL PROCEDURES
Animals
Mice with a ﬂoxed FAS locus (FASlox/lox) (Chakravarthy et al., 2005) were
crossed with transgenic mice (a gift from Evan Rosen, BI Deaconess) expressing Cre recombinase under the control of the adiponectin promoter (Eguchi
et al., 2011) to obtain FASKOF mice that were studied after backcrossing
R7 times with pure C57BL/6J mice. Genotyping was performed using previously described primer sets and diets included Purina 4043 control chow,
Harlan Teklad TD 88137 high fat diet, and Harlan Teklad TD03314 high carbohydrate/zero fat diet. Unless indicated otherwise, male FASKOF mice and
control littermates at 8–12 weeks of age were used for experiments. For
antisense oligonucleotide studies, 8-week-old C57BL/6J mice were used.
All protocols were approved by the Washington University Animal Studies
Committee.

psPAX2 (12260), envelope vector pMD2.G (12259), and scrambled shRNA
plasmid (1864) were obtained from Addgene. 293T cells in 10 cm dishes
were transfected using Fugene 6 with 2.66 mg psPAX2, 0.75 mg pMD2.G,
and 3 mg shRNA plasmid. After 48 hr, media were collected, ﬁltered using
0.45 um syringe ﬁlters, and used to treat cells. After 36 hr, cells were selected
with puromycin and knockdown was assessed after an additional 48 hr.
Identiﬁcation of Alkyl Ether GPC Lipids Associated with PPARg
The strategy for detecting endogenous lipids associated with PPARg involved
adenovirus-mediated expression of FLAG-tagged PPARg or GFP (as control)
in cells induced to differentiate into adipocytes. Nuclear fractions, prepared
from cell lysates and subjected to hypotonic lysis as described (Chakravarthy
et al., 2009), were incubated with an antibody recognizing the FLAG epitope to
capture the PPARg construct and any associated lipids under conditions (no
detergent or high salt elution buffers) unlikely to disrupt potential ligand/
nuclear factor interaction.
Afﬁnity matrix eluates (with equal protein content) of nuclear fractions from
cells treated with Ad-GFP (as a control) or Ad-PPARg were subjected to lipid
extraction. These extracts were mixed with an internal standard [(14:0/14:0)GPC] and analyzed as [M+Li]+, [M+H]+, or [M+Na]+ ions by positive ion
ESI/MS or as [M+CH3CO2]- ions by negative ion ESI/MS (Hsu and Turk,
2007; Hsu et al., 2003). To determine the identity of the lithiated lipid species
of m/z 752, we performed multigenerational tandem MS on a linear ion
trap instrument. Collisionally activated dissociation (CAD) was employed to
deduce structures of R1 and R2 substituents. Additional details are provided
in Figure S3.
GST-PexRAP Pull-Down Assays
3T3-L1 adipocytes were lysed using a buffer containing 50 mM HEPES
(pH 7.4), 4 mM EDTA, 2 mM EGTA, 2 mM sodium pyrophosphate, 1% Triton
X-100, 10 mM NaF, and protease inhibitors. Lysates were mixed with an equal
volume of the same buffer lacking Triton X-100, then 5 mg of GST or GSTPexRAP was added and samples were rocked at 4 C. After 2 hr, samples
were centrifuged at 2500 3 g for 1 min, beads were washed 5 times with
1 ml of the lysis buffer containing Triton X-100, then 2X SDS-PAGE sample
buffer was added and samples were subjected to SDS-PAGE.
Antisense Oligonucleotides
ASOs were synthesized by TriLink Biotechnologies (San Diego, CA). The ﬁrst 5
and last 5 nucleotides were substituted with 20 O-methyl RNA bases; all of the
bases had phosphorothioate linkages. The PexRAP ASO (RNA bases underlined) is: 50 GGUUGGTGTGTCTGTCCCUG 30 . The control oligonucleotide is:
50 CCUUCCCTGAAGGTTCCUCC 30 . Both were puriﬁed by anion exchange
HPLC, lyophilized, reconstituted with 0.9% normal saline, and then injected
intraperitoneally.
Statistical Analysis
Data are expressed as mean ± SEM. Comparisons between two groups were
performed using an unpaired, two-tailed t test. ANOVA was used for more than
two groups and post testing was performed using Tukey’s post test.
SUPPLEMENTAL INFORMATION

Cell Culture
Primary mouse embryonic ﬁbroblasts (MEFs) were isolated at 13.5 days post
conception from FASlox/lox embryos as previously described (Razani et al.,
2001) and maintained in DMEM+10% FBS. MEFs were differentiated to adipocytes by treatment with 1 mM dexamethasone, 5 mg/ml insulin and 0.5 mM
IBMX for 14 days, followed by supplemental 5 mg/ml insulin alone for an additional 4 days. 3T3-L1 cells were maintained in DMEM+10% NCS and differentiated to adipocytes as previously described (Lodhi et al., 2007). CV-1, HEK293
and HEK293T cells were maintained in DMEM+10% FBS.

Supplemental Information includes four ﬁgures, three tables, Supplemental
Experimental Procedures, and Supplemental References and can be found
with this article online at http://dx.doi.org/10.1016/j.cmet.2012.06.013.

Lentiviral shRNA-Mediated Knockdown
Plasmids encoding shRNA for mouse FAS (TRCN0000075703), PexRAP
(TRCN0000181732 and 0000198546), and DHAPAT (TRCN0000193539)
were obtained from Open Biosystems (Huntsville, AL). Packaging vector
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Comparison of the expression and activity of the lipogenic pathway in human
and rat adipose tissue. J. Lipid Res. 44, 2127–2134.
Lodhi, I.J., Chiang, S.H., Chang, L., Vollenweider, D., Watson, R.T., Inoue, M.,
Pessin, J.E., and Saltiel, A.R. (2007). Gapex-5, a Rab31 guanine nucleotide
exchange factor that regulates Glut4 trafﬁcking in adipocytes. Cell Metab. 5,
59–72.

Please cite this article in press as: Lodhi et al., Inhibiting Adipose Tissue Lipogenesis Reprograms Thermogenesis and PPARg Activation to Decrease
Diet-Induced Obesity, Cell Metabolism (2012), http://dx.doi.org/10.1016/j.cmet.2012.06.013

Cell Metabolism
Lipogenesis and Adipose Programming

Lodhi, I.J., Wei, X., and Semenkovich, C.F. (2011). Lipoexpediency: de novo
lipogenesis as a metabolic signal transmitter. Trends Endocrinol. Metab. 22,
1–8.
Lu, M., Sarruf, D.A., Talukdar, S., Sharma, S., Li, P., Bandyopadhyay, G.,
Nalbandian, S., Fan, W., Gayen, J.R., Mahata, S.K., et al. (2011). Brain
PPAR-g promotes obesity and is required for the insulin-sensitizing effect of
thiazolidinediones. Nat. Med. 17, 618–622.
Masuzaki, H., Paterson, J., Shinyama, H., Morton, N.M., Mullins, J.J., Seckl,
J.R., and Flier, J.S. (2001). A transgenic model of visceral obesity and the
metabolic syndrome. Science 294, 2166–2170.
McDevitt, R.M., Bott, S.J., Harding, M., Coward, W.A., Bluck, L.J., and
Prentice, A.M. (2001). De novo lipogenesis during controlled overfeeding
with sucrose or glucose in lean and obese women. Am. J. Clin. Nutr. 74,
737–746.
McIntyre, T.M., Pontsler, A.V., Silva, A.R., St Hilaire, A., Xu, Y., Hinshaw, J.C.,
Zimmerman, G.A., Hama, K., Aoki, J., Arai, H., and Prestwich, G.D. (2003).
Identiﬁcation of an intracellular receptor for lysophosphatidic acid (LPA):
LPA is a transcellular PPARgamma agonist. Proc. Natl. Acad. Sci. USA 100,
131–136.
McIntyre, T.M., Snyder, F., and Marathe, G.K. (2008). Ether-linked lipids and
their bioactive species. In Biochemistry of lipids, lipoproteins and membranes,
D.E. Vance and J.E. Vance, eds. (Amsterdam, Boston: Elsevier), pp. 245–276.
Miles, P.D., Barak, Y., He, W., Evans, R.M., and Olefsky, J.M. (2000). Improved
insulin-sensitivity in mice heterozygous for PPAR-gamma deﬁciency. J. Clin.
Invest. 105, 287–292.
Moreno-Navarrete, J.M., Botas, P., Valdés, S., Ortega, F.J., Delgado, E.,
Vázquez-Martı́n, A., Bassols, J., Pardo, G., Ricart, W., Menéndez, J.A., and
Fernández-Real, J.M. (2009). Val1483Ile in FASN gene is linked to central
obesity and insulin sensitivity in adult white men. Obesity (Silver Spring) 17,
1755–1761.
Novikoff, A.B., and Novikoff, P.M. (1982). Microperoxisomes and peroxisomes
in relation to lipid metabolism. Ann. N Y Acad. Sci. 386, 138–152.
Novikoff, A.B., Novikoff, P.M., Rosen, O.M., and Rubin, C.S. (1980). Organelle
relationships in cultured 3T3-L1 preadipocytes. J. Cell Biol. 87, 180–196.
Pedraza, N., Solanes, G., Iglesias, R., Vázquez, M., Giralt, M., and Villarroya, F.
(2001). Differential regulation of expression of genes encoding uncoupling
proteins 2 and 3 in brown adipose tissue during lactation in mice. Biochem.
J. 355, 105–111.
Postic, C., and Girard, J. (2008). Contribution of de novo fatty acid synthesis to
hepatic steatosis and insulin resistance: lessons from genetically engineered
mice. J. Clin. Invest. 118, 829–838.
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targeted to treat lipid disorders, diabetes, and obesity, is
highly expressed in the liver. Its induction by fasting promotes lipid uptake, fatty acid ␤-oxidation, ketogenesis,
and gluconeogenesis (1, 2). Ligand binding to PPAR␣
causes it to heterodimerize with retinoid X receptor
(RXR)␣, allowing activation of gene transcription at
peroxisome proliferator response elements (PPRE) (3, 4).
Synthetic PPAR␣ ligands, such as ﬁbrates, used for human
lipid disorders (5) have been known for decades, but potential endogenous ligands were identiﬁed only recently
(6, 7). Mice with liver-speciﬁc deletion of the lipogenic
enzyme fatty acid synthase (FAS) have impaired PPAR␣
activity (8), and FAS activates PPAR␣ by producing an
endogenous phospholipid ligand (6). FAS also activates
PPAR␣ in brain and macrophages (9, 10).
Mammalian FAS synthesizes long-chain fatty acids, primarily palmitate, through the activities of seven functional domains: acyl carrier, acyl transferase, ␤-ketoacyl synthase,
␤-ketoacyl reductase, ␤-hydroxyacyl dehydratase, enoyl reductase, and thioesterase (11). Like PPAR␣, FAS is highly
expressed in liver (12). In times of nutrient excess, hepatic
FAS converts carbohydrate to lipid that is stored in lipid droplets or secreted in the form of VLDL (13). Nutrient excess is
associated with elevated levels of insulin, known to induce
FAS expression.
These accepted physiological roles for PPAR␣ and FAS appear to conﬂict with the observation that inactivation of FAS
impairs PPAR␣ activation. How might FAS activate a process
stimulated by feeding such as insulin-responsive lipogenesis
and also activate a process stimulated by fasting such as the
induction of PPAR␣-dependent gene expression?
We hypothesized that distinct subcellular pools of FAS
mediate these disparate effects. Compartmentalization
would permit regulation of an FAS pool generating lipids
for signaling that would be distinct from an FAS pool generating lipids for energy storage. In support of this hypothesis,
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Abstract Peroxisome proliferator-activated receptor
(PPAR)␣ is a nuclear receptor that coordinates liver metabolism during fasting. Fatty acid synthase (FAS) is an enzyme
that stores excess calories as fat during feeding, but it also
activates hepatic PPAR␣ by promoting synthesis of an endogenous ligand. Here we show that the mechanism underlying this paradoxical relationship involves the differential
regulation of FAS in at least two distinct subcellular pools:
cytoplasmic and membrane-associated. In mouse liver and
cultured hepatoma cells, the ratio of cytoplasmic to membrane FAS-speciﬁc activity was increased with fasting, indicating higher cytoplasmic FAS activity under conditions
associated with PPAR␣ activation. This effect was due to
a nutrient-dependent and compartment-selective covalent modiﬁcation of FAS. Cytoplasmic FAS was preferentially phosphorylated during feeding or insulin treatment at
Thr-1029 and Thr-1033, which ﬂank a dehydratase domain
catalytic residue. Mutating these sites to alanines promoted PPAR␣ target gene expression. Rapamycin-induced
inhibition of mammalian/mechanistic target of rapamycin
complex 1 (mTORC1), a mediator of the feeding/insulin
signal to induce lipogenesis, reduced FAS phosphorylation,
increased cytoplasmic FAS enzyme activity, and increased
PPAR␣ target gene expression. Rapamycin-mediated induction of the same gene was abrogated with FAS knockdown.
These ﬁndings suggest that hepatic FAS channels lipid synthesis through speciﬁc subcellular compartments that allow
differential gene expression based on nutritional status.—
Jensen-Urstad, A. P. L., H. Song, I. J. Lodhi, K. Funai, L. Yin,
T. Coleman, and C. F. Semenkovich. Nutrient-dependent
phosphorylation channels lipid synthesis to regulate PPAR␣.
J. Lipid Res. 2013. 54: 1848–1859.

we demonstrate that FAS at two separate subcellular locations is differentially regulated by nutrients and insulin,
that this regulation involves preferential dehydratase domain phosphorylation for the FAS pool that regulates
PPAR␣, and that the effects of the kinase mammalian/mechanistic target of rapamycin complex 1 (mTORC1) on PPAR␣
activity require FAS.

FAS solubility
Solubility assays were performed as previously described (15) with
minor modiﬁcations. Membranes were isolated from mouse liver by
ultracentrifugation and resuspended in buffer containing 20 mM
HEPES buffer (pH 7.4), 1 mM EDTA, and 255 mM sucrose. The
membrane fraction was subjected to treatment with various solvents
(1 M NaCl, 0.1 M Na2CO3 at pH 11.5, 1% SDS or 1% Triton X-100)
and then centrifuged once more (4°C, 180,000 g, 30 min). The resulting pellets and supernatants were analyzed by western blotting.

Cell culture

MATERIALS AND METHODS
Animals
Male C57BL/6J mice at eight weeks of age were provided ad
libitum access to chow diet (Purina #5053) or fasted for 18 h. All
mice were kept on Aspen bedding and had free access to water.
Protocols were approved by the Washington University Animal
Studies Committee.

Using a modiﬁcation of a previously described assay (14), 20 μl
of sample at 1 μg protein/μl was added to 70 μl of assay buffer
[0.14 M potassium phosphate buffer (pH 7.0), 1.4 mM EDTA
(pH 8.0), 1.4 mM DTT, 0.24 mM NADPH, 0.1 mM acetyl-CoA].
The rate of NADPH oxidation was monitored at 340 nm at baseline and again after adding 10 μl of 0.85 mg/ml malonyl-CoA
(Sigma). The substrate-dependent rate was determined by subtracting the baseline NADPH oxidation rate from the rate after
addition of malonyl-CoA. The rate of NADPH oxidation was normalized to FAS protein levels as determined by western blotting
and densitometry to determine speciﬁc activity.

Subcellular fractionation
Perfused liver from C57BL/6J mice was homogenized in 20 mM
HEPES buffer (pH 7.4) and centrifuged at 100 g for 30 min, and
then the pellet was discarded. The supernatant was centrifuged at
500 g for 60 min; 1,200 g for 20 min; 10,000 g for 20 min; 20,000 g
for 30 min; 40,000 g for 30 min; 70,000 g for 30 min; 100,000 g for
60 min; and 179,000 g for 75 min. After each spin, the pellet was
washed and resuspended, while the supernatant was centrifuged
again. All spins were done at 4°C. To obtain crude membrane and
cytoplasmic fractions from mouse liver, freshly isolated perfused
liver was homogenized in HEPES buffer and centrifuged at 10,000 g
for 45 min at 4°C. The resulting pellet was discarded, and the supernatant centrifuged at 179,000 g for 180 min at 4°C. The supernatant (cytoplasm) and pellet (crude membrane) were collected,
and the pellet was washed and resuspended in HEPES buffer. To
obtain membrane and cytoplasmic extracts from Hepa1-6 cells, a
Subcellular Protein Fractionation Kit for Cultured Cells (78840)
from Thermo Fisher Scientiﬁc was used according to the manufacturer’s protocol.

Antibodies
Rabbit polyclonal antibodies against FAS (ab22759), PMP70
(ab3421), and phosphothreonine (ab9337) were from Abcam.
Mouse monoclonal antibody against ␣-tubulin (sc-5286) and rabbit polyclonal antibodies against Cav1 (sc-894) and ␤-tubulin (sc9104, used to control for loading in western blotting experiments)
were from Santa Cruz Biotechnology. Rabbit polyclonal antibodies against PDI (226), GM130 (2296), Na+/K+ ATPase (3010), Akt
(9272), phospho-Akt (S473) (9271), S6 ribosomal protein (2217),
and phospho-S6 ribosomal protein (Ser235/236) (2F9/4856),
and rabbit monoclonal antibodies against p70 S6 kinase (2708)
and CoxIV (4850) were from Cell Signaling Technology.

Pulse-chase study
Conﬂuent Hepa1-6 cells in 6 cm dishes were incubated in methionine-free media for 30 min. The cells were then pulsed with 500
35
μCi of S-methionine per dish. After 1 h, cells for the “0” time point
were harvested. For subsequent time points, cells were washed with
PBS, chased with nonradioactive complete media, and incubated
for an additional 45, 90, or 180 min before harvesting. Cells were
fractionated into cytoplasm and membrane as described above. FAS
was immunoprecipitated from each fraction, samples were subjected
to SDS-PAGE, the gel was transferred onto PVDF membrane, and
the bands corresponding to labeled FAS were visualized by autoradiography. Autoradiograms were then analyzed by densitometry.

RT-PCR
Total RNA was extracted with TRIzol reagent (Invitrogen) and
reverse transcribed using an iScript™ cDNA synthesis kit (Invitrogen). Semiquantitative RT-PCR was performed using SYBR®
Green reagent (Applied Biosystems) with an ABI Prism 7700 PCR
instrument.

Mutagenesis and plasmid construction
A retroviral plasmid, pBABE-Puro, containing human FAS
(16) generated by Max Loda (Dana Farber) was utilized to generate FAS phosphosite mutants. A 3.4 kb fragment of FAS/pBABEPuro, including the two putative phosphorylation sites (hFAS
S1028 and T1032) and two ﬂanking BsrGI sites, was ampliﬁed by
PCR and subcloned into an intermediate Topo vector. Site-directed mutagenesis of the Topo-FAS plasmid changed the codons
corresponding to S1028 and T1032 to alanines, yielding two single mutants. The S1028A/T1032A double mutant was made by
sequential mutagenesis, using the S1028A mutant as a template.
Mutated FAS fragments were then excised and cloned back into
pBabe-Puro using the two BsrGI sites to generate mutant, fulllength FAS cDNAs. Mutations as well as correct orientation of the
reinserted FAS fragments were veriﬁed by DNA sequencing.
Green ﬂuorescent protein (GFP)-tagged FAS was generated by
amplifying the cDNA encoding FAS from pBabe-Puro-FAS by
RT-PCR, adding restriction sites for XhoI and EcoRI on the
5′ and 3′ ends, respectively. The ampliﬁed product was cloned
into pEGFP-C3 using the XhoI and EcoRI sites, yielding an
N-terminal GFP-tagged FAS construct.

Lentiviral shRNA-mediated knockdown and human FAS
expression
A plasmid encoding a mouse FAS shRNA (TRCN0000075703)
was obtained from Open Biosystems. The packaging vector
psPAX2 (12260) and envelope vector pMD2.G (12259) were
obtained from Addgene. Hek293T cells at 70% conﬂuence in a
15 cm dish were transfected using Lipofectamine 2000 with 8 μg
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FAS enzyme activity assay

Hepa1-6 and Hek293T cells were maintained in DMEM + 10%
FBS. Prior to insulin treatment for FAS activity assays, Hepa1-6
cells were cultured in DMEM + 0.5% FBS for 6 h. All insulin treatments were performed in DMEM + 10% FBS.

psPAX2, 2.25 μg pMD2.G, and 9 μg shRNA. After 48 h, media was
collected and ﬁltered through 0.45 μm syringe ﬁlters. Polybrene
was added and the media used to treat 50–70% conﬂuent Hepa1-6 cells. After 24 h, the media was aspirated and replaced with
media containing retroviral particles encoding human FAS (see
below). Forty-eight hours after addition of the retroviral media,
cells were selected with puromycin. After another 48 h, cells were
harvested and knockdown of mouse FAS as well as expression of
human FAS were assessed.
To generate retroviral particles encoding human FAS, Hek293T
cells in 10 cm dishes were transfected using Lipofectamine 2000
with 3 μg FAS plasmid and 3 μg A helper plasmid. After 48 h,
media were collected, ﬁltered using 0.45 μM syringe ﬁlters, then
polybrene was added, and the media was used to treat 50–70%
conﬂuent Hepa1-6 cells. After 48 h, 2 μg/ml puromycin was added,
and after an additional 48 h, cells were harvested.
In experiments assessing PPAR␣ target gene expression in
cells expressing mutant FAS, the endogenous murine FAS of
Hepa1-6 cells was knocked down prior to retroviral expression of
human FAS as described above.

Media containing lentiviral particles encoding shRNA for murine FAS and media containing retroviral particles encoding
wild-type or S1028A/T1032A double-mutant human FAS were
prepared as described above. Seventy percent conﬂuent Hepa1-6
cells in 10 cm dishes were treated with retroviral media for either
wild-type or S1028A/T1032A FAS for 24 h, after which the media
was aspirated and replaced with lentiviral media. After another
24 h, the media was again aspirated and replaced with fresh media containing puromycin.
After two days of puromycin selection, the media was aspirated, replaced with charcoal-stripped media, and incubated for
1 h. Charcoal-stripped media was also used for subsequent steps.
Hepa1-6 cells were transfected with plasmids encoding 3× PPREluciferase and Renilla luciferase by electroporation. The electroporation for each 10 cm dish of cells was done as follows: 5 μg
of PPRE-luciferase plasmid and 5 μg of Renilla luciferase plasmid
were added to the bottom of a cuvette. Cells were harvested by
trypsinization and spun after adding media. The media was aspirated, and cells were washed once with PBS. The PBS was aspirated, and cells were resuspended in 0.5 ml PBS and transferred
to the cuvette followed by electroporation at 360 V and 250 μF
⫺1
(time constant of 4.5–5 s ). One milliliter of media was added to
the cuvette, cells were transferred to a 15 ml tube, and media
containing puromycin was added up to 6 ml. Cells were allowed
to recover for 10 min, then plated.
One day following transfection, cells were harvested by scraping, washed with room-temperature PBS three times, resuspended in PBS, and plated on a 96-well plate. Luminescence
from ﬁreﬂy luciferase and Renilla luciferase was then measured
using the Dual-Glo Luciferase Assay System (Promega) according
to the manufacturer’s instructions. PPRE-luciferase activity was
calculated as the ratio of ﬁreﬂy luciferase to Renilla luciferase
luminescence.

Mass spectrometry
To identify posttranslational modiﬁcations in hepatic FAS,
perfused C57BL/6J mouse livers were homogenized in lysis buffer containing 1% Triton X-100. The lysate was spun at 10,000 g
for 45 min, and the pellet was discarded. FAS was immunoprecipitated from 10 mg of the lysate by overnight incubation using
a polyclonal rabbit anti-FAS antibody. IP beads were washed,
boiled in sample buffer, and subjected to SDS-PAGE. The gel was
stained with Coomassie, the gel segment corresponding to FAS
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Statistics
Data are presented as mean ± standard error of the mean.
Comparisons between two groups were performed using an unpaired, two-tailed t-test. ANOVA was used for comparisons involving more than two groups.

RESULTS
Hepatic FAS is present in subcellular compartments
FAS synthesizes palmitate, and FAS deﬁciency in liver
decreases PPAR␣ target genes. If the effect of FAS deﬁciency on PPAR␣ simply reﬂects palmitate availability,
then exogenous palmitate should rescue the effect. It did
not. Treatment of Hepa1-6 cells with 50 μM palmitate
failed to rescue expression of the PPAR␣ target gene
ACO following FAS knockdown (Fig. 1A). Higher concentrations of palmitate (125–500 μM) were toxic (data
not shown).
Since the FAS knockdown effect was not rescued with
exogenous palmitate, it is plausible that not only the product of the FAS reaction but also the location of its synthesis
mediates downstream effects. Dogma holds that FAS is a
cytoplasmic enzyme. To determine whether FAS is also
present at other sites, we fractioned mouse liver FAS by
ultracentrifugation (Fig. 1B). FAS cofractionated with the
cytoplasmic marker S6K but also with markers for several
organelles. Immunoﬂuorescent staining for FAS in murine Hepa1-6 liver cells demonstrated colocalization of
FAS with endoplasmic reticulum (ER) and Golgi markers

Downloaded from www.jlr.org at Washington Univ Medical Library, on July 1, 2013

PPRE-luciferase reporter assay

was excised and further cut into small pieces (1 mm2), destained
with 50% CH3CN containing 25 mM NH4HCO3, dehydrated, reduced with 20 mM DTT for 1 h at 55°C, washed and dehydrated,
alkylated with 100 mM iodoacetamide for 1 h in the dark at room
temperature, then subjected to cycles of washing and dehydration followed by drying in a centrifugal evaporator. In-gel digestion was performed with 0.02 mg/ml trypsin overnight or 0.02
mg/ml chymotrypsin for 6 h at 37°C. Peptides were extracted
from the gel pieces using 5% TFA in 50% CH3CN and reconstituted in 0.1% FA in 3% CH3CN.
Immobilized metal ion afﬁnity chromatography (IMAC) was
used to enrich the sample for phosphopeptides. The sample was
incubated with IMAC beads for 1 h at room temperature. Peptides were eluted from the beads in IMAC buffer, and the sample
was diluted with 0.1% FA in 3% CH3CN. Samples were then analyzed by LC-MS/MS with a NanoLC-LTQ-Orbitrap mass spectrometer (Thermo Fisher Scientiﬁc) in data-dependent mode.
Acquired spectra were searched against Swiss-Prot database
through Mascot server to identify the protein and its posttranslational modiﬁcations. Nonenriched samples were also run to allow a universal search for protein modiﬁcations as well as to
search for acetyl modiﬁcations.
To identify FAS modiﬁcations speciﬁc to membrane-associated FAS and cytoplasmic FAS, membrane and cytoplasmic
fractions were isolated from C57BL/6J mice as described
above. FAS was immunoprecipitated from equal amounts of
membrane and cytoplasmic lysates (1–10 mg/each) by overnight incubation using a polyclonal rabbit anti-FAS antibody.
The samples were then subjected to SDS-PAGE and analyzed as
described above.
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Fig. 1. Hepatic FAS is not exclusively cytoplasmic. (A) Expression levels of FAS (left) and the PPAR␣-dependent gene ACO (right) in
Hepa1-6 cells. Cells were treated with a control (scrambled, sc) shRNA or an FAS shRNA in the presence of exogenous BSA-conjugated
palmitate or vehicle (BSA alone) for 8 h. *P ⭐ 0.05, **P ⭐ 0.005, ***P ⭐ 0.0005. NS, not signiﬁcant. (B) Subcellular distribution of FAS
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but not peroxisomal or mitochondrial markers (Fig. 1C).
FAS did not appear in the nucleus (Fig. 1C).

Cytoplasmic FAS is preferentially phosphorylated
To address the possibility that differential regulation of
cytoplasmic and membrane-associated FAS is caused by a
covalent modiﬁcation, we immunoprecipitated hepatic
FAS from fasting and fed mice, and then tested different
fractions for the presence of phosphothreonine by western blotting. Cytoplasmic FAS in fed mice was strongly
threonine phosphorylated, a modiﬁcation that was almost
undetectable in fasted mice (Fig. 4A). Phosphorylation of
membrane-associated FAS was low under both conditions
(Fig. 4A). In Hepa1-6 cells, insulin treatment (a mimic of
feeding) stimulated threonine phosphorylation of cytoplasmic but not membrane-associated FAS (Fig. 4B).
Analysis of FAS protein from unfractionated mouse liver
by mass spectrometry revealed only a single peptide that
was threonine phosphorylated. This modiﬁcation was detected at two residues, Thr-1029 and Thr-1033 (a representative spectrum is shown in Fig. 5A). When liver FAS was
separated into cytoplasmic and membrane-associated fractions and subjected to the same analysis, the phosphorylated
peptide was found predominantly in the cytoplasm (Fig. 5B)
despite similar total amounts of the peptide in both fractions
(data not shown). These results suggest that the phosphorylated FAS species detected in the cytoplasm with feeding or
insulin (Fig. 4A, B) is modiﬁed at Thr-1029 and Thr-1033.
These residues are in the dehydratase domain of FAS.
The function of this domain requires two catalytic residues,
His-878 and Asp-1032, and a third residue, Gln-1036, that
maintains the orientation of the catalytic residues (21). The
phosphorylated residues we identiﬁed (denoted by * in Fig.
5C) are in close proximity to the catalytic residue D1032
and the structural residue Q1036 (denoted by # in Fig. 5C).
Sequence alignment of the dehydratase regions from different species revealed that in addition to strict conservation of
the active site residues D1032 and Q1036 (denoted by #),
the phosphoresidues we identiﬁed are also conserved as either serines or threonines in humans, mice, rats, D. melanogaster, and C. elegans (boxes in Fig. 5D).
Since the evolutionary conservation of these phosphorylation sites suggests involvement in FAS function, we mutated S1028 and T1032 in human FAS (corresponding to
the T1029 and T1033 in murine FAS) to alanines, generating two single mutants (S1028A and T1032A) and one
double mutant (S1028A/T1032A) (Fig. 5E, mutated sites

protein in mouse liver by differential centrifugation followed by western blotting. Organelle markers: S6K = P70/S6 kinase (cytoplasmic
marker), GM130 = Golgi Matrix protein 130 (Golgi marker), Cav1 = Caveolin1 (caveolae marker), PDI = protein disulﬁde isomerase (endoplasmic reticulum marker), Na+/K+ ATPase (plasma membrane marker), PMP70 = peroxisomal membrane protein 70 (peroxisomal
marker), and COXIV = cytochrome C oxidase IV (mitochondrial marker). (C) Immunoﬂuorescent staining of FAS and expression of GFPtagged organelle markers in murine Hepa1-6 cells. Nuclei stained with DAPI are presented on the far left, GFP images are presented second from left, FAS images are presented second from right, and merged GFP/FAS images are presented on the far right.
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Membrane-associated and cytoplasmic FAS are
differentially regulated
FAS is induced by insulin and nutrients (12). Surprisingly, the speciﬁc activity of mouse liver cytoplasmic FAS
was not increased in the fed state when insulin levels are
high (Fig. 2A). Membrane-associated, FAS-speciﬁc activity
was increased with feeding (Fig. 2B). The cytoplasmic/
membrane activity ratio in liver was increased with fasting,
when PPAR␣ is activated (Fig. 2C). In Hepa1-6 cells, a
transformed liver cell line, insulin signiﬁcantly decreased
cytoplasmic FAS activity (Fig. 2D), an effect that was not
seen in the membrane fraction (Fig. 2E). As with mouse
liver, the cytoplasmic/membrane activity ratio in Hepa1-6
cells was increased in the absence of added insulin (Fig. 2F),
a mimic of fasting.
To begin to address the possibility that membrane-associated FAS is an artifact of preparation, we treated isolated
fractions with different solvents. Membrane-associated
FAS resisted solubilization by 1 M NaCl, remaining in the
pelleted fraction, but it was largely solubilized by 0.1 M
Na2CO3 (Fig. 3A). Treatment with detergent (1% SDS or
1% Triton X-100) solubilized most FAS protein (Fig. 3A).
These results suggest (17–19) that FAS manifests a strong
peripheral membrane interaction.
A pulse-chase study showed that radiolabeled FAS decreased over time in the membrane-associated and cytoplasmic compartments (Fig. 3B), suggesting that there was no
ordered ﬂux of protein from one compartment to another
over the time course of this experiment. There was no discernible change in the distribution of FAS between membrane and cytoplasm when cells were treated with insulin
(Fig. 3C).
Given the presence of a putative open reading frame
(with a potential alternative start codon) 5′ to the published ﬁrst exon of both mouse and human FAS, we
considered the possibility that compartmentalized FAS
represented differential splicing leading to nonidentical
protein isoforms, only one of which is membrane-targeted.
However, mass spectrometric analysis of FAS in membrane
and cytoplasm failed to detect the predicted alternative
amino acids at the N-terminus, and it identified the
published FAS protein sequence as being N-terminally
acetylated (Fig. 3D). This modiﬁcation, which marks the
N-terminus of most eukaryotic proteins (20), was present
in membrane and cytoplasmic fractions of FAS, precluding the existence of an additional N-terminal sequence.
All regions of the FAS protein were similarly represented in each fraction, decreasing the possibility that
compartment location was determined by altered protein

sequence due to a process such as exon exclusion (data
not shown).
Collectively, these results suggest that the enzyme activities of cytoplasmic and membrane-associated FAS are differentially regulated, a phenomenon that does not appear
to be due to intracellular trafﬁcking of the protein or differences in its primary structure.

are indicated by boxes and the active site residues by #).
Wild-type or mutant human FAS was then expressed in
Hepa1-6 cells following knockdown of endogenous mouse
FAS. Compared with cells expressing wild-type human
FAS, cells expressing the S1028A mutation had increased
levels of the PPAR␣ target gene CPT1 (Fig. 5F), whereas
cells expressing the T1032A mutation did not show changes
in PPAR␣ target genes (Fig. 5G). However, expression of
the double-mutant S1028A/T1032A was associated with
increased levels of both ACO and CPT1 (Fig. 5H). To implicate PPAR transcriptional activity in this effect, we performed a PPRE-luciferase reporter assay. After expression of
wild-type or S1028A/T1032A double-mutant FAS and knockdown of endogenous mouse FAS, cells were transfected with
a plasmid encoding three tandem PPREs fused to a ﬁreﬂy
luciferase reporter gene. Luciferase activity was increased in
cells expressing the S1028A/T1032A double-mutant FAS

compared with wild-type FAS (Fig. 5I), suggesting that
effects of the FAS mutant on PPAR␣ target genes are
mediated by PPAR␣ transcriptional activity. One interpretation of these data is that the inability to phosphorylate
FAS disinhibits FAS enzyme activity to promote PPAR␣
transcription.
mTORC1 phosphorylates and inactivates FAS and
inhibits PPAR␣ activity
mTORC1 was recently identiﬁed as a physiologically
important negative regulator of hepatic PPAR␣ (22).
mTOR, the kinase component of mTORC1, is a serine/
threonine kinase that preferentially phosphorylates sites
with hydrophobic residues at the +1 position (23). Since
the phosphorylated residues we identiﬁed have the
highly hydrophobic phenylalanine (F1030) and methionine (M1034) at the +1 positions, we addressed a role for
Lipid channeling and PPAR␣ activation
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Fig. 2. Differential regulation of the activities of membrane-associated FAS and cytoplasmic FAS. (A) Speciﬁc activity of FAS in the cytoplasmic fraction of mouse liver. Mice were fed ad lib (fed) or fasted for 18 h
(fasted). Activity was normalized to FAS protein levels as measured by western blotting. N = 9/group. (B)
Speciﬁc activity of FAS in the membrane (Golgi/ER) fraction of mouse liver. Mice were fed ad lib (fed) or
fasted for 18 h (fasted). Activity was normalized to FAS protein levels as measured by western blotting. N =
5/group. **P ⭐ 0.005. (C) FAS-speciﬁc activities in (A) and (B) expressed as the ratio of FAS-speciﬁc activity
in cytoplasm to FAS-speciﬁc activity in membrane. *P ⭐ 0.05. (D) Speciﬁc activity of FAS in the cytoplasmic
fraction of Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated times. Activity was normalized
to FAS protein levels as measured by western blotting. N = 3/group. *P ⭐ 0.05. (E) Speciﬁc activity of FAS in
the membrane (Golgi/ER) fraction of Hepa1-6 cells. Cells were treated with 100 nM insulin for indicated
times. Activity was normalized to FAS protein levels as measured by western blotting. N = 3/group. (F) FASspeciﬁc activities in (D) and (E) expressed as the ratio of FAS-speciﬁc activity in cytoplasm to FAS-speciﬁc
activity in membrane. *P ⭐ 0.05.
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Fig. 3. Distinct characteristics of membrane and cytoplasmic FAS. (A) Detection of FAS protein by western blotting in pellets and supernatants of membrane fractions following high-salt, carbonate, and detergent treatments. Mouse liver homogenate was fractionated by differential centrifugation into cytoplasm (not shown) and membrane pellet (lane 1). The pellet was resuspended, exposed to solvents as
indicated, and again centrifuged to separate pellet (P) from the new supernatant (S). (B) Pulse-chase analysis of FAS protein in membrane
35
and cytoplasm of Hepa1-6 cells. Cells were pulsed with S-labeled methionine for 1 h, then chased with media containing nonlabeled
methionine for the indicated times. (C) Expression of GFP-tagged human FAS in Hepa1-6 cells treated with insulin for the indicated times.
Images demonstrate no detectable shifts of FAS between cytoplasmic and membrane sites with insulin treatment. (D) Representative spectrum of N-terminally acetylated peptide of FAS. N-terminal acetylation effectively marks the initial amino acid of the protein, precluding
the existence of additional expressed N-terminal exons that might constitute distinct FAS isoforms.
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mTORC1 in FAS phosphorylation. Treating Hepa1-6 cells
with the mTORC1 inhibitor rapamycin for 30 min abolished the insulin-induced increase in cytoplasmic FAS
threonine phosphorylation (Fig. 6A) and was associated
with an increase in cytoplasmic FAS-specific activity
(Fig. 6B). Treatment of these cells with Torin 1 at 250 nM
also abolished insulin-induced FAS phosphorylation (data
not shown). Treating Hepa1-6 cells with rapamycin for
24 h (a sufﬁcient time to reach a new steady state for mRNA
levels) increased expression of the PPAR␣ target gene
CPT1 (Fig. 6C). These ﬁndings conﬁrm those made in a
different system (22) and extend that work by implicating
FAS in the mTORC1-PPAR␣ axis.
To better deﬁne the interaction between mTORC1,
FAS, and PPAR␣, FAS was knocked down in Hepa1-6 cells
followed by rapamycin treatment. FAS knockdown, conﬁrmed in the presence of rapamycin (Fig. 6D), decreased
CPT1 expression (Fig. 6E). The induction of CPT1 levels
with rapamycin occurring with FAS expression (Fig. 6C)
was lost with FAS knockdown (Fig. 6E, solid bar). These
results suggest that in this cell line under these conditions,
the induction of the PPAR␣ target gene CPT1 caused by
inhibition of mTORC1 is FAS-dependent.

DISCUSSION
FAS synthesizes lipid for energy storage and participates
in the generation of a lipid ligand involved in the activation of fatty acid oxidation. Energy storage occurs with
feeding, and activation of fatty acid oxidation occurs with
fasting. To clarify how the same enzyme mediates both
processes, we pursued the possibility that distinct pools of
FAS are differentially regulated in the liver.
We found FAS in the cytosol, but we also localized FAS
to organelles (Fig. 1) through a strong peripheral membrane interaction (Fig. 3A). FAS-speciﬁc activity was relatively higher with feeding/insulin in membranes and
relatively higher with fasting in the cytosol (Fig. 2). This
effect did not appear to involve movement of FAS between
compartments or primary sequence differences between
these pools of FAS. Instead, this activity difference was associated with preferential phosphorylation of cytoplasmic
(but not membrane) FAS with feeding (Fig. 4) at conserved sites within a catalytic domain (Fig. 5). Mutation of
these sites increased endogenous PPAR␣ target gene expression as well as activity of a PPRE-dependent reporter
gene (Fig. 5), consistent with disinhibition of FAS in the
Lipid channeling and PPAR␣ activation
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Fig. 4. Cytoplasmic FAS is threonine phosphorylated with feeding or insulin treatment. (A) FAS threonine
phosphorylation in response to feeding in mouse liver. FAS was immunoprecipitated from cytoplasmic and
membrane fractions and analyzed for phosphothreonine by western blotting. Mice were fed ad lib (fed) or
fasted for 18 h (fasted). Representative blots are shown. Data are averages of two independent experiments.
*P ⭐ 0.05. (B) FAS threonine phosphorylation in response to insulin in Hepa1-6 cells. FAS was immunoprecipitated from Hepa1-6 cytoplasmic and membrane fractions and analyzed for phosphothreonine by western
blotting. Cells were cultured in 0.5% FBS media for 4 h prior to harvest (starved) or in 0.5% FBS media for
4 h, then treated with 1 nM insulin in 10% FBS media for 15 min (refed/insulin). Representative blots are
shown. Data are averages of two independent experiments. *P ⭐ 0.05.

absence of phosphorylation. Inhibition of mTORC1 with
rapamycin decreased FAS phosphorylation, increased cytosolic FAS enzyme activity, and increased expression of
the PPAR␣ target gene CPT1, an effect that was FAS-dependent (Fig. 6). One interpretation of these ﬁndings is
that hepatic FAS exists in at least two differentially regulated subcellular pools, cytoplasmic and membrane-associated (Fig. 7). Cytoplasmic FAS is phosphorylated with
feeding to limit PPAR␣ activation, and it is dephosphorylated with fasting to promote PPAR␣ activation.
Our ﬁndings provide molecular deﬁnition and physiological context to an observation made nearly four decades ago in
1856
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birds. Using pigeon liver as a model and exclusively studying
FAS in the cytoplasm, Qureshi and colleagues found that
feeding induced 32P incorporation into FAS, which was associated with a loss of enzyme activity (24). In vitro treatment with
phosphatases dephosphorylated FAS and restored enzyme
activity. The authors of this study did not identify a physiological role for this covalent modiﬁcation, and it is not known
whether the phosphosites we found are conserved in pigeon
FAS due to the unavailability of sequence data for this species.
Regardless, our work suggests that the phosphorylation state
of cytoplasmic FAS may channel lipid ﬂow to impact phospholipids inducing gene expression in the nucleus.
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Fig. 5. Phosphorylation of cytoplasmic FAS at the dehydratase domain catalytic site controls downstream PPAR␣ target gene expression.
(A) Representative spectrum of the FAS P-T1029/P-T1033 phosphopeptide from wild-type mouse liver. (B) Distribution of P-T1029/P-T1033
phosphopeptides identiﬁed by mass spectrometry in cytoplasm and membrane fractions of mouse liver. Although the proportion of phosphorylation differed based on fraction, peptide abundances (phosphorylated + nonphosphorylated) were similar for the membrane and
cytoplasm fractions (not shown). (C) Position of P-T1029 and P-T1033 amino acid residues in relation to the FAS dehydratase domain active site residues. D1032 is one of two dehydratase domain catalytic residues in FAS. (D) Sequence alignment of the FAS putative phosphoamino acids and dehydratase domain active sites in several species. (E) FAS phosphosite mutants in human FAS. (F) RT-PCR analyses of
PPAR␣ target gene expression in Hepa1-6 cells expressing wild-type or S1028A mutant FAS. Endogenous FAS was knocked down using
lentiviral shRNA for murine FAS. Wild-type or mutant human FAS was expressed using retroviruses. Data are averages of three independent
experiments. *P ⭐ 0.05. (G) RT-PCR analyses of PPAR␣ target gene expression in Hepa1-6 cells expressing wild-type or T1032A mutant
FAS. Assay performed as in (F). Data are averages of three independent experiments. (H) RT-PCR analyses of PPAR␣ target gene expression in Hepa1-6 cells expressing wild-type or S1028A/T1032A mutant FAS. Assay performed as in (F). Data are averages of three independent experiments. *P ⭐ 0.05. (I) PPRE-luciferase activity in Hepa1-6 cells expressing wild-type or S1028A/T1032A mutant FAS. Wild-type
or mutant human FAS was expressed using retroviruses. Endogenous FAS was knocked down using lentiviral shRNA for murine FAS. Cells
were cotransfected with plasmids encoding 3× PPRE-ﬁreﬂy luciferase and Renilla luciferase. PPRE-luciferase activity is reported as the ratio
of ﬁreﬂy/Renilla luciferase luminescence. N = 3–6/group. ***P ⭐ 0.0005.

Physiological, mass spectrometric, and crystal structure
data indicate that phospholipids interact with nuclear receptors (6, 25–29). FAS appears to be linked to PPAR␣
through phosphatidylcholine synthesis mediated by the
Kennedy pathway (6). Viewed with previous studies showing that phosphorylation regulates the CDP-choline branch
of the Kennedy pathway (30, 31), our identification of
functionally relevant FAS phosphorylation sites raises the
possibility that phosphorylation at several nodes within a
cascade of lipid signaling from the cytoplasm to the nucleus
coordinates FAS-mediated PPAR␣ activation.
Palmitate is the direct product of the FAS reaction. If
the mere availability of palmitate were required to activate
PPAR␣, exogenous palmitate would correct FAS deﬁciency. However, the addition of palmitate to liver cells
with FAS deﬁciency does not restore defects in PPAR␣dependent genes (Fig. 1), and elevated serum palmitate
levels that accompany inactivation of liver FAS in mice
does not rescue impaired activation of PPAR␣-dependent
genes (8). Thus, palmitate produced by FAS appears to be
compartmentalized, a notion supported by our ﬁnding of

preferential phosphorylation depending on cellular location and nutritional state.
There is precedent for compartmentalization in metabolism. Exogenous administration of T3, the active form
of thyroid hormone that can be produced locally from its
precursor T4, does not rescue gene expression defects in
the setting of hypothyroidism. But administration of T4,
which is metabolized to generate T3 locally, restores
downstream effects (32). There is also precedent for compartmentalization in lipid signaling. Phosphatidic acid
derived from glycerolipid synthesis has effects on mTORC2
that are opposite from those induced by phosphatidic
acid derived from membrane lipolysis (33). These observations are consistent with our model (Fig. 7). In the fed
state, cytoplasmic FAS is phosphorylated to limit lipid production resulting in PPAR␣ activation, while membrane
FAS, less susceptible to phosphorylation, likely produces
lipids for energy storage or export. Given the rapid demands of lipid synthesis prompted by transition from the
fasting to the fed state, the induction of membrane FAS
may be predominantly substrate-driven through allosteric
Lipid channeling and PPAR␣ activation
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Fig. 6. FAS phosphorylation is inhibited by rapamycin and impacts CPT1 expression. (A) Cytoplasmic FAS
phosphorylation in response to rapamycin in Hepa1-6 cells. Hepa1-6 cells were treated with vehicle, 100 nM
insulin, or 100 nM insulin + 100 nM rapamycin for 30 min. The cytoplasmic fractions were isolated, and then
FAS was immunoprecipitated and analyzed for phosphothreonine by western blotting. *P ⭐ 0.05. (B) Cytoplasmic FAS activity in response to rapamycin in Hepa1-6 cells. Cells were treated with 100 nM insulin and
vehicle (DMSO) or 100 nM insulin + 100 nM rapamycin for 30 min, and then FAS enzyme activity was assayed. Activity was normalized to FAS protein levels as measured by western blotting. Data are averages of two
independent experiments. *P ⭐ 0.05. (C) CPT1 expression levels in response to rapamycin in Hepa1-6 cells.
Cells were treated with vehicle (DMSO) or 100 nM rapamycin for 24 h. Data are averages of two independent
experiments. *P ⭐ 0.05. (D) FAS expression levels following FAS knockdown in Hepa1-6 cells. N = 3–5/
group. ***P ⭐ 0.0005. (E) CPT1 expression levels in response to rapamycin following FAS knockdown in
Hepa1-6 cells. N = 3–5/group. *P ⭐ 0.05. NS, not signiﬁcant.

activation by the glycolytic intermediate fructose-1,6-bisphosphate (34).
mTORC1 may control the reciprocal activity of FAS in
different compartments. mTORC1 is activated by insulin
and nutrients, prefers substrates like those we identiﬁed in
the dehydratase domain, and is known to suppress PPAR␣
in the liver (22). FAS and mTORC1 appear to interact in
the central nervous system where the physiological effects
of FAS inhibition are blunted by rapamycin (35), consistent with our model suggesting that mTORC1 inhibition
would increase FAS activity.
Our work provides evidence that hepatic FAS is in the
cytoplasm as well as peripherally associated with membranes. These two pools are differentially regulated by nutrients and insulin, and they are differentially susceptible
to phosphorylation, thus providing a conceptual framework for understanding how FAS-mediated PPAR␣ activation is linked to the fasting state. These observations could
have clinical implications. Selective pharmacological targeting of FAS to achieve inhibition of lipid storage without
impairing PPAR␣ activation could treat fatty liver and
other disorders associated with nutrient excess.
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